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Summary
The objective of this thesis was to exeunine the effects of cotreat­
ment of taprostene, a synthetic stabilised prostacyclin analogue, 
together with the thrombolytic agent recombinant unglycosylated 
single chain urokinase-type plasminogen activator (r-scuPA) in in- 
vivo thrombolysis.
In an open chest anaesthetized canine model r-scuPA-thrombolysis of 
thrombin-induced occlusive coronary artery thrombi was examined in 
2 series of experiments.
- After LAD coronary artery thrombosis, r-scuPA infusion (20
fig*kg **min  ^, for 60 min) restored LAD flow in 6 of 6 dogs trea­
ted, 2 of which were not analyzed after fatal ventricular fibri­
llation. The interval from infusion start to LAD reflow was 25 
5 min (x SEM, n <= 4) . Compared to r-scuPA untreated animals 
undergoing 6 h continuous LAD ligation or stable thrombotic occlu­
sion (n = 6) r-scuPA treated animals had a 80% smaller relative 
infarct size at 6 h, a more rapid rise in plasma creatine kinase 
(CK) activity, concurrent with reperfusion, and signs of systemic 
plasmin generation (partial CL^antiplasmin and fibrinogen deple­
tion in plasma).
- After 90 min of LCX coronary artery thrombosis, r-scuPA infusion 
(20 p g * kg lmrnin * for 30 min) either alone or started together 
with taprostene (2 dose groups: 0.1 pg*kg **min * for 2 h, and
0.215 pg'kg * *min 1 for 2 h) restored LCX flow in all 21 animals 
treated. Taprostene cotreatment did not significantly change the
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time required by r-scuPA to induce LCX recanalization (r-scuPA 
alone (group II): 22 2.1 min, n - 9 (x SEM); with low dose
taprostene (group III): 18.2 1.7 min, n =* 6; with high dose
taprostene (group IV) : 20.2 2.0 min, n =  6) .
Compared with vehicle treated animals with stable LCX occlusive 
thrombi (group I, n = 4) and group II animals (r-scuPA alone) high 
dose taprostene cotreatment (group IV) exerted significant effects 
on the following haemodynamic parameters: ventricular contractility 
(decreased) and reperfusion arrhythmias (ventricular ectopic beat 
frequency reduced). The mean arterial blood pressure, heart rate 
and heart rate x pressure products were similar between all groups. 
High dose, but not low dose taprostene cotreatment attenuated the 
steep rise in CK activity on reperfusion seen in the r-scuPA alone 
treated group. The mean 6 h relative infarct size was smaller in 
group II relative to group I as a result of reperfusion induced 
myocardial salvage. Taprostene cotreatment further reduced enzyma­
tic and morphological indices of infarct size. The systemic gene­
ration of plasmin by r-scuPA may have been greater in the low dose 
taprostene cotreatment group compared to the other 2 r-scuPA trea­
ted groups, as seen by a slight increase in the depletion of AP and 
plasminogen in this group.
In a rabbit model of carotid artery thrombosis the effects of infu­
sions of r-scuPA (21.5 (ig*kg * 9min *, 40 min) and a non-hypotensive 
dose of taprostene (0.215 pg'kg **min 100 min) alone, and in 
combination, were examined. Taprostene and r-scuPA both separately 
reduced the rate of occlusion and temporarily increased the flow
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rate through the stenosis. Cotreatment with the 2 compounds poten­
tiated this effect; flow was maintained at a higher level than in 
both separate treatment groups and no occlusion of the carotid ar­
tery occurred during the 3 h observation period. The frequency of 
cyclical flow variations caused by platelet aggregate formation and 
embolization was increased by r-$cuPA but attenuated by taprostene, 
both alone and in combination with r-scuPA (group IV). In neither 
group treated with r-scuPA were fibrinogen levels affected. Tapros­
tene reduced collagen-induced platelet aggregation in vitro (Born 
method). Treatment with r-scu-PA did not affect platelet aggregabi- 
lity here compared to vehicle controls and r-scuPA cotreatment did 
not alter the inhibitory potency of taprostene infusion in vivo.
Finally, the effect of taprostene infusion (80 and 400 pg/2h i.v. 
and placebo) on selected haemostatic and fibrinolytic parameters in 
healthy male volunteers was examined to determine its potential 
contribution to fibri- nolysis. High dose taprostene increased the 
endogenous fibrinolytic activity over the infusion period (statisti­
cal significance was not reached due to small number of volun­
teers) . Plasma levels of the plasmin inhibitor AP and the clotting 
factor fibrinogen were unaffected. Plasma activity of the endoge­
nous rapid plasminogen activator inhibitor (PA1-1) may have been 
decreased modestly by high dose taprostene infusion.
Therefore during coronary thrombolysis therapy with r-scu-PA, ta­
prostene at non-hypotensive doses, contributes to a possible fur­
ther reduction in infarct size without markedly affecting central 
haemodynamic parameters with the exception of arrhythmia which was 
reduced.
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1. Introduction
1.1 Relevance of Acute Myocardial Infarction (AMI)
"Cardiovascular disease is a major cause of disability and accounts 
for 50 % of deaths in individuals over the age of 50 years"
(Collen, Stump, Gold et al., 1988 a).
"Until comparatively recently, the epidemic of ischaemic heart di­
sease was continuing unabated in industrialized countries, particu­
larly among males in their peak years of economic activity. Begin­
ning in the late 1960s, however, mortality from the disease began 
to recede in some countries and, in fact, has fallen by 30 % or 
more in Northern America and Australia. Moreover, since ischaemic 
heart disease is the leading cause of death in these countries, 
typically accounting for about one fifth of all deaths, even modest 
declines in mortality can result in a substantial saving of lives 
and an overall reduction in death rates.” World health statistics 
annual 1987; WHO, Geneva.
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1.2 Predisposing factors in thrombosis
Virchow proposed, in 1856, 3 prothrombotic changes known as Vir­
chow's Triadt
a) changes in the vessel wall,
b) changes in the local blood flow pattern,
c) changes in the blood composition.
The experimental induction of thrombi normally requires the inter­
action at least 2 of these factors but Virchow's Triad simplifies 
aetiological analysis.
a) vessel wall changes:
Under normal conditions the vascular endothelium exhibits net non­
reactivity to blood components. Prostacyclin, PGI^ (Moncada, Gry- 
glewski, Bunting et al. 1976; Moncada and Vane 1979), endothelial- 
derived relaxing factor, EDRF (Sneddon and Vane 1988) 13-hydroxy- 
octadecadienoic acid, 13 HODE (Buchanan, Haas, Lagarde et al. 1985) 
and ectoenzymes which degrade ADP and ATP (Lieberman, Lewis and 
Peters 1977; Bassenge and Busse 1988) have been proposed as 
antiplatelet metabolites of vascular origin while platelet-endothe- 
lium electrostatic repulsion has alsov been postulated (Sawyer 
1972).
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In addition to the inhibition of platelet activation and adherence, 
normal endothelium possesses various anticoagulant mechanisms: anti­
thrombin activity via the release of heparan sulphate (Busch and 
Owen 1982), protein C activation in conjunction with thrombomodulin 
and protein S (Esmon 1983) and the release of plasminogen activa­
tors (Erickson, Schleef, Ny et al. 1985) (see diagram 1) .
Thrombosis often occurs following mechanical and chemical damage to 
the endothelium, and after atherosclerotic plaque rupture which, in 
addition to disrupting the endothelial antithrombotic devices, ex­
pose adhesive proteins and collagen (especially types I and III), 
resulting in platelet adherence and aggregation. Thrombin genera­
tion is amplified by positive feedback of platelet aggregation, and 
with decreasing local flow rate an increasing proportion of fibrin 
is formed binding the platelet aggregates (Hawiger 1987, Zimmer- 
mann, Zeltsch and Lange 1979) .
b) changes in local blood flow pattern:
Turbulence and stasis are associated with enhanced thrombosis and 
increasing shear rates promote platelet aggregation (Baumgartner,
H.R. 1973). Pathologically these deviations in the normal laminar 
flow of blood in arteries may result following atherosclerotic and 
vasospastic stenosis, and occur naturally at vessel bifurcations 
(Born 1978) .
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c) changes in blood composition:
Apart from inherited thrombopathies, literature is laden with ex­
amples of acquired, induced or fluctuational changes in blood com­
ponents which have been proven or inferred to render a "hyperthrom- 
botic" condition. The early morning peak frequency in myocardial 
infarction onset (Muller, Rao, Greenberg et al. 1985; Muller, Tof- 
ler and Stone 1989; Willich, Linderer, Wegscheider et al. 1989; 
Schroder and the ISAM Study Group 1989) coincides with increased 
platelet aggregability (Tofler, Brezinski and Schafer 1987), re­
duced fibrinolytic capacity (Rosing, Brakman, Redwood et al. 1970) 
resulting from lower tissue plasminogen activator (tPA) levels and 
increased levels of its inhibitor, plasminogen activator inhibitor 
1 (PAI-1) (Grimaudo, Hauert, Bachmann et al. 1988). Elevated fibri­
nogen, plasma factor VIIc levels and cholesterol have been shown in 
a prospective study to be significantly associated with an increa­
sed incidence of ischaemic heart disease (Meade, Mellows, Brozovic 
et al. 1986). In addition, increased fibrinogen levels cause in­
creases in platelet aggregability (Meade et al. 1985), blood vis­
cosity (Lowe 1985) and fibrin formation (Gurewich, Lipinski and 
Hyde 1976) .
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Diagram 1: Endothelial functions related to blood coagulation and
fibrinolysis. Endothelial cells synthesize and release 
activators and inhibitors of coagulation and fibrinoly­
sis; endothelial cells may interact with leukocytes (see 
section 1.6) and platelets which influence in their turn 
coagulation and fibrinolysis; endothelial cells present 
a surface for adsorption of coagulation and fibrinolysis 
factors entailing a balance of the coagulation and 
fibrinolysis systems. On the abluminal site of the cells 
adhesive proteins may be expressed for fixation of the 
cells to their substratum. (Miiller-Berghaus 1987)
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1.3 Acute myocardial infarction: Cause: spasm or thrombosis?
Assuming that restoring adequate blood flow to an ischaemic area of 
the myocardium is a valid means of limiting the loss of normal 
heart pump function, a knowledge of the factors predisposing, pre­
cipitating and perpetuating vessel obstruction is required before 
this goal, reperfusion, can be achieved efficiently. Apart from 
anecdotal reports most attempts to define the factors precipitating 
coronary artery occlusion are based on retrospective angiographical 
and post mortem examination. Proponents of obstruction of thrombo­
tic origin lost resolve following the inconclusive outcome of the 
preliminary, poorly planned trials with streptokinase. Maseri do­
cumented vasospasm as the cause of angina at rest in all 76 pa­
tients studied, 6 of which evolved into myocardial infarction and 
concluded that coronary vasospasm was the precipitating (and throm­
bosis the perpetuating) event in this subset of patients with AMI. 
(Maseri, Labbate, Baroldi et al. 1978)
In contrast, De Wood et al. demonstrated arteriographically the 
prevalence (87%) of coronary occlusion, mostly thrombotic, within 4 
hours of AMI onset and that the observed frequency of occlusions 
decreased to 67% over 24 hours implying spontaneous resolution. (De 
Wood, Spores, Notske et al. 1980). Betriu showed a 45% incidence of 
occlusion 1 month after infarction (Betriu, Castaner, Sanz et al. 
1982).
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The central idea of atherosclerotic plaque rupture and subsequent 
thrombosis in acute coronary artery obstruction was demonstrated by 
Davies and Thomas in 1985: In victims of sudden cardiac death,
meticulous pathological study revealed intraluminal thrombi in 74 
of 100 hearts examined. Intraintimal thrombi were seen in 21 of the 
remaining 26 hearts. In total, of the 115 thrombi 103 were plaque- 
fissure related. In this study an inherent selection criterion, 
mortality, may bias the results if extrapolated to include non fa­
tal myocardial infarction.
Vasospasm may also aid plaque rupture and is therefore not exhone­
rated, in fact atherosclerotic arteries may tend to vasospasm as a 
result of deficient EDRF-mediated vasodilatory balance (Ludmer, 
Selwyn, Shook et al. 1986; Forsterman, Miigge, Haverich et al. 1988) 
(see diagram 2) . In this context, 2 extremely potent endogenous 
vasoconstrictor peptides endothelin (Yanigasawa, Kiruhara, Kimura 
et al. 1988) and neuropeptide Y (Franco-Cereceda, 1989) have re­
cently been discovered. Their role(s) in ischaemic heart disease is 
being fervently researched at present.
The systemic elevation of specific platelet activation markers pla­
telet factor 4 (PF4) and beta-thromboglobulin (BTG) (Kaplan and
Owen 1981) in myocardial infarction (Gallino, Haeberlif Baur et al. 
1985; Rasi, Ikkala and Torstila 1982; Nichols, Owen, Kaplan et al. 
1982), together with the post mortem abundance of platelets in 
occlusive thrombi, and anterograde accumulation of platelets after 
occlusion (Henriksson, Edhag and Wennmalm 1985a) demonstrate a 
major role of platelet aggregation in coronary artery occlusion.
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Fibrin binds the platelet aggregates thereby stabilizing the throm­
bus. Concurrent fibrinogenesis in myocardial infarction has been 
demonstrated by some groups by increased plasma levels of fibrin 
monomer and fibrin-related antigens (Kruskal, Commerford, Franks 
et al. 1987; Gallino, Haeberli, Baur et al. 1985; Rapold, Haeberli, 
Kuemmerli et al. 1989).
Current consensus of opinion, that thrombosis is the cause of the 
majority of prolonged coronary artery occlusions which lead to 
acute myocardial infarction, is substantiated by the results of 
recent fibrinolytic trials where fibrinolytic treatment restored 
coronary patency in the majority of patients, and infarction was 
limited (GISSI 1986, ISIS-2 1988).
The success of fibrinolytic agents in thrombolysis is attributed 
predominantly, if not entirely, to thrombus destabilization via 












Diagram 2: Summary of proposed mechanisms of coronary artery 
occlusion and their interactions.
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1. 4 Effects of AMI
1.4.1 Functional changes
Seconds after the onset of regional ischaemia a depression of local 
contractile function is seen (Ross and Franklin 1976). The contrac­
tion of the ischaemic area then evolves through 4 abnormal pat­
terns: dysynchrony, hypokinesis, akinesis and paradoxical expansion 
or systolic bulging (Forrester, Wyatt, Daluz et al. 1976). The net 
effect of regional ischaemia on ventricular function is directly 
related to the proportion of myocardium affected (Pfeffer, Pfeffer, 
Fishbein et al. 1979), at 8 % of left ventricle a reduction in dia­
stolic distensibility is seen, above 10 % the ejection fraction is 
reduced, and at 15 to 17 % the left ventricular end-diastolic pres­
sure and volume are increased. Insiduous myocardial insufficiency 
sets in when the abnormally contracting area exceeds 23 % of the 
ventricular wall, and cardiogenic shock at about 40 % (Rackley, 
Russell, Mantle. et al. 1977). During ventricular systole the pas­
sive wall segment may exhibit compliance by bulging, which greatly 
exacerbates the already impaired ventricular function (Swan, 
Forrester and Diamond 1972) (see diagram 3). Six to eight hours 
later oedema and cell infiltration increase regional stiffness, 
which is eventually superseded by inelastic scar formation.
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Diagram 3: Series of functional changes which may occur after coro­
nary artery occlusion, depending on the proportion of 
left ventricle affected, and showing the vicious circle 
which may lead to cardiogenic shock.
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Superimposed on a partial loss of contractile function, ischaemia-
induced ventricular arrhythmias may further reduce pump efficiency.
Three phases are seen after canine coronary artery ligation:
- Initial biphasic arrhythmogenesis with peak deviant activity at 
5-6 and 15-20 minutes postocclusion (Wainwright and Parratt 1988; 
Rosen, Janse and Myerburg 1987), often associated with 
ventricular fibrillation and sudden death in man (Braunwald and 
Sobel 1980),
- A second phase of arrhythmia accompanying progressing myocardial 
necrosis, and
- A later phase from 8 hours onwards with a lesser tendency to 
ventricular fibrillation (Campbell 1987).
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1.4.2 AMI: biochemical changes
The very high mitochondria content of left ventricular myocytes, 
35 % of volume (Page and McCallister, 1973) and the precipitous 
fall in tissue oxygen content following ischaemia imply a high rate 
of oxidative metabolism closely coupled with oxygen supply. The 
onset of myocardial ischaemia is very rapidly accompanied by local 
cyanosis. The terminal components of the mitochondrial electron 
system become reduced under conditions of oxygen scarcity. Glycoge- 
nolysis and anaerobic glycolysis rapidly substitute the preferen­
tial fatty acid utilization and aerobic glycolysis as sources of 
high energy phosphates (HEP), with a resulting loss of efficiency - 
2 moles of ATP formed per molecule of glucose, compared with 38 
moles ATP with aerobic glycolysis. Shortly thereafter, in severe 
ischaemia, the anaerobic glycolytic rate slows as increasing con­
centrations of NADH, H+ and lactate inhibit glyceraldehyde-3-phos- 
phate dehydrogenase activity. Increasing tissue acidosis and ci­
trate levels inhibit phosphofructokinase activity.
Consequently creatine phosphate levels become depleted after 3 mi­
nutes, followed by a slower fall in ATP levels (Opie 1976). Lactate 
accumulates rapidly as do purine bases, produced by adenine nucleo­
tide breakdown.
The fall in contractility resulting from the imbalance in HEP sup­
ply/demand and degradation of the adenine nucleotide pool is also 
paralleled by an accumulation of metabolic end-products possibly to 
the further detriment of the contractility. These include H+, lac­
tate, inorganic phosphate (PJ and products of fatty acid metabo­
lism, as well as oxygen free radicals.
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Fatty acid esters, especially lysophospholipids have been implica­
ted in arrhythmogenesis and membrane damage due to their detergent
action (Corr, Gross and Sobel 1984). Fatty acids have been shown to
impair contractile function (Liedtke, Nellis and Mjos 1984), to un­
couple oxidative phosphorylation (Katz and Messineo 1982) and to
inhibit a number of enzymes. Ionic haemostasis is lost concurrent
with HEP depletion, characterized by a cellular K+ efflux and an
• 2~f"
increase in cytosol Ca
Phospholipase and neutral protease activities increase slowly lea­
ding to liberation of arachidonic acid (Chien, Han, Sen et al.
1984) and digestion of cytoskeletal proteins respectively. The 
latter potentially affecting plasmalemmal integrity (Steenbergen, 
Hill and Jennings 1985).
Accumulation of diverse catabolites causes osmotic loading of the 
membrane, which may be unexplainably weakened by decreased 
glycolysis (Ganote and van der Heide 1988).
The indirect demonstration of oxygen free radical production in the 
ischaemic myocardium (Rao, Cohen and Mueller 1983/ Romaschin, 
Rebeyka, Wilson, et al. 1987) in addition to their demonstrable 
toxicity to liposome and erythrocyte membranes (Kellog and 
Fridovich 1977), microvasculature (Del Maestro, Bjork and Arfors 
1981), sarcoplasmic reticulum calcium transport (Hess, Okabe, Ash 
et al. 1984), cardiac myocytes (Burton, McCord and Ghai 1984) and 
on contractility (Jackson, Mickelson, Stringer et al. 1986) led to 
their implication in ischaemia-induced damage. Multiple sources of 
oxygen free radicals have been demonstrated in experimental models 
of ischaemia and reperfusion: via catecholamine auto-oxidation
(Freeman and Crapo 1982), following conversion of hypoxanthine to 
xanthine, as a result of xanthine dehydrogenase conversion to
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xanthine oxidase during ischaemia (Granger, Rutili and McCord 
1981); by mitochondrial electron transport (Loschen, Azzi, Richter 
et al. 1974; Boveris 1977; Guarnieri, Muscari, Ventura et al. 
1985), following cyclooxygenase action on arachidonic acid (Mason, 
Kalyanaraman, Tainer et al. 1980); and by NADPH oxidase in the 
neutrophil membrane (Babior, Rosin, McMurrich et al. 1981; Rowe, 
Eaton and Hess, 1984).
The higher levels of oxygen free radicals in the early stage of 
reperfusion, may be of greater relevance to myocardial injury and 
dysfunction, than those occurring during complete ischaemia.
Although the relative contribution of the various biochemical chan­
ges to irreversible ischaemic damage is still in debate (Poole-Wil- 
son 1984; Reimer and Jennings 1986), the most certain manifestation 
is the loss of sarcolemmal integrity, which precedes the loss of 
mitochondrial function (Schaper 1987) and to which mechanical shea­
ring may also contribute (Gamster and Kaltenbach 1979).
Following membrane disruption large intracellular molecules are re­
leased, including enzymes, creatine kinase and lactic dehydrogena­
se; nicotinamide adenine dinucleotide (NAD + NADH); and a mitochon­
drial protein which may activate complement (Rossen, Michael, Kagi- 
yama et al. 1988; Kagiyama, Savage, Michael et al 1989). These he­
rald the transition to the inflammatory phase.
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1.4.3 AMI: progression and prognosis
The two major determinants of myocyte death are the duration and 
severity of ischaemia (Reimer and Jennings 1979).
Duration of Ischaemia
Starting 20 to 25 minutes after coronary artery ligation in dogs a 
myocardial necrosis "wavefront” progresses radially, within the 
hypoperfused bed, until an ultimate infarct size of 30-80 % of the 
hypoperfused zone, or area at risk (AaR), is achieved at 6 hours 
(Reimer, Lowe, Rasmussen et al. 1977). Similar temporal progression 
of necrosis from subendocardium to subepicardium is observed in 







O urotion  of occlusion followed by reperfusion ( h )
A ,R abb it; O .p ig ; • ,d o g ; A ,cat; □  .guinca-pig.
Diagram 4: The relation of infarct size (expressed as % of risk 
area) to the duration of ischaemia - showing species 
variation in the rate and ultimate extent of infarction 
(Hugenholtz 1988, modified from Schaper 1984).
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Severity of Ischaemia
Ischaemia is defined as a subtotal or total cessation of regional 
perfusion, characterized not only by a severe oxygen supply/demand 
imbalance, as in anoxia, but also by accumulation of physio- and 
pathophysiological metabolites.
The rate, and ultimate extent, of transmural infarction is deter­
mined primarily by the severity of ischaemia under conditions of 
stable coronary artery occlusion (Maroko, Kjekhus, Sobel et al. 
1971, Schaper, Binz, Sass et al. 1987) . The determinants of myocar­
dial oxygen supply and demand and hence severity of ischaemia are 




































Diagram 5: Showing the major determinants of myocardial oxygen 
supply and demand.
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The inverse relationship between wall tension and local blood flow 
across the myocardium explains the transmural gradient in the seve­
rity of ischaemia and the onset of myocyte necrosis in the subendo­
cardium (Lee, Ideker and Reimer 1981). An inverse gradient rela­
tionship between HER and lactate content of the myocardium was re­
corded (Murry, Reimer, Hill et al. 1985) in accordance with this 
observation.
Anatomical variables and infarct size
After sudden canine coronary artery occlusion, the ultimate propor­
tion infarcted has been shown to be related to the size of the oc­
cluded artery bed or risk area (AaR) (Reimer and Jennings 1979), 
and the anatomical coronary artery bed involved (Becker, Schuster, 
Jugdutt et al. 1983; Ohzono, Koyanagi, Urabe et al. 1986). Both 
effects have been explained by a differing degree of residual, col­
lateral, flow during occlusion (Reimer, Ideker and Jennings 1981; 
Gumm, Cooper, Thompson et al. 1988). Cohen and Rentrop, (1986) de­
monstrated that anginal pain, ST-ECG changes, and regional hypomo- 
tility are less prominent in patient groups with well developed 
collaterals following coronary occlusion. Thus the extent of exi­
sting collateral flow is a major determinant of the severity of 
regional ischaemia and thereby governs the rate and ultimate extent 
of the transmural evolution of necrosis.
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Contractile state and infarct size
Under conditions of minimal collateral perfusion of an ischaemic 
bed secondary determinants of infarct size assume greater impor­
tance. Elevated heart rate (Przyklenk, Vivaldi, Schoen et al. 1986) 
and increased heart rate/blood pressure product (Schaper et al. 
1987) were associated with increased infarct size. Garcia-Dorado, 
Theroux, Elizaga et al. (1988) showed that, for similar rate 
pressure product estimates of cardiac energy demand during ischae- 
mia, hypertension caused more extensive infarction than did 
tachycardia.
The size of an infarct is therefore determined primarily by 4 fac­
tors arranged in descending order of importance:
- Duration of occlusion
- Collateral blood supply
- Myocardial energy demand prior to and during occlusion
- Size (absolute) of the occluded bed
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Prognosis following AMI in man
In-hospital mortality, due primarily to left ventricular pump fai­
lure and arrhythmias, decreased from 30-40 % 20 years ago (Lown,
Falho, Hood et al. 1976) to 10-20 % at present (Scholz, Herrmann, 
Tebbe et al. 1988). Attributed to this reduction are acute inter­
ventions, with the greatest success against arrhythmias: defibril­
lation, pacemakers and antiarrhythmic drugs. Consequently, cardiac 
failure, a function of infarct size now causes over 50 % of in-hos­
pital deaths after AMI (Franzosi, Mauri, Pampallona et al. 1987). 
Long term mortality is affected by age, previous infarction, the 
site and size of infarction, the degree of mechanical dysfunction 
and arrhythmias at the time of discharge (Geltman, Eshani, Campbell 
et al. 1979; Bigger, 1986).
1.5 Possible pharmacological interventions in AMI
Disregarding antiarrhythmic therapy, drug intervention in AMI is 
aimed at reducing infarct size due to its correlation with morta­
lity and morbidity (Caulfield, Leinbach and Gold 1976). Infarct 
size reduction is defined as a relative decrease in the ultimate 
extent of irreversible myocyte damage in treated groups compared to 
controls, at the end of the infarction process.
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Drug interventions may be aimed at one or more of the following:
(1) Reducing energy demand
a) by reducing work by - negative inotropy
- bradycardia
- preload and afterload 
reduction
b) by reducing cell metabolism directly
(2) Increasing energy production potential
a) by restoring adequate artery perfusion
by  -  macro and micro 
thrombolysis
-  spasmolysis
- redistribution of flow
-  prevention of thrombosis 
and intermittant 
occlusions
b) by improving collateral flow contribution
by - increasing diastolic 
blood pressure (or)
- vasodilatation
-  reduction of diastolic 
wall tension
- prevention of vascular 
compression due to 
oedema
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c) by increasing essential metabolite concentrations 
in blood
d) increasing glucose utilization as this is more 
efficient than FA oxidation
e) activation of pyruvate dehydrogenase
(3) Reducing myocardial catabolism




(4) Stabilization of cell structure and composition
by - reduction of elec­
trolyte migration
membrane stabilization




(5) Prevention of microvascular damage or blockage
by - prevention of neutrophil
and platelet adhesion
and aggregation
(6) Reducing the inflammatory response
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Of the many drugs which exhibit multiple antiischaemic affects in 
test models few are irrefutably beneficial in a clinical situation. 
Here the extreme variability in infarct "substrate" and timing de­
tracts from statistical resolution, requiring very large studies. 
Most clinical trials have concentrated on restoring the balance of 
oxygen supply/ demand to the ischaemic myocardium. Calcium channel 
antagonist treatment, however, failed to improve any clinical end­
points (reviewed by Yusuf 1988), whereas nitrovasodilator therapy 
reduced the short term risk of death by 30 % (Yusuf and Collins
1985), presumably by a limitation of infarct size as measured by 
creatine kinase blood levels. Beta adrenoceptor antagonists, 
including metoprolol, propranolol and atenolol, reduced short to 
long term death risk, by up to 40 % in high risk subgroups, pre­
sumably by an additional antifibrillatory mechanism, by decreasing 
cardiac rupture (Julian, Chamberlain, Sandoe et al. 1988) and 
decreasing reinfarction rates (Rehnqvist and Olsson 1987). Theore­
tically, rapid restoration of normal coronary perfusion with 
accommodative flow reserve should be more rewarding than decreasing 
(global) energy demand or statically increasing subordinate 
(collateral) perfusion modes.
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1.6 Coronary artery reperfusion
1.6.1 Reperfusion: theory and aim
Reperfusion, by restoring an adequate oxygen supply should halt the 
progression of ischaemia-induced necrosis if reversibly injured 
myocytes are still present at the time of institution. The resul­
ting myocardial salvage and infarct size limitation should lead to 
partial alleviation of the loss of ventricular function with an 
attendant reduction in mortality and complications.
1.6.2 Effects of reperfusion on infarct size
Animal studies demonstrate unequivocally that reperfusion salvages 
jeopardized myocardium if instituted within a limited period of 
ischaemia. Infarcts in dog hearts reperfused at 3 hours were 10 % 
smaller than infarcts arising from permanent occlusion, and 60 to 
70 % smaller after reperfusion at 40 minutes. No reduction in in­
farct size was seen by reperfusing after 6 hours (Reimer and Jen­
nings 1979) in anesthetized dogs (Ginks, Sybers, Maroko et al. 
1972; Constantini, Cordan, Lang et al. 1975) in baboons (Greary, 
Smith, McNamara et al. 1982) and rats (Hochmann and Choo 1987).
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Effects of reverfusion on left ventricular function
The rate of contractile recovery of ischaemic segments is generally 
inversely proportional to the duration of the preceding ischaemia. 
In conscious dogs 5 and 15 minute occlusion periods required grea­
ter than 3 and 6 hours of reperfusion respectively to restore re­
gional function even though no myocyte necrosis occurred (Heyn- 
drickx, Millard, McRitchie et al. 1975). Lavallee, Cox, Patrick et 
al. (1983) demonstrated a graded rate and ultimate extent in the 
return of segmental contractile function following 1, 2 and 3 hours 
of occlusion. Bush, Buja, Samowitz et al. (1983) demonstrated that 
prolonged reperfusion improved contractile function after 2, but 
not after 4 hours of ischaemia and that this was independent of 
infarct size.
The delayed recovery in regional ventricular function after relati­
vely brief periods of ischaemia, referred to as "stunning” may be 
attenuated in dogs by pharmacological interventions including: 
postischaemic coronary vasodilation (Stahl, Aversano and Becker, 
1986), xanthine oxidase inhibition (Holzgrefe and Gibson, 1988), 
hydroxyl radical scavenging (Bolli, Wei-Xi, Hartley et al. 1987 a), 
iron chelation (Bolli, Patel, Wei-Xi et al. 1987 b) and iloprost 
infusion (Farber, Pieper, Thomas et al. 1988).
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Reoerfusion and mvocvtes
In reversibly injured myocytes reperfusion rapidly reverses ultra- 
structural changes (Jennings, Schaper, Hill et al. 1985), and re­
starts oxidative phosphorylation (Reimer, Hill and Jennings 1981) 
although adenine nucleotide levels may require days to recover.
Reperfusion of irreversibly injured myocytes accelerates myocyte
destruction as a result of explosive swelling (Reimer and Jennings,
• , +  2+
1985), and contraction band necrosis. K and Mg efflux, and mas-
2+ , + , 
sive Ca influx, accompanied by lesser Na and water influx is
seen. Reintroducing molecular oxygen disrupts myocyte integrity 
(Hearse, Humphrey and Chain 1973) in isolated hearts, and is 
therefore arguably coupled with the calcium influx (Hearse, Humph­
rey and Bullock 1987). Large intracellular enzymes, and other ma­
cromolecules are released into the circulation (Hearse, Humphrey 
and Chain 1973) including a mitochondrial protein which activates 
complement (Rossen, Michael, Kagiyama et al. 1988; Kagiyama, 
Savage, Michael et al. 1989).
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Polymorphonuclear leukocyte (PMN) involvement in reverfusion iniurv 
and no-reflow phenomenon
PMN depletion prior to 90 minutes ischaemia and prolonged reperfu­
sion reduces the terminal infarct size by 30-40 % in dogs (Romson, 
Hook, Kunkel et al. 1983; Mitsos, Askew, Fantone et al. 1986; Jol­
ly, Kane, Hook et al. 1983). Pretreatment with diverse antineutro­
phil agents may increase (Allan, Bhattacherjee, Brook et al. 1985), 
delay (Chambers, Yellon, Hearse et al. 1983; Klein, Pich, Bohle et 
al. 1988) or reduce (Bednar, Smith, Pinto, et al. 1985; Jolly and 
Lucchesi 1983; Mullane, Read, Salmon et al. 1984; Simpson, Todd, 
Fantone, et al. 1988) the evolution of necrosis, shown to be pa­
ralleled by PMN infiltration in these studies. Conversely, phorbol 
ester-activated PMNs reduced myocardial flow and contractile func­
tion in Langendorff-perfused rabbit hearts (Gillespie, Kojima, Ku- 
nitomo et al. 1986). In vivo, intracoronary infusion of complement 
C5a produced a similar contractile defect in pigs - attributed to 
PMN (Martin, Chenoweth, Engler et al. 1988).
Ischaemic hearts produce a chemotactic ”beaconn (Hartmann, Robinson 
and Gunnar 1977) initially involving complement (Hill and Ward 
1971) activated by heart subcellular components (Giclas, Pinckard 
and Olson 1979; Rossen et al. 1988), then N-formyl-methionyl-pep- 
tides of mitochondrial origin (Carp 1982), Leukotriene B (Sasaki, 
Ueno, Katori et al. 1988) and possibly products of superoxide ra­
dical action on a plasma component (Petrone, English, Wong et al. 
1980) and arachidonic acid (Perez, Weksler and Goldstein 1980) .
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PMN release a spectrum of inflammatory mediators including oxygen 
derived free radicals, arachidonic acid metabolites, platelet acti­
vating factor and lysosomal enzymes (reviewed by Lucchesi and Mul- 
lane 1986) which may contribute to the "reperfusion injury" repor­
ted by many groups.
During ischaemia, complement activation (Rossen, Swain, Michael et 
al. 1985; Pinckard, O'Rourke, Crawford et al. 1980) enables poly­
morphonuclear leucocyte (PMN) adhesion (Tonnesen, Smedley and Hen­
son 1984) causing accumulation (Mullane, Read, Salmon et al. 1984; 
Engler, Schmid-Schonbein and Pavelec 1983). Reperfusion enhances 
PMN trapping (Engler, Dahlgren, Peterson et al. 1986 a) leading to 
capillary plugging (Schmid-Schonbein 1987) and associated oedema 
(Engler, Dahlgren, Morris et al. 1986 b) . This reflow attenuation, 
or no-reflow phenomenon and oedema is reduced by prior PMN deple­
tion (Engler et al. 1986 b) or inactivation (Olafsson, Forman, 
Puett et al. 1987).
More important from a therapeutic aspect is the recent demonstrat­
ion (Litt, Jeremy, Weisman et al 1989) that reperfusion after 90 
min of LCX ligation, with leucocyte filter treated blood led to a 
50 % reduction in the early (2 h) infarct size (I/AaR) in dogs with 
low collateral flow rates. The specificity of the filters in de­
pleting PMN is low and other (co) effects could not be excluded but 
the zone of no reflow was also reduced by leucopenia. Using a simi­
lar model with a 15 min period of LAD ligation Westlin and Mullane 
(1989) reported enhanced ventricular functional recovery and a di­
minished reflow attenuation in dogs with leucocyte and platelet 
depletion.
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The relative contribution of oxygen-derived free radicals (OFR) to 
reperfusion injury is still in debate, as is the relative contribu­
tion of the various intra- and extracellular OFR sources. OFR sca­
vengers may reduce reperfusion injury in blood-free Langendorff 
preparations (Gauduel and Duvelleroy 1984) and may even augment the 
myocardial salvage produced by PMN depletion in dogs (Mitsos, As­
kew, Fantone et al. 1986).
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1. 7  Fibrinolytic agents
1.7.1 General mechanism of action
The central event in fibrinolysis is the conversion of the proen­
zyme plasminogen to the serine protease plasmin by hydrolysis of
560 561 . . .
the Arg -Val peptide bond linking the A- and B-chain. Native
Glu- plasminogen is split by a variety of activators to yield two
75 76
chain Glu-plasmm. The "preactivation” peptides (Glu - Lys ) are 
subsequently cleaved by autodigestion to yield Lys-plasmin (Collen, 
1980) accompanied by the unmasking of lysine binding sites, which 
mediate the interaction between plasminogen, fibrin and a-2-anti- 
plasmin (AP) (Wiman, Lijnen and Collen 1979). Plasmin lyses fibrin, 
but lacking substrate specificity in vitro it also degrades fibri­
nogen and clotting factors V and VII (Collen 1980) . Physiological 
fibrinolysis is, however, highly fibrin specific and systemic fi- 
brinogenolysis does not occur because free plasmin is very rapidly 
inhibited by 1:1 complexation with AP (Mullertz and Clemmensen 
1976; Moroi and Aoki 1976) (diagram 6) . The plasma concentration of 
plasminogen (2 pM) exceeds that of AP (1 pM) and only after exten­
sive plasmin formation do other serpins (serum proteinase inhibi­
tors) assume relevance after complete AP exhaustion (Collen 1980). 
Equimolar amounts of plasminogen and AP bind, via lysine binding 
sites, to fibrin (Kimura and Aoki 1986) initially stabilizing the 
clot. With increasing plasminogen activation partial fibrin dige­
stion causes enhanced plasminogen binding (Tran-Thang, Kruithof, 
Atkinson et al. 1986), which when activated overcomes local AP in­
hibition accelerating clot lysis (Bachman 1987).
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Diagram 6: Schematic representation of the interactions between 
fibrinogenf plasmin(ogen), alpha^-antiplasmin and 
plasminogen activator. The size of the arrows is roughly 
proportional to the affinity between the different com­
ponents (Lijnen 1988).
In addition, Collen (1980) calculated a half life of inhibition by 
AP to be 2 orders lower for fibrin bound plasmin (10 s) than for 
free plasmin (100 ms).
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1.7.2 Streptokinase, t-PA and APSAC
Plasminogen activation may be induced therapeutically by xenobiotic 
molecules, streptokinase and anisoylated plasminogen-streptokinase 
activator complex (APSAC) or physiologically and therapeutically by 
tissue type and urokinase type plasminogen activators (t-PA and 
u-PA) .
Streptokinase (SK) is a 3-haemolytic streptococci-derived protein 
devoid of enzyme activity. Indirect plasminogen activation results 
from 1:1 stoichiometic complexation of SK with human plasminogen in 
plasma. The complex undergoes transition to reveal a proteolytic 
site in the modified plasminogen moiety, and intramolecular clea­
vage forms a SK-plasmin complex (Reddy 1988) . The plasminogen acti­
vator capacity of the former is 2 - 3 times that of the latter (Mar- 
kus, Evers and Hobika 1978). Species specificity of activation is 
observed: Human, cat, dog and rabbit plasminogen is bound and acti­
vated by SK, whereas cow, sheep, pig, mouse and rat plasminogen 
does not complex with SK (Reddy 1988) . Reversible p-anisoylation of 
the active site (Ser740) on the plasminogen-SK complex yields APSAC 
(anisoylated plasminogen-streptokinase activator complex) (Smith, 
Dupe, English et al. 1982), which still binds fibrin, but is slowly 
reactivated by deacylation in vivo. This prolongs the plasma clea­
rance time and fibrinolytic activity, enabling bolus injection (re­
viewed by Monk and Heel 1987).
Yusuf, Collins, Peto et al. (1985) pooled the results of 24 cli­
nical trials to confirm that intravenous fibrinolytic treatment, 
with diverse agents, reduced mortality by approximately 20 % after 
myocardial infarction. Subsequently, the two largest trials of
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intravenous streptokinase showed a reduction in mortality, by about 
25 % at 2 - 5 weeks (ISIS-2 1988, GISSI 1986), still evident 1 year 
later (GISSI 1987). Smaller studies showed a reduction in enzymatic 
estimate of infarct size (Serruys, Suryapranata, Simoons et al. 
1987; Simoons, Serruys, Brand et al. 1986; ISAM 1986), increased 
ejection fraction and a trend to decreased mortality (Kennedy, Mar­
tin, Davis et al. 1987). Treatment with intravenous APSAC was repor­
ted to produce a dramatic reduction (47 %) in later mortality recor­
ded at 1 month and even 1 year after infarction (AIMS 1988). With 
both agents, however, the side effects inherent to the SK moiety; 
antigenicity, allergic response, and rarely, anaphylaxis (ISIS-2 
1988; AIMS 1988), in addition to systemic degradation of fibrino­
gen, plasminogen and clotting factors, has prompted the development 
of "pseudo-physiological" plasminogen activators with greater clot 
selectivity.
The two most important endogenous fibrinolytic agents are tissue- 
type and urokinase-type plasminogen activators (tPA and u-PA).
Native tPA is a single chain serine protease released by the vascu­
lar endothelium (Rijken, Wijngaards and Welbergen 1980). Single 
chain tPA (sc-tPA) and plasminogen bind via kringle domains to fi­
brin forming a cyclic ternary complex resulting in a 400 fold in­
crease in plasmin generation (Hoylaerts, Rijken, Lijnen et al. 
1982; Ranby and Wallen 1985) . sc-tPA is lysed to two-chain tPA 
(tc-tPA) which retains the plasminogen activator efficacy with a 
slight loss of fibrin specificity.
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Conditioned cell culture media and recombinant DNA methods provide 
sufficient tPA for experimental and clinical thrombolysis.
Thrombolysis with tPA in dogs and rabbits was not associated with 
systemic depletion of fibrinogen, AP and plasminogen (Korninger, 
Matsuo, Stassen et al. 1982; Collen, Stassen and Verstraete 1983), 
and coronary artery recanalisation rate and frequency showed dose- 
dependency (Gold, Fallon, Yasuda et al. 1984; Kopia, Kopaciewicz, 
Fong et al. 1988). In dogs and baboons coronary thrombolysis with 
tPA limited the progression of myocardial necrosis (Gold et al. 
1984; Flameng, v.d.Werf, Verstraete et al. 1985; Longridge, Foil- 
enfant, Maxwell et al. 1988). Despite more frequent recanalisation 
with tPA compared to SK (62 % versus 31 %) (TIMI 1988) only compa­
rable reductions in 1 month mortality, 26 % for tPA (Wilcox, v.d.- 
Lippe, Olsson et al. 1988) were seen. The less frequent reocclusion 
rates associated with SK-induced systemic lytic states may contri­
bute to this (Sherry 1988).
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1.7.3 Single chain urokinase-twe vlasminoaen activator (scu-PA)
The first reports of a urokinase-related "proenzyme” occurred in 
the mid seventies. Two groups (Bernick and Gller 1973; Bernick, 
White, Oiler et al. 1974; Nolan, Hall, Barlow et al. 1977) demon­
strated an enhanced ability of cell culture supernatants to ac­
tivate plasminogen following their pretreatment with trypsin. 
Elucidation of the origin, interrelationship and identity of these 
variants was aided by primary structure analysis (Gunzler, Stef­
fens, Otting et al. 1982 a and b; Steffens, Gunzler, Otting et al. 
1982, reviewed in Floh6, Steffens, Gunzler et al. 1985) .
Native u-PA circulates in plasma at a concentration of 2 to 20 
ng/ml in man (40 to 400 pM), as a high molecular weight (54 KD) 
single chain glycoprotein precursor, scu-PA (Bachmann 1987), known 
previously as pro~Urokinase (pUK or proUK) prior to the recommendat­
ion of the Subcommittee on Fibrinolysis in 1985 (Collen 1985) . 
Cleavage at position 158 by plasmin or kallikrein produces two 
chain or high molecular weight urokinase (tcu-PA - HMW-UPA) 
(Ichinose, Fujikawa and Suyama 1986), which has 200 to 1000 times 
the intrinsic plasminogen activator capacity of scu-PA (Nelles, 
Lijnen, Collen et al. 1987; Pannell and Gurewich, 1978). The 
mechanism regulating the relative fibrin selectivity of scu-PA, 
superficially similar to that of tPA (Collen, Stassen, Blaber et 
al. 1984; Lijnen, De Wreede, Demarsin et al. 1984; Zamarron,
Lijnen, van Hoef et al. 1984; Marder and Sherry 1988), is uncer­
tain. scu-PA-fibrin binding affinity has been reported (Kasai,
Arimura, Nishida et al. 1985; Bando, Okada and Matsuo 1987) and
refuted (Stump, Thienpoint and Collen 1986).
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Lijnen, Zamarron, Blaber et al. (1986) postulated that an inhibi- 
tor-scuPA complex is formed in plasma that is destabilized by fi­
brin. To date no inhibitior has been isolated however. Alternati­
vely , Gurewich's group propose a mechanism which might also explain 
the observed time lag before scu-PA-clot lysis. This is as follows: 
limited plasmin digestion exposes carboxy-terminal lysine residues 
on fibrin which bind native Glu-Plasminogen (Harpel, Chang and Ver- 
derber 1985) inducing conformational changes which greatly enhance 
its susceptibility to scu-PA activation (Pannell,’ Black and Gure­
wich 1988) .
Recombinant techniques involving c-DNA expression in Eschericia 
coli (Holmes, Pennica, Blaber et al. 1985) and hamster ovary cells 
(Nelles, Lijnen, Collen et al. 1987) enabled ”scaled-up" production 
of scu-PA for characterization. These methods replace the 
extraction from urine (Husain, Gurewich and Lipinski 1981), plasma 
(Wun, Schleuning and Reich 1982 a) and kidney and endothelial cell 
culture media (Wun, Ossowski and Reich 1982 b) . E.coli-derived 
scu-PA lacks the natural glycosyl group which effectively lowers 
the molecular weight from 54 to 47 k Daltons.
Recombinant scu-PA (rscu-PA) obtained from E.coli retains the clot 
selective properties of natural scu-PA (nscu-PA) but exhibits an 
increased catalytic efficiency (Lijnen and Collen 1988) .
In a rabbit venous thrombosis model nscu-PA and rscu-PA infusion 
induced dose-dependent, clot-specific fibrinolysis (Gurewich, Pan­
nell, Louie et al. 1984; Hanbiicken, Schneider, Gunzler et al. 1987; 
Collen ' et al. 1984). In canine (van de Werf et al. 1987; Collen, 
Stump, van de Werf et al. 1985) and primate (Flameng, Vanhaeke, 
Stump et al. 1987) coronary artery thrombosis models rscu-PA infu­
sion (< 20 pg* kg * * min * i.v.) recanalized the artery concerned
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with minimal evidence of systemic fibrinogenolysis. In the canine 
model under these conditions a plateau level of r-scu-PA antigen of 
3.5 pg/ml plasma was observed. On stopping the infusion plasma anti­
gen levels decreased with an initial half life of 7 minutes follo­
wed by a slower rate . In these experiments Flameng showed an atten­
dant reduction in infarct size after r-scu-PA thrombolysis. Sohngen 
et al. (1988) observed a similar effect in a canine 
electrically-induced thrombus model, but large loading doses and 
high infusion rates of rscu-PA caused systemic fibrinogenolysis. 
Initial clinical studies with r-scu-PA in recent myocardial infarc­
tion showed coronary recanalisation in 50 - 80 % of a total of 110 
patients (van de Werf, Vanhaeke, De Geest et al. 1986 A; van de 
Werf, Nobuhara and Collen 1986 b; Diefenbach, Erbel, Mathey et al. 
1988) . CL-2-antiplasmin and fibrinogen plasma levels were decreased 
marginally and significantly in the low and high infusion rate 
groups respectively, but no severe bleeding was observed.
A very recent, double blind, multicentre comparison of treatment
with r-scu-PA (saruplase: 20 mg bolus, 60 mg infusion over 1 hour,
6
both i.v.) against SK (1.5 x 10 IU i.v. infusion over 1 hour) m  
AMI, demonstrated multiple advantages of r-scu-PA treatment under 
these conditions (PRIMI Trial Study-group 1988): r-scu-PA treatment 
yielded a higher patency rate and earlier reperfusion (at 60 mi­
nutes: 12 % vs. 48 %, p < 0.001; at 90 minutes: 71 % vs. 63.9 %, 
p  — 0.15). Fewer bleeding complications and a reduced clotting de­
fect (Clauss assay) were also observed in the r-scu-PA treated 
patients compared with SK treated patients.
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Diagram 7: The fibrinolytic system of human plasma.
t-PA 1 : single-chain tissue-type plasminogen activator 
(set-PA)
t-PA 2 : two-chain t-PA (tct-PA)
PAI-1 : plasminogen activator inhibitor 
HMWK : high molecular weight kininogen 
Pro UK : pro-urokinase, single chain urokinase-type PA 
(scu-PA)
HMW-UK : high molecular weight urokinase, two chain u-PA 
(tcu-PA)
C fl-INH: Cl-inhibitor 
a^AP •' alpha^-antiplasmin 
cl -M : alpha -macroglobulin 
HRG : histicline-rich glycoprotein 
(Bachmann 1987)
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Diagram 8: Hypothetical model to explain the fibrin specificity
of scu-PA (proUK) (Lijnen and Collen, D. 1986) .
cooh
Diagram 9a: Two-dimensional structure of human single - chain
urokinase-type plasminogen activator (scu-PA). The 
arrows indicate cleavage sites for various proteolytic 
enzymes (see text) . Cleavage of the Lys g - I l e b o n d  
results in the active two chain form. The zigzag line 
indicates the N-glycosylation site, and the stars show 
the three active site amino acid residues. (Modified 
from Holmes et al. 1985)
-  44 -
1.8 Prostacyclin and analogues (including taprostene)
The discovery of prostacyclin (PGI^) (Moncada et al. 1976) and re­
cognition of its potent vasodilator, antiplatelet and cytoprotec- 
tive effects (reviewed by Vane, J.R. 1985) precipitated a search 
for analogues with enhanced chemical and metabolic stability. This 
yielded a number of prostacyclin mimetics including iloprost (ZK 
36374) and taprostene (CG 4203).
Compared with taprostene exhibits a relative platelet anti­
aggregatory potency of 0.46 (in vitro), an hypotensive potency of 
0.14 (anaesthized rat i.v.) and a four-fold longer duration of an­
tiplatelet action after bolus injection i.v. (FlohS, Bohlke, Fran- 










Diagram 9b: Structure of taprostene
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1.8.1 Effects of PGI^ a n d  analogues on AMI
3 lines of evidence point to prostacyclin as being an important 
antiischaemic mediator.
(1)
Atherosclerosis, the major pathological substratum in AMI, may lo­
wer vascular PGI^ production in animals (Dembinska-Kiec, Gryglews- 
ki, Zamuda et al. 1977) and in man (Sinzinger, Feigl an d . Silber- 
bauer 1979).
(2)
During myocardial infarction in man (Henriksson, Wennmalm, Edhag, 
et al. 1986; Fitzgerald, Roy, Catella et al. 1986) and animals 
(Karmazyn 1986; Prosdocimi, Finesso, Gorio et al. 1985) local pro­
stacyclin production is increased. In platelet free systems, cyclo- 
oxygenase inhibition may worsen the contractile defect resulting 
from ischaemia, and exogenous pGI^ replacement is palliative 
(Schror 1987; Berti, Rossoni, Magni et al. 1988).
(3)
In experimental myocardial ischaemia exogenous prostacyclin and 
mimetics show beneficial effects on various infarction indices in­
cluding: electrocardiographic (Muller et al. 1984; De Langen, Van 
Gilst and Wesseling 1985; Ogletree, Lefer, Smith et al. 1979), en­
zymatic (Muller et al. 1984; Araki and Lefer 1980; Schror, Darius, 
Ohlendorf et al. 1982; Ogletree et al. 1979), contractile (Araki 
and Lefer 1980; Nayler, Purchase and Dusting 1984; Farber et al.
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1988) and morphological (Jugdutt, Hutchins, Bulkley et al. 1981; 
Melin and Becker 1983; Simpson, Mitsos, Ventura et al. 1987). 
Furthermore during ischaemia an antiarrhythmic and antifibrillatory 
action of PGI^ and mimetics has been reported for non-hypotensive 
doses in rats (Muller et al. 1984; Johnston, Macleod and Walker 
1983), dogs (Au, Collins, Harvie et al. 1979; Starnes, Primm, Woos- 
ley et al. 1982; Fiedler and Mardin 1986) and pigs (De Langen et 
al. 1985).
Numerous diverse cardioprotective mechanisms of PGI^ and mimetics 
in ischaemia and reperfusion have been proposed:
(1)
Preload and afterload reduction and hence reduced myocardial oxygen 
demand (Lefer, Ogletree, Smith et al. 1978).
(2)
Increased regional blood supply via collateral vasodilation (Jud- 
gutt et al. 1981; Lupinetti, Starnes, Laws et al 1986).
(3)
Inhibition of platelet activation and trapping in the ischaemic 
myocardium (Ogletree et al. 1979; Michael, Hunt, Lewis et al.
1986) .
(4)
Inhibition of ischaemia-enhanced catecholamine release within the 
myocardium (Schror, Addicks, Darius et al. 1981; Funke and Schror 
1984; Schror and Funke 1985).
(5)
Inhibition of intracellular lysosomal membrane disruption and re­
lease of potentially deleterious enzymes (Ogletree et al. 1979, 
Hieda, Toki, Sugiyama et al. 1988).
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(6)
Preservation of myocyte superoxide free-radical scavenging 
potential (Thiemermann, Steinhagen-Thiessen and Schror 1984).
(7)
Preservation of high energy phosphate reserves (Gercken, Gallenkam- 
per, Schror et al. 1982; Pissarek, Goos, Nohring et al. 1987).
(8)
Cytoprotection or reduction of myocyte membrane degradation and 
disruption by undefined mechanism(s) (Araki and Lefer 1980; Smith, 
Kloster, Stocklin et al. 1984; Muller, Schneider, Hennies et al. 
1984; Darius, Osborne, Reibel et al. 1987). The effect is not 
confined the myocardium as taprostene exhibited antiproteolytic 
effects in pancreas homogenates (Bitterman, Smith, Lefer et al. 
1988) .
(9)
Inhibition of neutrophil mediated injury (Simpson et al. 1987). 
Prostacyclin inhibits PMN adhesion to endothelial cells (Boxer, 
Allen, Schmidt et al. 1980; Zimmerman, Wiseman and Hill 1985 a) and 
has been shown by some (Simpson et al. 1987; Smolen, Korchak and 
Weissman 1980; Fantone and Kinnes 1983), but not all (Boxer et al. 
1980; Gryglewski, Szczeklik and Wandzilak 1987) to attenuate super­
oxide release. Taprostene (Stahlberg, Loschen and Floh6 1988) 
showed potent inhibition of formyl-methionyl-leucyl-phenylalanine
(FMLP) -stimulated cytochrome-C reduction by human PMN in vitro
- 7    .
(IC-. - 5 x 10 M) . PMN migration is inhibited by PGI m  vitro 
50 2
(Zimmerman et al. 1985 a) and in vivo (Simpson et al. 1987; Rampart 
and Williams 1986).
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1.9 Rationale for coadministration of taprostene with scu-PA
Taprostene, and other PGI^ mimetics, may exert many pharmacological 
effects of potential value in thrombolysis. Schumacher (1985) sho­
wed that PGI^ and/or heparin cotreatment with SK increased the re­
flow rate in a canine coronary thrombolysis model, and PGI^ dimi­
nished the intermittent reocclusions seen with SK alone. pGI^ did 
not shorten the time to recanalisation. Infarct size was unfortu­
nately not recorded. Prostaglandin E ( P G E ^ )  enhanced the urokinase 
lysis of fresh, but not matured, platelet-fibrin thrombi in vitro 
(Terres, Beythien, Kupper et al. 1988; Terres, Beythien, Kupper et 
al. 1989), and after PGE coinfusion with tPA in rabbits accele­
rated fibrin degradation was recorded (Vaughan, Plavin, Schafer et 
al. 1988). Sharma, Wyeth, Heinemann et al. (1988) demonstrated en­
hanced ventricular function and short term coronary patency after 
intracoronary PGE together with SK in AMI patients.
The effects of fibrinolytic agents on platelet activity are com­
plex. Fibrin degradation products (FDP) (Kopec and Latallo 1978) 
and plasmin mediated degradation of platelet glycoprotein receptors 
(GP), fibrinogen, adhesive proteins and clotting factors may impair 
platelet function and clotting (Marder and Sherry 1988). Conversely 
reports of platelet hyperaggregability after SK and tPA infusion in 
rabbits (Ohlstein, Storer, Fujita et al. 1987) and in man (Fitzge­
rald, Catella, Roy et al. 1988), and ex vivo treatment of platelets 
(Fitzgerald and Fitzgerald 1987), may be a result of prothrombin 
activation (Seitz, Blanke, Praetorius et al. 1988) or increased 
thromboxane levels (Fitzgerald, Catella, Roy et al. 1988).
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Thrombin inactivates scu-PA (Gurewich and Pannell 1987). Heparin 
therapy which itself augments scu-PA activation (Lijnen and Collen
1986), may also promote platelet aggregation (Salzman, Rosenberg, 
Smith et al. 1980; Barradas, Mikhailidis, Epemolu et al. 1987; Cola 
and Ansell 1990). Prostacyclin's anti-platelet effect is 
complemented by its potentiation of heparin's anticoagulative 
effect (Miletich, Jackson and Majerus 1978). By inhibiting platelet 
release, taprostene may influence the dynamic balance of thrombosis 
and thrombolysis: CL-granules contain both a) fast acting plasmi­
nogen activator inhibitor (PAI-I) (Kruithof, Nicoloso and Bachmann
1987), which inhibits two-chain urokinase (tcu-PA) (Bachmann 1987) 
and endogenous t-PA, and b) platelet factor 4, which exerts modest 
antiheparin effects (Niewiarowski 1977). Severe stenoses, as in in­
complete thrombolysis, cause the attachment and progressive growth 
of platelet aggregates (Badimon, Badimon, Turitto et al. 1987; 
Uchida, Yoshimoto and Murao 1975; Folts, Crowell, Rowe, 1976). The 
platelet thrombus may break off and regrow repeatedly producing a 
"saw toothed" flow pattern, culminating in permanent vessel 
occlusion (Falk 1985) . PGI^ not only prevents the experimental 
formation of coronary thrombi (Romson, Haack, Abrams et al. 1981; 
van der Giessen, Mooi, Rutteman et al. 1984) but also abolishes the 
cyclical flow phenomenon (Aiken and Shebuski 1980) . Although 
platelet depletion in dogs does not affect infarct size after non- 
thrombotic occlusion and reperfusion (Mullane and Me Giff 1985), 
and ibuprofen salvages myocardium independent of antiplatelet ac­
tion (Romson, Hook, Rigot et al. 1982), hypercholesterolemia in 
rabbits causes a platelet-associated increase in both infarct size 
and no-reflow phenomenon (Golino, Maroko and Carew 1987) .
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Therefore, while antiplatelet agents probably do not have a marked 
and direct effect on infarction produced by mechanical occlusion of 
the artery, they may prolong the salvaging effect of fibrinolytic 
agents by maintaining patency, ideally until supportive regional 
collateral supply develops. This is exemplified in the ISIS-II 
study in which aspirin cotreatment further augmented the SK reduc­
tion in mortality from 23 % (SK alone) to 39 % (SK + aspirin) and 
the excess reinfarction rate in the SK group was reduced to a level 
below that recorded in the aspirin alone group. The demonstration 
of EDRF's antiplatelet properties (Radomski, Palmer and Moncada 
1987 a, b) , its synergy with PGI^ * e r e  (MacDonald et al. 1988) and 
the free radical inactivation of EDRF (Moncada, Palmer and Higgs
1987) is interesting insofar as PGI^ analogies including taprostene 
may limit OFR production by PMN (Stahlberg, Loschen and Floh6
1988).
Prostacyclin coadministration may have another aspect: In patients 
with peripheral arteriovascular disease prostacyclin infusion was 
reported to increase endogenous fibrinolytic activity, as estimated 
by the euglobulin clot lysis time (ECLT) (Dembinska-Kiec, Kostka- 
Trabka and Gryglewski 1982; Szczeklik, Kopec, Sladek et al. 1983; 
Musial, Wilczynska, Sladek et al. 1986). Winther, Snorrason, Knud- 
sen et al. (1987) suggested an enhanced tPA production mechanism 
and Levin and Santell (1988) showed that elevated cAMP may promote, 
or reduce, the expression of tPA after stimulation of endothelial 
cells in vitro. Prostacyclin (Hussaini and Moore 1985) and tapro­
stene (Schneider 1987) infusion in rats has been shown to increase
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endogenous fibrinolysis dose-dependently, although in perfused rat 
hindlimbs peptidoleukotriene - but not PGI^-infusion, liberated tPA 
(Tranquille and Emeis 1988) . As tPA has been shown to act synergi- 
stically with scu-PA in vivo (Collen, Stassen, Stump et al. 1986; 
Collen, Stassen and De Cock, 1987; Gurewich and Pannell 1986;
Ziskind, Gold, Yasuda et al. 1989) this effect may be of signifi­
cance in prostacyclin analogue-scu-PA cotreatment.
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1.9.1 Potential limitations and side effects of combination 
therapy in AMI
During myocardial infarction platelet sensitivity to inhibition by 
PGI^ maY  decrease (Muller, Raof Greenberg et al. 1985; Jaschonek, 
Karsch, Weisenberger et al. 1986), as it does in unstable angina 
(Swan and Wallentin 1987) and after tPA infusion in rabbits (She- 
buski and Ohlstein 1987) . Prolonged PGI^ infusion (> 12 hours) is 
often accompanied by waning efficacy (Sinzinger, Silberbauer, 
Horsch et al. 1981) and even rebound hyperaggregability after ces­
sation of infusion (Dembinska-Kiec, Zmuda, Grodzinska et al. 1981).
Common to all vasodilators is the potential to produce coronary 
flow maldistribution ("steal") . This has been reported by one group 
after infusion of iloprost in A.M. I. patients (Bugiardini, Galvani, 
Ferrini et al. 1987) but not mentioned by others infusing iloprost 
or PGI2 (Henriksson, Edhag, Edlund et al. 1985 a; Bergman, Daly, 
Atkinson et al. 1981; Firth, Winniford, Campbell et al. 1983; Swed- 
berg, Held, Wadenvik et al. 1987).
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1.10 Aim
The aim of this research Is to answer the following questions expe­
rimentally:
(1)
Does taprostene cotreatment affect the thrombolytic rate, extent or 
frequency of recanalisation seen with scu-PA alone?
(2)
If so, is this accompanied by deleterious, or beneficial, effects 
on haemostatic and haemodynamic parameters?
(3)
Is the established myocardial protective effect of prostacyclin and 
mimetics during ischaemia and reperfusion still observed when: 
the infusion is started late in the ischaemia phase but before re­
perfusion, in an animal model of thrombotic occlusion undergoing 
fibrinolytic therapy?
(4)
Does taprostene contribute to the maintenance of arterial patency 
above and beyond that of fibrinolytic therapy?
(5)
What is the effect of taprostene alone on the endogenous fibrino­
lytic system in man and is this relevant to clinical fibrinolysis?
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2.0 Materials and methods
2.1 Materials
2.1.1 Drugs tested
Recombinant single-chain urokinase type plasminogen activator of 
recombinant origin (r-scu-PA) was obtained from Eschericia coli by 
expression of c-DNA coding for full length unglycosylated scu-PA 
(411 amino acid chain, 46,420 Daltons). A specific activity of
161,000 lU/mg protein was recorded after plasmin activation and 
subsequent incubation with the chromogenic peptide substrate 
(S-2444, Kabi Vitrum) (Dr. W. Gunzler, Griinenthal, personal 
communication 1986) (see diagram 9a) .
Taprostene - CG 4203 - [5Z, 9a, 11a, 13E, 15S)-2, 3, 4-Trinor-l, 5- 
inter- (m-phenylene) -6,9 epoxy-11,15-dihydroxy-15-cyclohexyl-l 6, 17, 
18, 19, 20-penta-nor]-prosta-5,13-dien-l-oic acid, monosodium salt 
(Flohe et al. 1983) was dissolved in 1.3 % sodium bicarbonate solu­
tion prior to infusion (see diagram 9b) .
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2.1.2 Chemicals and Reagents
Unless otherwise specified all chemicals and reagents were obtained
from Merck, Darmstadt, FRG.
Suppliers of the exceptions were:
- Boehringer Mannheim, FRG: Citrate buffer (0.11 M), Owren's 
veronal buffer, human thrombin (fibrinogen a reagent), Platelet 
factor 4 (PF4) ELISA kit, creatine kinase assay kit (CK-NAC)
-  Kabi Vitrum, Munich, FRG: chromogenic substrates S-2444 and 
S-2251, human plasmin
- Cheva, Bad Segeberg, FRG: pentobarbitone (Nembutal)
- Bio MSrieux, Asni£res, France: bovine thrombin
- Fluka, Switzerland: heparin, sodium salt
- Serva, Heidelberg, FRG: e aminocaproic acid
- Diagnostica Stago, France: CTAD tubes
Reference compounds and standards:
- fibrinogen standard and platelet factor 4 assay kit: Boehringer 
Mannheim, FRG
- PAI-depleted plasma: Kabi Vitrum, Munich, FRG
- Collagen: Hormon Chemie, Munich, FRG
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2.1.3 Equipment
Haemodynamic measurements and ECG recordings were carried out using 
equipment described in the Methods section.
- Photometer: Model 1101, Eppendorf FRG, maintained at 37 *C I'C 
with a heated air hood for ECLT assay
- Coagulometer: Amelung FRG, using plastic tubes, 3.5 ml from
Sarstedt, FRG
- Blood gas analyser: Model ABL2, Radiometer, Copenhagen, Denmark
-  Infusion pumps: Perfusor VI, Braun, Melsungen, FRG
-  Planimeter: Kontron, Munich, FRG
- Respirator: developed within Grunenthal, Aachen, FRG
- Blood pressure transducers and tip manometer were calibrated 
weekly with an open ended mercury manometer
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2.2 Methods
2.2.1 Dog coronary artery thrombosis models
3 experimental fibrinolysis protocols were employed in 2 canine 
open-chested coronary artery thrombosis models (Diagram 10) :
2.2.1.1
Left anterior descending coronary artery (LAD) model:
Aim:
to establish a coronary artery thrombosis model, then to 
determine:
- the stability of untreated thrombi produced by the 
method used over 6 hours
- the effect of r-scu-PA treatment (alone) in this model 
and hence to fix an experimental platform upon which 
r-scu-PA and taprostene cotherapy could be tested in 
later experiments (diagram 10)
3 animal groups were compared:
a) LAD ligation for 6 hours (group a)
b) LAD thrombosis: untreated controls (group b)
c) LAD thrombosis: treated with intravenous r-scu-PA
infusion (20 fig*kg min 60 minute duration) started
90 minutes after onset of ischaemia.
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2.2.1.2
Further LAD thrombosis studies with a prolonged ischaemic 
phase together - prior to thrombolytic treatment - with 
antiarrhythmic prophylaxis (diagram 10);
Aim:
to decrease the proportion of animals failing to 
complete the experiment as a result of ventricular 
fibrillation
r-scu-PA infusion was started 120 minutes after LAD 
thrombotic occlusion (20 pg'kg **min 30 min duration) 
and
lignocaine was administered to attenuate ventricular 
fibrillaton (75 mg loading dose at the onset of 
ischaemia, and 3 mg'kg **min * i.v. infusion for 120 
minutes started with r-scu-PA treatment) .
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2.2.1.3
Left circumflex coronary artery (LCX) experiments 
(diagram 11)
Aim:
to test taprostene cotherapy with r-scu-PA in a model 
established after conclusion of the previous two 
experiments.
4 groups were tested:
group I - LCX thrombosis-vehicle treated controls 
group II - r-scu-PA infusion started 90 minutes after the
onset LCX thrombotic occlusion (20 fig*kg min * ; i.v.; 
30 minute duration) 
group III- r-scu-PA infusion as above (group II) together with 
taprostene at a low infusion rate (0.1 fig*kg **min * 
i.v.; 120 min duration) 
group IV - r-scu-PA infusion (as in group II) together with 
taprostene at a higher infusion rate 
(0.215 p g mkg min * i.v.; 120 min duration)
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Summary of  Exper imental  Protocols:  
Dog coronary thrombolysis
(T \  LAD . I * n  ............
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v -venous blood samples 
a -haemodynamic recordings 
H -heparin bolus (1000U. i.v.)
Diagram 11
Diagrams 10 and 11: Summary of experimental protocols used in 
canine coronary artery (LAD and LCX) thrombolysis experiments
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Surgical preparation and instrumentation of canine models
Adult beagle dogs (both sexes, 13.6-19.8 kg), kept indoors and
maintained on a 12 hour light /dark cycle had their normal chow diet 
withdrawn 18 hours prior to operation. Anaesthesia was induced by 
thiopentone (10 mg'kg * i.v.), and maintained with pentobarbitone 
as required to abolish the corneal reflex. Body temperature was 
maintained at 39.0 £  1.0 * C  using a heating pad. Abdominal aortic 
blood pressure (BP) was measured by inserting a polythene catheter, 
connected to a precalibrated pressure transducer (Statham P23Db), 
into the femoral artery. Mean arterial blood pressure was calcula­
ted as MABP = diastolic blood pressure + (0.42 x blood pressure
amplitude). Left ventricular end diastolic (LVEDP) and peak-pres- 
sure (LVPP) were measured using a tip manometer (Millar PC 350) 
inserted via the left carotid artery. Left ventricular contractili­
ty, expressed as the maximum rate of increase in systolic pressure 
(+dP/dt), was calculated on a Hellige analogue computer. Cannul- 
ation of the femoral and jugular veins enabled drug administration 
and blood sampling respectively. Subcutaneous needles were implan­
ted to record a Lead II electrocardiogram (ECG) . A tracheal tube 
with an inflatable collar was inserted enabling positive-pressure 
respiration (tidal volume 15-20 ml'kg frequency 10 min *). Res­
piration was adjusted continually so that blood gases were main­
tained in the physiological range (Po^ 100-140 mm Hg, Pco 32-40 mm 
Hg) . Haemodynamic parameters and ECG's were recorded on paper using 
a multichannel recorder (Hellige 330 P) .
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A fifth intercostal thoracotomy and suspension of the heart in its 
pericardium provided an anterior aspect. Starting 1-2 cm from its 
origin, a 3 cm segment of the coronary artery (LAD or LCX) was 
prepared by gently separating the overlying connective tissue. Two 
snares were loosely placed around the artery, 1 cm apart. All of 
the small side branches lying between the snares were ligated 
except for 1 which was cannulated for thrombin introduction later. 
An electromagnetic flow probe was placed around the artery proximal 
to the snares.
Thrombus formation
After more than 30 minutes equilibration time the snares were drawn 
and the artery segment lying in between was crushed repeatedly with 
blunt forceps in order to damage the endothelium. Thrombin (10 
units, human) and fresh blood were then injected into the occluded 
artery segment via the previously cannulated small side branch. 
After allowing the thrombus to mature for approximately 50 minutes 
the upper snare was released followed by the distal snare after 5 - 
10 minutes. Thrombotic occlusion was confirmed after release of 
both snares by a zero flow reading, the dark appearance locally and 
by the absence of a sudden burst of arrhythmic activity.
LAD experiments (1 + 2) were carried out ”open label”, whereas LCX 
experiments (3b + 3c) were carried out blind and randomized. After 
fulfilling the inclusion criteria: stable thrombotic occlusion, ECG 
S-T segment elevation (> 0.2 mV, lead II) and marked visible
cyanosis of the ischaemic region, the animals were randomised to
-  63 -
receive treatment: The treatment regimens, as well as the admini­
stration of heparin (1000 units i.v. bolus) and the venous blood 
sampling times are shown in diagrams 10 and 11.
Plasma assays
Venous blood samples were anticoagulated as specified in the va­
rious assays (section 2.2.4) and centrifuged immediately (2000 g, 
15 minutes, 20-25 *C) . Plasma aliquots for the creatine kinase
(CK), d-2-antiplasmin (AP) and plasminogen assays were carefully 
aspirated from the supernatant, and stored at -30 'C for up to 2 
months before use. Fibrinogen determination was carried out 
directly on fresh plasma.
Estimation of relative infarct size
Six hours after the intial coronary artery occlusion heparin (1000 
units, i.v. bolus) was given followed by a massive overdose of pen­
tobarbital. The hearts were excised and immediately treated as des­
cribed: A dual-perfusion method, adopted from Lucchesi, Romson, 
and Jolly (1984) (Diagram 12) was used to simultaneously stain: a) 
the myocardial region supplied by the (previously) occluded 
coronary artery i.e. the anatomic area at risk of infarction (AaR) 
and b) the necrotic region or infarcted area (I) . Triphenyl 
tetrazolium chloride (TTC, 1.5 % in 70 mmol91 * phosphate buffer, 
pH 7.0, 37*C) was perfused into the coronary artery using a cannula 
inserted just distal to the lower snare. Evan's blue (1 % in 
physiological saline, 37 *C) was perfused into the remaining 
coronary circulation following cannulation of the aorta.
-  64 -
Perfusion pressure was maintained at 120 mm Hg for 5 minutes. The 
right ventricle free wall was cut away and the left ventricle slic­
ed perpendicularly to its axis at 1 cm intervals. The slices were 
photographed (Kodak Ektachrome 50, Tungsten light) . Area not stai­
ned with Evan's blue was assumed to have been at risk (AaR) . The 
heart slices were placed in TTC solution (37 *C) for 5 min to check 
that TTC perfusion of the myocardium was thorough. Tissue not 
staining deep red with TTC, and confined to within the AaR, was 
classified as infarcted (I) (Vivaldi, Kloner and Schoen 1985). 
Computer assisted planimetric assessment of photographs enabled the 
following to be estimated for each heart: the proportion of the 
left ventricle myocardium directly perfused by the artery in que­
stion (% AaR/LV) and the proportion of the risk area and left ven­
tricle that were necrotic, as detected by TTC, (% I/AaR and % I/LV 
respectively) .
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MYOCARDIAL STAINING . on
TECHNIQUE______ j 120mmHg
Diagram 12
Balanced pressure myocardial staining technique
Coronary artery perfusion ex — vivo with TTC and Evan's blue 
solutions to determine infarct size and anatomic area at risk (AaR)
Arrhvthmias
The number of ectopic beats per 20 consecutive beats was recorded
at 4 separate times for each time interval specified:
-1 h to 0 h, 0 h to 1 hf 1 h to 1.7 h, 1.7 h to 3 hf
3 h to 4 h, 4 h to 5 h, 5 h to 6 h
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2.2.2 Experiments to study the separate and combined effects of 
taprostene and r-scu-PA on blood flow through a carotid 
artery stenosis in rabbits
Male white New Zealand rabbits (1.8 - 3.1 kg) were anaesthetised 
with pentobarbitone (30 mg*kg  ^ i.v.). An electromagnetic flow 
probe (Hellige, FRG) was placed around the right carotid artery. 
Blood flow was recorded continuously both as the instantaneous flow 
rate, and interval mean flow rate over the specified intervals. 
The latter was obtained by electronically converting the flow probe 
voltage to counting rate. Total counts for a specified period were 
converted to milliliters blood using a calibration curve, and mean 
flow rate over the specified interval obtained by dividing interval 
blood flow (ml) by interval duration (min) . Both flow rate values 
were converted to a standard body weight of 1 kg by dividing by the 
animals weight. The left and right femoral v e i n s  were cannulated 
for drug administration and blood sampling. Arterial blood pressure 
was recorded using a pressure transducer (Statham P23D) after 
cannulation of the right femoral artery with saline-filled 
polythene tubing.
The pretreatment parameters were recorded, including plasma fibri­
nogen, platelet aggregation ex vivo, blood pressure and carotid 
artery flow.
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The animals were then allocated randomly into 4 groups to receive: 
group J: saline (n=6),
group II: r-scu-PA (21.5 (±g*kg 1 *min 1 i.v. for 40 min, n=5),
group III: taprostene (0.215 fig*kg min * i.v. for 100 min, n-5)
group IV: taprostene and r-scu-PA cotreatment according to their
separate protocols (groups II and III) (n-5)
(see diagram 13) .
Infusion rates were low (< 0.5 ml/h), and withdrawn blood samples 
were replaced with an equal volume of saline. Ten minutes after 
starting the infusions a critical stenosis was introduced by im­
planting a 12 mm segment of polythene tubing (internal diameter 
0.86 mm) in the carotid artery. This was done after clamping a 2 cm 
artery segment with 2 artery clamps. The polythene tubing was inser­
ted in the occluded artery segment through an oblique incision and 
was fixed in position by ligatures at both ends. The flow probe was 
calibrated to read 0 ml/min and the artery clamps removed (t - 0) . 
In no instance was the carotid blood flow interrupted for longer 
than 30 seconds. Blood flow readings and venous samples were taken 
at regular intervals according to diagram 13. The experiment was 
terminated at 180 minutes after implantation of the stenosis. A 
cyclical flow variation (CFR) event was defined as a rapid increase 
in flow rate (> 0.5 ml/min within 30 seconds), followed by a re­
newed decrease in flow rate. These CFR were clearly visible on the 
flow rate paper traces.
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Diagram 13
Study protocol used to examine the effect of r-scuPA and/or 
taprostene infusions on thrombosis in a carotid artery stenosis 
model in rabbits.
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2.2.3 Experiments to study the effects of taprostene infusion on 
endogenous fibrinolytic activity in man
Subjects:
Six male volunteers (19-45 years old, 60-90 kg, Broca index 80-120) 
took part in the study after giving their informed consent and 
after having fulfilled the test inclusion criteria:
(1) Perfect health, certified after recent examination by an 
external consultant internist.
(2) No exposure to the agents specified during the preceeding
periods:
- hepatic enzyme inducing drugs: 3 months
- drugs affecting blood coagulation or fibrinolysis: 1 
month
- drugs affecting platelet aggregation: 1 month
- alcohol: 7  days
Study design:
A randomised, single blind, controlled, cross-over study regimen 
was used. Each of the volunteers received only one of the three 
treatments per experimental day. A 7-day interval between experimen­
tal days was observed for each volunteer and each volunteer eventual­
ly received each of the three treatments (Diagram 14) :
- placebo infusion (buffer, i.v. infusion of 2 hours duration)
- low dose taprostene infusion (80 pg over 2 hours i.v.)
- high dose taprostene infusion (400 pg over 2 hours i.v)
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Before starting the experiment, the volunteers assumed a supine 
position, which was maintained for the duration of the infusion. 
Pretreatment venous blood samples, brachial blood pressure and 
heart rate readings were taken. The identity of the infusion was 
unknown to the volunteers and to the haematology laboratory. Blood 
samples, taken at the times specified in diagram 14, were anticoa­




- plasminogen activator inhibitor 1 (PAI-1)
- platelet factor 4 (PF4)
- euglobulin clot lysis time (ECLT)
The volunteers had fasted overnight until 1 hour after the end of 
the infusion, when they had a light lunch. A small evening meal was 
eaten 8 hours after this at 19.00 hours.
After termination of the infusion the volunteers assumed upright 
positions and were permitted to walk. Subsequent blood samples were 
taken after a few minutes in a supine position. The last blood 
samples were taken 23 hours after termination of the 2 hour infu­
sion on each experimental " d a y " .
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Diagram 14
Protocol for taprostene study in healthy male volunteers 
a AP = a antiplasmin, ECLT = euglohulin clot lysis time,
P&4 = platelet factor 4, PAI = plasminogen activator inhibitor
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When an excess of thrombin is added to diluted citrated plasma, the 
time to the appearance of a fibrin clot is inversely proportional 
to the fibrinogen concentration (Clauss 1957).
Procedure:
Venous blood was citrated (9 parts + 1 part Na-citrate, 0.11 M) and 
centrifuged (15 min, 2000 g, 20-25'C). The resulting fresh citrated 
plasma was diluted (1 part plasma + 9 parts Owren's veronal buffer, 
pH 7.35). Aliquots (200 pi) of diluted plasma were incubated at 
37 *C for 1 minute in an automatic 2 channel coagulometer. Human 
thrombin (100 pi, 100 NIH units/ml) was added and the time to 
coagulation recorded. For each batch of thrombin a calibration 
curve was obtained using reference human fibrinogen, from which 
plasma sample concentrations were calculated in mg/100 ml. For each 
animal the preischaemic plasma fibrinogen concentrations served as 
the 100 % value from which subsequent values were calculated (%) . 
Duplicate assays were performed.
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Comments:
The measurement of fibrinogen with this method was possible in the 
presence of heparin (dog studies) due to the supplier's addition of 
a heparin inhibitor to the human thrombin reagent.
The addition of plasmin inhibitors, e.g. Aprotinin, was not neccessary 
in order to prevent in vitro fibrinogenolysis due to r-scu-PA as 




When an excess of plasmin (Pli) is added to diluted plasma an 
inactive 1 : 1  stoichiometric complex plasmin : CL^-antiplasmin
complex is very rapidly formed. The remaining free plasmin activity 
can be measured photometrically by the rate of paranitroaniline 
(pNA) release from the peptide substrate S-2251 (H-D-Val-leu-lys- 
pNA* 2HC1) (Teger-Nilson, Friberger and Gyzander 1977; Friberger 
1982).
(1) AP + Pli , , ------------>  AP : Pli + Pli
(xs)
Pli
(2) S-2251 -> peptide + pNA
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Procedure:
Citrated plasma was diluted (1 : 3 in Tris buffer 0.05 M, pH 7.4, 
1=0.15) and aliquots (300 /ll) were equilibrated at 3 7 'C for 2 to 6 
minutes. Human plasmin (100 pi aliquots, 0.3 CU/ml in 2 mM HC1 con­
taining 50 % v/v glycerol) was added, mixed, and incubated for 
exactly 20 seconds. Peptide substrate S-2251 (100 pi, 3.5 mM in
distilled water) was added and the initial rate of change of ex­
tinction (AE/min) measured at 405 nm. Total plasmin activity was 
recorded for each series by substituting Tris buffer for diluted
plasma (=0% antiplasmin, R ).
o
Duplicate assays were performed. For human plasma samples a cali­
bration curve was obtained by serial dilution of a reference human 
plasma pool from 15 healthy volunteers (9 male, 6 female, ages 21 - 
45) . Undiluted pool plasma was taken as 100 % antiplasmin activity 
(R ). In the dog studies the pretreated antiplasmin activity 
served as the 100 % value (R2qq) ^or eac* percentage of AP










where R is the activity (AE/min) of the sample tested 
x is the % antiplasmin of the sample tested
R j q q is the activity of - the plasma pool (human study) 
- the preischaemic plasma sample
(dog study)
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Comments:
Antiplasmin activity in plasma reflects the function of several 
inhibitors including CL^-macroglobulin and cl ^-antitrypsin. The 
initial rate of inhibition of plasmin is however widely regarded as 
being CL^-antiplasmin-specific, due to its extremely rapid effect 





When an excess of urokinase or streptokinase is added to diluted 
plasma containing plasminogen a complex is formed which itself 
catalyses the amidolytic liberation of the chromophore pNA from the 
substrate S-2251. The rate of pNA release is proportional to the 
amount of plasminogen in the sample (Friberger et al. 1978; Scully 
and Kakkar 1978).
Procedure:
Citrated plasma was diluted (1 : 61 with 50 mM Tris buffer, pH 8.8, 
containing 8.3 mM E -aminocaproic acid) and aliquots (100 pi) were 
incubated with recombinant light chain urokinase (clUK, 100 pi, 
3,500 Ploug units/ml) at 3 7 'C for 3 minutes. Tris buffer (40 pi, 
1M, pH 10.6) was added followed by the chromogenic substrate 
S-2251, (300 pi, 1 mM in Tris/maleate buffer 67 mM, pH 6.0). The
initial rate of reaction (AE /min) was recorded photometrically at 
405 nm and 37 *C. Blanks were obtained by substituting diluted 
plasma samples with Tris buffer. Duplicate assays were performed. 
The pretreatment value of plasminogen served as the 100 % value for 
each dog, from which the subsequent values were calculated.




Creatine kinase (CK) catalyses the formation of adenosine triphos­
phate (ATP) and creatine from adenosine diphosphate (ADP) and crea­
tine phosphate (CP) :
CK
ADP + CP = = = = = = = >  ATP + creatine
ATP thus formed is linked to the reduction of NADP, which can be 
followed photometrically at 334 nm.
(Rosalki 1967) .
Hexokinase
Glucose + ATP = = = = = = = = = = = = >  Glucose-6-P + ADP
G6P-DH
Glucose-6-P + NADP* -=======> 6-phosphogluconate + NADPH
Procedure:
Venous blood (9 parts) was added to heparin (1 part 1000 U/ml) and 
centrifuged (2000 g, 15 min, 25'C) . Aliquots (20 pi) of heparinized 
plasma were added to the CK reagent solution (500 pi) and mixed. 
After 3 minutes incubation at 25 mC the rate of reaction (AE/min, 
334 nm) was recorded for 3 minutes. Plasma samples exhibiting CK 
activity of more than 0.2 AE/min were diluted 1 : 10 with physiolo­
gical saline.' Duplicate assays were performed.
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Plasma CK activity (U/l) was calculated using the formula provided
by the test kit suppliers:
U/l (25*C) = 4207 /min
334 nm
Comments:
3 or more CK-isoenzymes exist: CK-MM, CK-BB and CK-MB. Human myo­
cardium contains about 70 % MM and 30 % MB. CK-BB and CK-MM occur 
mainly in the brain and skeletal muscle respectively. Loss of cell 
integrity results in the elution by, and appearance in, blood of CK 
activity. In man, CK-MB activity can be estimated by subtracting 
anti-CK-MM antisera treated plasma activity from total plasma CK 
activity (Wagner, Roe and Limberd 1973) . This technique has not 
been modified for animal studies, but the contribution by non-car­
diac sources (e.g. intercostal muscle enzyme release due to 
thoracotomy) can be estimated by blood sampling after surgical 
preparation and prior to myocardial ischaemia.
2.2.4.5
Eucrlobulin clot lvsis time (ECLT)
Principle:
When cold diluted plasma is acidified to pH 5.9 the euglobulin frac­
tion, containing fibrinogen, plasminogen and plasminogen activat­
ors, is precipitated. Most of the inhibitors of plasminogen acti­
vation remain in solution. The precipitate can be redissolved and 
coagulated with excess thrombin. The rate of autolysis of the clot 
at 37 *C is widely considered as an indicator of the fibrinolytic 
activity of the sample (Giddings 1988) .
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Procedure:
Aliquots (300 fil) of fresh citrated plasma were diluted In glass 
tubes with distilled water (4.6 ml, 4*C) and acidified with acetic 
acid (100 pi, 0.75 % v/v) to pH 5.9. The tubes were inverted then 
cooled for 15 minutes at 4 *C , followed by centrifugation (1500 g 
for 5  minutes) and aspiration of the supernatant. The tube walls 
were carefully swabbed and the pellet redissolved in saline phos­
phate buffer (300 pi, pH 7.2) . The euglobulin solution was trans­
ferred to sealed plastic cuvettes, thrombin (bovine, 300 pJL of 10 
NIH units/ml) added and the cuvettes mixed rapidly by vortexing. 
The cuvettes were placed in a photometer maintained at 37 * C  and the 
absorption at 578 nm measured at 10 minute intervals over the 
following 9 hours. Triplicate assays were performed. The lysis time 
was recorded as the time required for the photometric absorption to 
decrease to 20 % of the stable terminal absorption value which
corresponded to visual detection of complete lysis. The endogenous 
fibrinolytic rates were calculated as the reciprocal of the lysis 
times (in minutes).
Comments:
Fast acting plasminogen activator inhibitor (PAI-I) is precipitated 
in the euglobulin fraction along with minimal Cl inactivator. The 
reciprocal of the clot lysis time (1/ECLT) quantifies therefore the 
composite effect of plasminogen activators and inhibitors (Kluft 
and Brackman 1975; Wijngaards 1979).
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CTAD plasma
Special commercially avalaible tubes (Diatube-H) were employed for 
collecting blood samples to avoid ex vivo platelet activation. Free 
flowing venous blood (4.5 ml) was collected in precooled CTAD tubes 
containing antiplatelet agents: citrate, theophylline, adenosine
and dipyridamole. The tubes were kept on ice for 15 minutes, then 
centrifuged at 2000 g for 15 minutes at 6'C. The platelet poor plas­
ma was immediately aspirated from the middle of the supernatant 
column and stored at -30 ’C  for less than 2 weeks. Before use the 
plasma samples were thawed quickly at 3 7 'C to prevent cryoprecipi- 
tation, then mixed by vortexing and kept at 2 *C. CTAD plasma 
samples were used in the determination of platelet factor 4 (PF4) 
and plasminogen activator inhibitor (PAI-1) .
2.2.4.6
Plasminogen activator inhibitor-1 (PAI-1) assay 
Principle:
When a fixed amount of tPA is added in e x c e s s  t o  plasma an inactive 
PAI-1* tPA complex is formed (1). The excess tPA can be measured, 
after complete stimulation, by the amount of plasmin formed from 
plasminogen (2) . Plasmin activity is measured spectrophotometri- 
cally with the peptide substrate S-2251 (3).
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PAI-1 + tPA , ,  ■> tPA* PAI-1 + tPA (1)
(xs)
tPA + tPA stimulator 
Plasminogen  > Plasmin (2)
Plasmin + S-2251 -----------> amidolysis product
+ chromophore pNA (3)
Procedure
The samples and standards were prepared as follows:
STANDARDS SAMPLES
Step 0 AU/ml 40 AU/ml (CTAD plasma)
1 25 pi 25 pi 25 111
40 IU/ml t-PA Tris buffer 40 IU/ml t-PA
2 25 111 25 pi 25 ill
PAI-1-depleted PAI-1 -depleted CTAD plasma
plasma plasma sample
3 Incubate 10 minutes at 20 - 25'C
4 4.0 ml sterile water
5 Mix
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By mixing corresponding volumes of the standards 0 and 40 AU/ml, 
further standards were obtained: 30, 20 and 10 AU/ml PAI-1.
Aliquots (100 pi) of the resulting diluted samples or standards 
were transferred to 96-well microtitre plates (flat bottom, 
Greiner, FRG) followed by aliquots (100 pi) of a freshly prepared 
plasminogen/chromogenic substrate solution (composition of the 
latter: human plasminogen: 2 CU/ml, Kabi chromogenic substrate
S-2251: 0.76 mM, Tris: 0.04 M, Tween: 0.008 %, pH 8.3).
After this, 50 pJ aliquots of t-PA stimulator solution (human fi­
brin (ogen) fragments, 0.67 mg/ml in 0.04 M  Tris) were added and the 
microplates incubated at 37 ’C  on a circular-displacement mixing 
table. After a predetermined optimal time of 90 minutes the incu­
bations were stopped with acetic acid (50 pJ. aliquots of 20 % v/v) 
and the absorbance at 405 nm read against distilled water. PAI-1 
activities in the plasma samples were calculated from the standard
curves, one of which was run per microplate. All assays were
■ >
carried out in triplicate.
Comments:
Platelets contain a significant proportion of the PAI-1 in blood 
(Bachmann 1987) and ex vivo platelet activation leads to elevated 
PAI-I values (Kruithof 1986). This source of error would additio­
nally be subject to a one-sided bias if antiplatelet drug- 
(taprostene) treated groups are compared with controls. A  meticu­
lous blood sampling/ treatment regime in addition to ex vivo anti­
platelet treatment (CTAD) reduces the degree of ex vivo activation. 
A platelet-release marker assay (Platelet factor 4, PF4) was car­
ried out in parallel with the PAI-1 assay and plasma samples with 
PF4 concentrations greater than the arbitrary cut off value of
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50 IU/ml were rejected as they were assumed to have undergone an ex 
vivo platelet release reaction.
2.2.4.7
Platelet Factor 4 (PF4) assay 
Principle:
PF4 has several antigenic determinants allowing a quantitative en- 
zyme-immunoassay (ELISA) based on the sandwich principle.
Procedure:
Micro-ELISA plates (Nunc. Immunoplate I, Denmark), coated overnight 
with Fab' anti-PF4 antibody solution, were washed and sequentially 
incubated with a) CTAD plasma samples or standard PF4, then b) 
anti-PF4 antibody-peroxidase conjugate, both for 1 hour at 25'C 
with washing between incubations.
Orthophenylene diamine (OPD) substrate was then added and incubated 
at 25 * C  . After the predetermined optimal reaction time had elapsed 
the reaction was stopped with hydrochloric acid (1 M) . The absor- 
bence was read at 492 nm within 1 hour. PF4 concentrations in the 
CTAD plasma samples were then calculated using a calibration curve 
run in parallel, employing standard PF4 supplied. All 
determinations were done in triplicate.
Comments:
PF4, like R-thromboglobulin, is a platelet specific substance with 
a distribution index (platelet/plasma) of 20,000 and an elevated 
level in plasma is therefore a sensitive and specific indicator of
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platelet activation. The normal healthy human plasma value is 0-5 
IU/ml (Zahavi, Jones, Leyton et al. 1980; Dawes, Smith and Pepper 
1978; Kaplan and Owen 1981) .
Venous blood was citrated (1 : 9 with 0.11 M  Sodium citrate) and 
centrifuged for 10 minutes at 200 g (22 mC) . The supernatant or pla­
telet rich plasma (PRP) was gently aspirated and the pellet centri­
fuged again for 10 minutes at 1,800 g (22 ’C) to obtain a platelet 
poor plasma (PPP) supernatant. PRP aliquots (300 ill), at room tem­
perature, were prewarmed to 37 ’C  in siliconized glass tubes for 3 
minutes and the light transmission recorded (T^). Collagen (native 
equine tendon) was then added in 25 fil of suspension to give end 
concentrations of 1, 2 and 5 fig/ml collagen. The change in light 
transmission was followed for 10 minutes and % aggregation (%A) 












T100 - absolute light transmission of PPP
Tq = absolute light transmission of unstimulated PPP
T^ — absolute light transmission of plateau after
collagen stimulation of PRP.
Single assays were performed.
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3 Results
3.1 LAD artery thrombolysis experiments in doers
Four of the 14 dogs entering this study were not assessed for the 
following reasons:
- 2 dogs succumbed to ventricular fibrillation at 7 and 14 minutes 
respectively after the onset of abrupt coronary occlusion (snares 
drawn). These animals had not yet been allocated to an 
experimental group at this time.
- 2 dogs, both in the r-scu-PA treated group (group c) underwent 
ventricular fibrillation, both 3 0 - 4 0  minutes after the onset
of ischaemia and both temporally associated with the onset of LAD 
reperfusion as detected by the flow probe.
The remaining 10 dogs completing the study were grouped 
accordingly (see Diagram 10) :
group a) 6-hour LAD ligation (n = 3)
group b) untreated LAD thrombosis (n = 3)
group c) LAD thrombosis, then after 90 min occlusion r-scu-PA
infusion (20 pg*kg 1%min 1, 60 min duration, n = 4)
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3.1.1 LAD artery oatencv/Doa
All six animals treated with r-scu-PA underwent successful LAD re­
canalisation; 2 of these however were excluded from the analysis 
after ventricular fibrillation (see above) . The mean time to recana­
lisation after commencing r-scu-PA infusion (20 pg*kg **min * for 
60 minutes) was 25 dz 5 minutes (x db S.E.M.), hence a mean duration 
of ischaemia of 115 minutes in this group (group c) . In the untrea­
ted thrombus group (group b) a zero LAD-flow reading was observed 
for the duration of the experiment demonstrating stability of throm­
bi formed by this method.
3.1.2 Haemodvnamic parameters /Doer LAD thrombolysis 
Heart rate/LAD/Doa
The heart rates were reproducibly high (group means (&.S.E.M.) 
groups a and b combined =  177 db  10 min * and group c 172 db 15 min * 
(beats/min)) prior to ischaemia. After LAD occlusion there was a 
general trend to increased heart rates which continued over the 6 
hour period in both the continuous occlusion groups (a and b) and 
the r-scu-PA treated group (group c) although at various scattered 
times before and after r-scu-PA infusion the heart rate in this 
group was significantly lower, b u t  this was not definitely attribu­
table to r-scu-PA infusion as it occurred before treatment started 
(table 1).
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Mean Arterial Blood Pressure (MABP) /LAD (1) /Doer
The initial preischaemic values of the mean arterial blood pressure 
(MABP) were similar in the 3 treatment groups (x ±.  S.E.M.) :
a) 6 hour LAD ligature (x = 110 mm Hg, n *= 3),
b) 6 hour LAD thrombosis (x — 102 mm Hg, n =  3),
c) r-scu-PA thrombolysis (96 db 9 mm Hg, n — 4)
(diagram 15, table 1).
The MABP fell moderately directly after occlusion of the LAD to 
approximately 85 mm Hg in all groups, but by 30 minutes post occlu­
sion had recovered slightly. This effect was very similar in the 3 
groups prior to the different treatments. In group (c) r-scu-PA 
infusion (20 fig*kg ^*min ^ i.v.), starting 90 minutes after throm­
botic occlusion was associated with a continuous fall in MABP to 
approx. 60 mm Hg at the end of the 60 minute infusion.
The MABP stabilized at about 50 mm Hg, 1 hour after the r-scu-PA 
infusion had been terminated until the end of the experiment which 
was 6 hours after the initial onset of ischaemia. In the ligature 
group (group a) and untreated thrombus group (group b) the MABP 
decreased more slowly than in the r-scu-PA group (group c), to a 6 
hour value of approximately 80 mm Hg in both continuous occlusion 
groups (groups a and b) . Application of the Student's 2-tail t-test 
showed statistically lower MABP (p>0.05) in the r-scu-PA group 
(group c) starting immediately after completion of the infusion (t 
- 2.5 h) and for approx. 2 h duration thereafter (up to t =  4.5 h) . 
Beyond this time (t - 4.5 h) the difference in MABP between the 
pooled continuous occlusion groups (groups a and b) and the 
r-scu-PA treated group was no longer significantly different.
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Left ventricular contractility (+dP/dt) /LAD/Doa
The m e a n s  of the +dP/dt values (+dP/dt - maximum rate of increase 
in left ventricular pressure) varied moderately between the 3 
groups prior to ischaemia (mean of groups a and b (3z S.E.M.) =* 1816 
i  249 mm Hg s * and group c — 1675 ^  249 mm Hg s ^) . They converged 
however within 1 hour of occlusion as the contractility decreased. 
Thereafter the contractility waned slightly and similarly in both 6 
hour occlusion groups (a and b) . In the r-scu-PA infusion group (c) 
the contractility decreased moderately below the values seen in the 
continuous occlusion groups (p<0.05) during the 2 hours of thrombo­
lytic induced reperfusion which the contractility tended to in­
crease slowly towards the values recorded in the continuous occlu­
sion groups (diagram 16, table 1).
Left Ventricular Peak (Systolic) (LVPP) and End Diastolic 
(LVEDP) Pressure/LAD (1)/Doer 
LVPP:
Preischaemic LVPP values were similar for the 3 groups (range of 
group means : 117 mm Hg (group c) to 136 mm Hg (group b). Continu­
ous LAD occlusion (groups a and b) was associated with a biphasic 
decrease in peak pressure developed; an initial slight fall in peak 
pressure seen in all 3 groups (~ 15 %) within minutes of LAD occlu­
sion, followed by a slower decrease in LVPP over the following 6 
hours seen in the 2 continuous occlusion groups (diagram 17, 
table 1).
r-scu-PA infusion did not significantly affect the peak ventricular 
pressure over the 6 hours observed when compared to the other 2
6-hour-occlusion groups after pooling them (groups a and b) .
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In all groups the terminal (t = 6 h) peak ventricular pressure va­
lues were similar and approx. 25 % less than the preischaemic va­
lues (diagram 17, table 1) . There was no significant difference (p 
> 0.05, Student's t-test, 2-tail, unpaired data) between r-scu-PA 
treated (group c) and untreated (groups a and b) groups.
LVEDP
No major change in the minimal ventricular pressure was seen during 
the 6 hours observed either as a result of ischaemia (thrombus or 
ligation) or thrombolytic treatment with r-scu-PA after thrombosis 
(diagram 17, table 1).
3.1.3 Haemostatic parameters/Doer LAD thrombolysis 
cl-2-Antiplasmin (AP) /LAD/Doa
No marked change of plasma AP activity in the groups without 
r-scu-PA treatment (groups a and b) was observed over the 6 hours 
studied. In contrast, in the r-scu-PA treated group (group c) a 
marked decrease in AP was observed:
A nadir of the group mean AP activity (Z 50 % of preischaemic va­
lue) occurred 3.5 hours after starting the 1 hour infusion of 
r-scu-PA. At this time (t = 5 hours), and 1 hour before and after, 
the AP activities were significantly depressed (p < 0.05) compared 
to r-scu-PA untreated controls (groups (a) and (b)) (diagram 18, 
table 2).
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Plasminogen/LAD/Doa
Plasma plasminogen levels remained roughly constant over the 6 hour 
period in both continuous occlusion groups (a+b) . In the r-scu-PA 
treated group (group c) plasma plasminogen decreased to a mean of 
66 % of the pretreatment level 2.5 hours after completing the 1 
hour infusion of r-scu-PA (20 pg’kg * mmin 1). No significant diffe­
rence (p > 0.05)between the r-scu-PA group (c) and the pooled 
groups (groups a and b) (diagram 19, table 2) was recorded however.
Fibrinogen/LAD/Doa
The plasma fibrinogen concentrations remained constant over the 6 
hour period in both continuous LAD occlusion groups (a) and (b) . A 
mean fall in plasma fibrinogen of 30% compared to pretreatment va­
lues was recorded 30 min after completing the r-scu-PA infusion. 
Thereafter the fibrinogen levels started to recover slowly. This 
decrease in fibrinogen accompanying the infusion of r-scu-PA (over 
1 hour) was significantly (p<0.05 Student's 2-tail t-test) diffe­
rent from the pooled levels from the 2 untreated groups (a) and (b) 
(diagram 20, table 2).
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3.1.4 Infarct size parameters including creatine kinase activity/ 
Dog LAD thrombolysis
Creatine Kinase/LAD/Dog
In both groups in which the LAD was permanently occluded (groups a 
and b) a very similar slow but continuous rise in plasma CK acti­
vity was measured, reaching 600 - 800 U/ml after 6 hours. In 
r-scu-PA treated animals (group (c)) a precipitous increase in plas­
ma CK activity accompanied the recanalisation of the thrombus-occlu­
ded LAD artery. In this group the peak mean CK activity (2665 183
U/ml (x di  S.E.M.)) was recorded 2.5 hours after starting the 1 hour 
infusion of r-scu-PA, after which a slight decrease in plasma CK 
activity occurred. The very high mean CK activity in the r-scu-PA 
treated animals was significantly greater (p < 0.01 at t-4 h) than 
that of the combined continuous occlusion groups (groups a and b) .
Infarct size estimation/LAD/Dog
Proportion of LAD perfused myocardium infarcted at 6 hours 
(% I/AaR)
Myocardium not stained deep red with TTC was classified as infarc­
ted. In the ligated and thrombus occluded groups (a and b) a simi­
lar proportion (~ 50%) of the LAD artery bed was unstained there­
fore necrotic at 6 hours I/AaR (51.7 i  15 % and 47.6 5 % respec­
tively; range 24 to 74 %) . r-scu-PA infusion after 90 minutes of 
LAD thrombotic occlusion resulted in a relative infarct size of 9.3 
± 2  % at 6 hours, which was significantly (p < 0.01, Student's t-
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t e s t ,  2-tail) smaller than that of the pooled continuous occlusion 
groups (groups a and b) (diagram 22, table 3) . The proportion of 
left ventricular myocardium supplied by the LAD (% AaR/LV) was s i m i ­
l a r  in all groups (18.9 £  2.5 %: 6 hour ligature (n=3); 14.6 i  1.5% 
6 hour thrombotic occlusion (n=3); 13.2 i  2.2 % (n-4) : r-scu-PA
group). The range of values (all groups) for AaR/LV was from 7.9% 
to 23.8%. The LAD therefore directly perfuses approximately 1/6 of 
the left ventricular myocardial mass (diagram 22, table 3) .
3.1.5 Further LAD experiments with prolonged duration of ischaemia 
and antiarrhythmic oroohvlaxis/Docx (Methods, section 2.2.1.2)
r-scu-PA infusion (20 fig*kg * *min * i.v.) started after 120 minutes 
of LAD thrombotic occlusion resulted in recanalization in all ani­
mals (n = 4) . The relative infarct size (%I/AaR) 6 hours after the 
initial occlusion was found to be 18.2 Jz 7.2 %. The LAD-perfused 
bed was 28.6 ^  0.5 % of the left ventricular myocardium (%AaR/LV) . 
Haemodynamic and haemostatic parameters were essentially similar to 
those of the corresponding treatment groups in the previous experi­
ment (data not given).
- 93 -
Summary of Dog LAD thrombolysis experiments
To summarize the results of the LAD experiments ligation or stable 
thrombotic occlusion of the LAD for 6 hours produced comparable 
effects on the haemostatic and haemodynamic variables (diagrams 15, 
16, 17). The infarct sizes were also similar in both groups of ani­
mals (X 50% of the anatomical risk area) (diagram 22) . Thrombolytic 
treatment with r-scuPA (20 p.g»kg *• min*, 60 min) starting 90 min 
after stable LAD thrombosis produced divergent effects on these 
variables however. MABP and left ventricular contractility were 
reduced (diagrams' 15 and 16) and limited plasmin activation was 
evident from a moderate decrease in plasma levels of cl~ antiplas­
min, plasminogen and fibrinogen (diagrams 18, 19, 20). Successful
thrombolysis occurred in all animals treated with r-scuPA, however 
2 of 6 animals underwent ventricular fibrillation within 1 hour of 
coronary reperfusion. Infarct size expressed as a % of the anatomic 
”risk area” was reduced in this treatment group(.9.3 £  1. 6%)relative 
to the dogs with 6 hour continuous LAD occlusion of the anatomic 
risk area (diagram 22) . The rapid rise and early peak of CK acti­
vity in plasma is further evidence of early reperfusion in the 
r-scuPA treated animals (diagram 21). Further studies were per­
formed using the LCX coronary artery as the mortality following LAD 
occlusion and reperfusion proved to be unacceptably high.
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Diagrams 15 and 16: Mean arterial blyod pressure (MABP) [mm Hg] and 
LV contractility (+dP/dt) [mm Hg s ]. Dogs underwent (a) 6 h LAD 
ligation, (b) 6 h LAD thrombotic occlusion, or (c) r-scu-PA
infusion 90 min after LAD thrombosis (x ± S.E.M.). * = p < 0.05
r-scu-PA- group (a) versus other 2 groups pooled (b+c), 2-tailed 
t-test. PIV = preischaemic value.
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Diagram 17: Left ventricular peak- and end-diastolic pressure
(LVPP/LVEDP) [mm Hg] (x S.E.M.). Dogs underwent (a) 6 h LAD
ligation, (b) 6 h LAD thrombotic occlusion, and (c) r-scu-PA
infusion starting 90 min after LAD thrombosis. No significant 
difference between group (c) and groups (a) + (b) (pooled) was
recorded using a 2-tailed t-test. PIV = preischaemic value.
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Diagrams 18 and 19: a -antiplasmin (AP) and plasminogen activities 
(both % of baseline) (x ±  S.E.M.) in plasma of dogs undergoing LAD 
a) ligation, b) thrombosis or c) thrombosis followed by treatement 
with r-scu-PA.
* = p < 0.05; ** p < 0.01, 2-tailed t-test, r-scu-PA group (c) ver­
sus other 2 groups (a+b) pooled. PIV = preischaemic value.
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Diagrams 20 and 21: Fibrinogen [% of pretreatment concentration] 
and creatine kinase activity (CK) [U/l] in plasma (x ±  S.E.M.).
Dogs underwent either a) 6 h LAD ligation, b) LAD thrombosis or c) 
LAD thrombosis followed by r-scu-PA infusion.
* = p<0.05, ** - p<0.01, 2-tailed t-test, unpaired data, r-scu-PA
group (c) versus pool of other 2 groups (a+b) .
PIV=preischaemic value.
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Diagram 22: Left ventricular planimetry showing: (A) the anatomic
area at risk as % of the total left ventricular myocardium (AaR/LV) 
and, (B) the infarct size as % of the area at risk (I/AaR)
(x £  S.E.M.). Infarct sizes were significantly smaller after
r-scuPA treatment (p<0.01, 2-tailed t-test unpaired data, versus 
pool of other 2 groups.
HAEMODYNAMIC VARIABLES / Dog Infarct LAD
Time [h]
group n PIV 0 0.25 0.5 1 1.25 1.5 1.75 2 2.5 3 3.5 4 4.5 5 5.5 6
HR a+b 6 177 201 201 204 204 204 204 195 198 198 201 207 213 216 213 219 213
(10) (4) (10) (8) (8) (8) (9) (11) (7) (9) (8) (10) (10) (8) (7) (7) (8)
c 4 172 189 184 176* 175* 178* 178 177 178 174 178* 196 185 197 194 192* 190
(15) (4) (4) (4) (4) (6) (6) (7) (7) (3) (5) (8) (6) (8) (6) (7) (7)
MABP a+b 6 106 84 92 93 91 - 96 100 90 97 94 92 92 88 81 79 77
(6) (4) (5) (5) (7) - (7) (7) (7) (8) (5) (9) (11) (11) (12) (12) (12)
c 4 96 87 89 91 87 - 82 87 60 58* 64 49* 49* 46* 50 47 48
________  JL - ___-
(9) (6) (6) (8) (9) - (8) (6) (8) (11) (16) (9) (14) (14) (15) (14) (13)
LV+dP/dt a+b 6 1816 1597 1517 1521 1527 1460 1449 1435 1449 1433 1356 1415 1415 1361 1211 1211 1232
(249) (202) (150) (171) (171) (108) (159) (154) (150) (148) (181) (199) (199) (180) (164) (178) (130)
c 4 1675 1375 1425 1500 1350 1263 1200 1075 998* 850* 1025 800* 800* 938 1063 913 975
(249) (131) (155) (168) (132) (85) (71) (131) (92) (104) (165) (71) (122) (99) (138) (59) (111)
LVPP a+b 6 133 125 131 128 129 125 124 110 110 107 103 107 110 105 97 92 83
(15) (22) (26) (26) (25) (17) (17) (16) (22) (22) (21) (20) (18) (16) (11) (13) (7)
c 4 117 92 97 108 102 99 95 83 79 76 85 62 67 76 77 69 80
(7) (7) (11) (12) (10) (12) (10) (11) (10) (13) (20) (8) (13) (11) (16) (8) (17)
LVEDP a+b 6 6 6 7 8 8 6 8 7 7 6 7 8 6 7 7 8 6
(3) (3) (3) (2) (2) (2) (2) (2) (2) (3) (3) (2) (3) (2) (2) (2) (2)
c 4 9 10 11 9 9 11 12 12 11 12 9 9 11 9 9 10 9
(2) (3) (1) (2) (2) (3) (3) (3) (3) (4) (4) (4) (3) (4) (4) (4) (4)
Table 1: Haemodynamic variables / Dog LAD
Group a dogs, 6 h LAD ligation (n=3); group b, 6 h stable LAD thombotic occlusion (n=3), therefore both groups (a+b) pooled. Group c: r-scu-PA infusion (froi t=1.5 h 
to t=2.5 h) after LAD thrombosis (n=4). HR = heart rate (beats/min); MABP = mean arterial blood pressure (mm Hg), LV +dP/dt = maximum rate of increase in left 
ventricular (L.V.) pressure (mm Hg/sec); LVPP = L.V. peak pressure (mm Hg); LVEDP = L.V. end diastolic pressure (mm Hg); PIV = preischaemic value. All values x t S.E. 
* = P < 0.05, Student's t-test, 2 tail, unpaired data, group c versus groups a + b combined.
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1.5 2 3 4 5 6
AP a+b 6 100 100 105 102 103 99 107 101 96
(1) (3) (5) (7) (5) (5) (7) (6)
c 4 100 103 103 85 84 72 68 * 50 ** 63 *
1 (11) (10) (19) (19) (14) (15) (10) (10)
PLG a+b 6 100 107 90 99 110 100 97 103 106i (16) (10) (8) (18) (16) (15) (11) (16)
c 4 100 94 94 87 89 84 66 75 65
L___ __
(4) (5) (8) (10) (4) (11) (12) (8)
| FIB a+b 6 100 127 120 108 103 113 118 108 124i (8) (2) (7) (4) (12) (11) (6) (19)
c 4 100 107 110 94 81 69 * 74 * 72 ** 77
(8) (7) (12) (11) (3) (3) (8) (1)
CK a+b 6 65 138 193 161 224 307 445 575 759
(7) (32) (33) (31) (33) (43) (62) (85) (113)
c 4 62 235 373 446 607 * 1647 ** 2665 “ 2357 ** 2493 “1 (12) (55) (73) (81) (160) (350) (183) (82) (68)
INFARCT SIZE / Dog LAD (table 3)
AaR/LV (%) I/AaR (t)





18.9 + 2.5 51.7 + 14.6





14.6 + 1.5 47.6 + 4.6
(a + b) (16.8 + 1.6) (49.7 + 6.9)
LAD 7.9 12.7
thrombosis 18.8 11.3
+ r-scu-?A 13.7 7.0
(group c) 12.5 6.3
(x + S.E.M.) 13.2 + 2.2 9.3 + 1.6 **
tables 2 and 3: PLASMA ASSAYS and INFARCT SIZE / Dog Infarct LAD
Dogs were subjected to 6 h LAD ligation (group a), or stable thrombotic occlusion (group b), (groups a + b
pooled). r-scu-PA was infused from t = 1.5 h to t = 2.5 h following LAD thrombosis (group c).
table 2: A?= a-2-antiplasmin activity; PLG= plasminogen activity (both as % of preischaemic value (PIV)),
FIB= % of baseline concentration for each animal (% of PIV). CX= creatine kinase activity (D/1).
table 3: Individual dog infarct size variables, as % of risk area (I/AaR), and proportion of left ventricle
"at risk" (AaR/LV).
All values x ± S.E.M.. *.•= p<0.05; ** = £<0.01 versus groups a and b combined, 2-tailed t-test, unpaired data
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3.2 Results/Doa LCX thrombolysis experiments r-scu-PA taprostene
A  total of 30 dogs were used in this study, 5 of which were exclu­
ded for the following reasons: Ventricular fibrillation prior to 
infusion (n =1); coronary vein or artery ruptured during prepara­
tion (n -2); no change from normal ECG following ligation (n - 1); 
abnormal ECG prior to ligation (n - 1). All of the remaining 25 
dogs fulfilled the following inclusion criteria: 6 hour survival
following initial thrombosis; ECG S-T segment change (2 0.2 mV
elevation starting within 5 minutes of the initial LCX occlusion) 
accompanied by a visible cyanosis of the ischaemic area, and stable 
thrombotic occlusion up to the start of the r-scu-PA (or saline) 
infusion. The 25 dogs were randomly allocated to the following 
treatments starting 90 min after thrombotic occlusion of the LCX:
group I vehicle controls (n =  4)
group II r-scu-PA infusion i.v. (20 pg'kg lmmin * for 30 min, 
n =  9)
group III combined i.v. infusion of r-scu-PA (as group II) plus
low dose taprostene (0.1 pg'kg **min 1 for 2 h, n - 6)
group IV combined i.v. infusion of r-scu-PA (as group II) plus
high dose taprostene (0.215 pgmkg **min 1 for 2 h, n - 6) 
(diagram 11)
Preocclusion LCX-flow [ml/min] (mean i  S.E.M.) was 19.3 i  1.3, 
19.0 £  1.0, 18.9 ^  1.5 and 18.7 i. 1.3 for groups 1 - 4  with no 
statistical difference between the groups.
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3.2.1 LCX artery vatencv/Doa
Spontaneous recanalisation occurred in none of the 4 control ani­
mals (group I). r-scu-PA infusion (20 pg*kg **min * i.v.) for 30 
minutes led to successful recanalisation in all animals tested 
(groups II, III, IV, n — 21). Concomitant infusion of taprostene 
(0.10 pg'kg ^*min group III and 0.215 pg*kg *mmin group IV)
slightly reduced the mean recanalisation time (time from start of 
infusions to the onset of reperfusion as detected by the flow meter: 
> 1.0 ml*min *) from 22.0 'jz 2.1 minutes (group II) to 18.2 i  1.7 
minutes and 20.2 2.0 minutes in groups III and IV respectively.
This slight reduction in mean lysis time by taprostene was not 
significant however. The duration of initial LCX occlusion was 
therefore approximately 110 min in all three r-scu-PA treated 
groups (groups II, III and IV), as the infusion of r-scu-PA was 
started 100 min after LCX occlusion (table 7) .
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3.2.2 Haemodvnamic parameters/Doa LCX/Results 
Mean arterial blood pressure (MABP) /LCX/Docr
MABP values preceding LCX thrombotic occlusion were similar for 
all groups (range of group means before ischaemia 135 sk 11 mm Hg to 
183 ^  5 mm Hg (x dr  S.E.M.); individual range: 181 mm Hg to 107 mm 
Hg) . Within minutes of LCX occlusion in all groups a ~  20 % fall in 
MABP was seen, followed by a slight recovery up to 100 minutes when 
the infusions were started. In the 2 groups receiving taprostene 
and r-scu-PA (III and IV) a trend to slightly lower MABP during and 
after taprostene infusion was observed when compared with both the 
taprostene untreated groups (I and II) . The relative MABP decrease 
associated with taprostene infusion was slight (X 20 mm Hg 
difference between corresponding group means) and prolonged but not 
significant (diagram 24, table 4) .
In contrast to the LAD experiments, the LCX thrombus animals showed 
virtually no change in MABP as a result of r-scu-PA infusion, when 
compared with vehicle infusion.
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Left ventricular veak (systolic) (LVPP) pressure/LCX/Doa
The peak ventricular pressure decreased shortly after LCX occlusion 
in all groups from a similar mean preischaemic value (group range 
of means: 137 £  10 mm Hg to 152 8 mm Hg (x A  S.E.M.), individual
range: 104 - 172 mm Hg) . The LVPP continued to decrease over the 6 
hour experimental period in all groups despite restoration of LCX 
patency in groups II to IV. A noticeably more rapid decline in LVPP 
took place during the infusion of the higher dose (0.215 pg'kg 
min *) of taprostene (group IV) . In spite of this, no significantly 
different LVPP value was observed between any 2 of the 4 treatment 
groups at equivalent time points (diagram 23, table 4) .
L.V. contractility (+dP/dt)/LCX/Doa
Variations in the group means of the left ventricular +dP/dt (maxi­
mum rate of increase in ventricular pressure) prior to ischaemia 
were large (range 1000 - 2400 mm Hg/s) and at this point 2 group 
means were statistically different (p < 0.05, t-test; group I: 2050 
i 132 (x *  S.E.M.) and group IV: 1400 ^  121 mm Hg/s). The groups 
mean values tended to decrease in a convergent manner, however, 
minutes after LCX occlusion by about 25 % to a common value. 
Regardless of the different treatments, and of the restoration of 
LCX patency in all members of groups II to IV, the left ventricular 
contractility decreased slowly and uniformly over the 6 hours in 
all 4 groups, so that the 6 hour contractility values were 38 db 7%, 
63 ^  6 %, 53 5 % and 51 ^  6 % (mean % of preischaemic value
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i  S.E.M.) for treatment groups I to IV respectively. Thus although 
the absolute mean contractility was lowest in the high dose 
taprostene group, and significantly different to the non-reperfused 
controls (group I, p < 0.05, t-test, 2-tail) at this time, the 
maximum % decrease in contractility occurred in the untreated 
control group. This may be an artefact related to the excessively 
high contractility in this group (group I) prior to ischaemia 
(diagram 25, table 5).
Heart rate (HR) and Double product (HR x MABP) /LCX/Doa
The heart rates remained virtually unchanged from the preischaemic 
values (X 200 beats/min, range: 165 - 225 /min) in all groups over 
the 6 hour period regardless of the different treatments.
As a result, the double product (HR x MABP) - an index of myocar­
dial oxygen demand - followed a similar course to the blood pres­
sure (MABP) over the experimental period. In brief, no significant 
changes between treatment groups were observed although in tapro­
stene treated groups (groups III and IV) a marginally lower energy 
demand may have resulted from slightly lower MABP values.
This very slight effect was at no time significant when compared 
with either continuous occlusion or r-scu-PA alone treated groups 
(diagram 27, table 6).
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Arrhythmias/LCX/Doa
No arrhythmic activity was observed before LCX thrombosis. Follow­
ing thrombosis a low mean frequency of ectopic beats was observed 
in all groups ( 1 - 2  per 20 beats) . A dramatic increase in arrhyth­
mic activity (approximately 4 x) occurred in all animals treated 
with fibrinolytic agent and was temporally associated with the on­
set of reperfusion as detected by the flow probe. In taprostene- 
cotreated groups (III and IV) dose-dependent reduction in 
reperfusion arrhythmias was observed when compared with the 
r-scu-PA-alone group (I) (diagram 29, table 8) . This was
significant for the higher dose of taprostene over the 3 to 6 hour 
period (p < 0.05 versus group II, 2-tailed t-test, unpaired data).
The relatively low incidence of arrhythmia in the continuous
occlusion group (gp I) tended to increase towards the end of the
experimental period (diagram 29, table 8) .
3.2.3 Infarct size parameters/Doa LCX/Results
LV myocardium "at risk"
The proportion of LV myocardium directly supplied by the LCX (% 
AaR/LV) was found, with the balanced pressure ex vivo dye perfusion 
method, to be relatively constant for all animals (38.8 1.1 %;
n=25, range: 26.6 % to 47.7 %) . The mean group values were very 
consistent (see diagram 28, table 7). 
group I: 42. 4 ^  3. 7 %
II: 38.4 ■£ 1.6 %
III: 39.3 £  2.5 %
IV: 36. 7 i  2.4 %
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Infarct size
Expressed as a % of the area at risk (% I/AaR) the relative infarct 
sizes (T.T.C. unstained) at 6 hours were found to be: 
group I: 48.3 dz 7.7 %
II: 25.3 i. 3.7 % (p < 0.05 vs group I)
III: 21.3 “t. 6.5 % (p < 0.05 vs group I)
IV: 17.1 3.5 % (p < 0.01 vs group I)
Thus r-scu-PA treatment was associated with a reduction in relative 
infarct size compared with the control animals (group I) in which 
LCX recanalisation was not achieved. Taprostene cotreatment showed 
a dose-related trend to further decrease the proportion of myocar­
dium staining as necrotic at 6 hours (diagram 28, table 7) . This 
possible further reduction in acute infarct size by taprostene was 
not statistically significant however when compared to the r-scu-PA- 
alone treated group. The taprostene/r-scu-PA combination treatment 
groups (groups III and IV) exhibited, like the r-scu-PA alone group 
(group II), statistically smaller infarcts than the untreated group 
(group I) . The restoration of LCX artery patency after 112 to 127 
min (group II) was associated with a major (48 %) reduction in in­
farct size. Taprostene under the conditions tested, starting late 
in the ischaemia phase, had a minor effect, if any, on the TTC 
stained morphometric acute infarct size, beyond that of r-scuPA 
alone. The magnitude of this additional effect however would re­
quire larger numbers per treatment group to be employed in order to 
demonstrate statistical significance.
-  108 -
3.3.2 Haemostatic parameters/LCX Doa/Results 
Pla smin ocren /LCX/Doa
All dogs, by definition, had a plasma plasminogen level of 100 % 
after surgical preparation and prior to ischaemia and infusion (s) . 
The r-scu-PA untreated dogs (group I) retained their baseline
plasminogen levels over the 6 hours of thrombotic occlusion of the 
LCX (range of minima: 91 - 95 %) . In the other groups, which were 
all treated with r-scu-PA, an initial plasminogen nadir was observed 
between 30 minutes and 1 hour after completing the r-scu-PA
infusion (range of minima for each group: group II: 61 - 105 %,
group III: 63 - 88 %, group IV: 56 - 96 %) . Taprostene
coadministration, at the lower dose, with r-scu-PA singificantly (p 
< 0.02, t-test, 2-tail) lowered the plasminogen levels compared
with r-scu-PA untreated controls (group I) although the r-scu-PA
alone treated group (group II) failed to differ significantly from 
the untreated group (group I). The high dose taprostene plus 
r-scu-PA group (group IV) showed marginally lesser depression of 
relative plasminogen levels than the low dose taprostene plus 
r-scu-PA group (group III) and again a significant depression of 
plasminogen compared to controls (group I) (diagram 31, table 9) .
g^-Antiolasmin (AP) /LCX/Doa
Again, by definition, the pretreatment AP activity for each animal 
was 100 %. In the control group (group I) the activity remained 
unchanged over the 6 hour period (range of minimum AP activity
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observed: 91 - 94 % of baseline) . In common with the plasminogen 
assays, the greatest indirect evidence of plasmin formation was in 
the low dose taprostene plus r-scu-PA group (group III) (p < 0.02, 
t-test, 2-tail vs. control group I). This was evident at multiple 
time points after completing the infusion of r-scu-PA. In the 
r-scu-PA alone treated group (group II) AP activities were 
significantly reduced at t = 5 h and t - 6 h (range of nadirs for 
each animal in this group: 52 - 105 % of baseline value) but this 
was to a lesser extent than in group III. Unexpectedly, high dose 
taprostene plus r-scu-PA infusions did not cause even greater AP 
activity depletion than in the low dose taprostene/r-scu-PA group 
(group III), but the effect of AP activity depletion seemed to have 
been marginally attenuated implying reduced systemic plasmin 
generation at the higher taprostene dose level. The range of 
minimum AP activity observed was from 59 - 88% in group III and 
from 66 to 98% in group IV (% of baseline AP activity for each 
animal) (diagram 30, table 9).
Plasma fibrinogen/LCX/Doa
The mean initial values of plasma fibrinogen (mg/100 ml) were 121£l 
9, 114 H  5, 136 £  17 and 125 ^  12 (x ±  S.E.M.) for groups I to IV, 
respectively. In individual animals, plasma fibrinogen concentra­
tions varied from 88.5mg/100 ml to one animal with an extremely 
high level of 313mg/100 ml fibrinogen. This animal can be identi­
fied in table 7  as being the group III animal with a peak CK value 
of 337 U/l. Infusion of r-scu-PA alone, or in combination with 
taprostene, did not alter the mean plasma fibrinogen levels
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significantly when compared with the baseline values of the same 
group or when corresponding time points were compared between 
different treatment groups.
The range of minimum plasma fibrinogen concentrations (nadirs, ex­
pressed as a percent of the baseline value for each animal) was as 
follows for each of the groups: 
group I : 75 - 98 %
group II : 70 -  89 %
group III: 61 - 84 %
group IV : 70 - 94 %.
The mean plasma fibrinogen concentrations are given in diagram 32, 
table 9 shows the % fibrinogen (% of each dog's baseline (PIV) 
value) to enable relative changes in fibrinogen levels between 
groups to be visualized.
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3.2.5 Plasma CK activitv/LCX Dog/Results
Plasma CK activity following surgical preparation and immediately 
before LCX thrombus formation was < 50 U/l for all dogs (individual 
range 9.5 to 40.0 U/l). In all groups a gradual increase in plasma 
CK activity was observed during the LCX occlusion period. In the 
continuous occlusion group (group I) the plasma CK activity 
increased slowly and linearly over the 6 hour experimental 
(ischaemic) period, resulting in a group mean value ( i  S.E.M.) of
766 ^  87 U/l at 6 h (range 557 - 978 U/l) . In animals treated with
r-scu-PA alone (group II) a rapid rise in CK activity coincided 
with the onset of reperfusion. This rate of rise was almost 
constant over the observed period, and a mean CK activity of 1990 
242 U/l (x —  S.E.M., range: 1220 to 2945 U/l) was recorded at the 
end of the experiment. High dose taprostene infusion (0.215 
fig*kg **min ^ , group IV) reduced the rate of rise of CK activity 
following r-scu-PA-induced recanalization when compared with group 
II, resulting in a mean CK activity of 750 dl 123 U/l (x ^  S.E.M, 
range: 399 to 1252 U/ml) at the end of the experiment. This was
significantly lower than the mean value of plasma CK activity of
the r-scu-PA alone treated group (group II) (p < 0.02, Student's 
t-test, 2-tail) . The lower dose taprostene infusion in group III 
showed no significant decrease in CK release compared to group II.
A lesser effect of this lower dose of taprostene to attenuate the 
rise in CK activity may have been masked by extraordinarily high 
CK activity in one member of the group (6 h value: 7152 U/l, other 
values in this group ranged from 337 to 1641 U/l at this time) 
(diagram 33, table 9).
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Summary of Dog LCX thrombolysis experiments
To summarize the results of the LCX experiments, r-scuPA infusion 
(20 fig-kg \ min 30 min duration) led to recanalization of the 
LCX in all animals treated (table 7). Taprostene coadministration 
with r-scuPA did not markedly affect the rate of recanalization. 
Taprostene coadministration also did not cause a significant change 
in any of the following haemodynamic parameters when compared to 
r-scuPA alone: left ventricular peak pressure, mean arterial blood 
pressure, heart rate and rate x pressure product (diagrams 23, 24,
26, 27). High dose taprostene cotreatment (0.215 fig, kg \ min 1, 2
hour infusion) caused a significant decrease in ventricular 
contractility after completion of the infusions compared to the
r-scuPA alone group (table 5, diagram 25). Also in the high dose
taprostene group a significant reduction in the frequency of 
ventricular ectopic beats was recorded (table 8, diagram 29) . As in 
the LAD experiments thrombolytic recanalization reduced the infarct 
size in these experiment from 48.3 i  7.7% (I/AaR) in the 6 h throm­
botic occlusion group to 25.3 ^  3.7% in the r-scuPA alone group 
(table 7, diagram 28) . Taprostene cotreatment starting after 90 
minutes of LCX occlusion produced a trend to a further reduction of 
infarct sizes as measured by left ventricular planimetry and a 
significant decrease in the maximum plasma CK activity after reper­
fusion in the higher dose group (group IV) (diagram 33) . Evidence 
of slight systemic plasmin generation was seen in most groups 
treated with r-scuPA. Low dose but not high dose taprostene may 
have enhanced this effect as shown by the changes in plasma levels 
of CL£- antiplasmin and plasminogen (diagram 30 and 31). Fibrinogen
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concentrations were not affected by any of the treatments, in 
contrast to the LAD experiments where a higher total dose of 
r-scuPA caused significant decrease (diagram 32) .
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Diagram 23
Diagram 23: Left ventricular peak pressure (LVPP) [mm Hg]
(x i  S.E.M.). Dogs underwent LCX thrombosis starting at t = Oh 
followed by: group I vehicle infusion, group II r-scu-PA infusion, 
groups III and IV r-scu-PA infusion together with low and high dose 
taprostene infusions respectively. No significant difference 
(p>0.05) was observed (2-tailed t-test, unpaired data).
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Diagrams 24 and 25: Mean arterial blood pressure £MABP) [mm Hg] and 
left ventricular contractility (+dP/dt) [mm Hg s J, fx t S.E.M.). 
Dogs underwent LCX thrombosis starting at t - Oh followed by: group 
I vehicle infusion, group II r-scu-PA infusionf groups III and IV 
r-scu-PA infusion together with low and high dose taprostene in­
fusions respectively. * = p<0.05, ** = p<0.01, 2-tailed t-testf
unpaired data, versus control group (LCX thrombosis, vehicle 
infusions).
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Diagrams 26 and 27: Heart rate (HR) [beats/min] and heart rate x 
mean arterial blood pressure [mm Hg/min] (x ±  S.E.M.).
Dogs underwent LCX thrombosis starting at t = Oh followed by: group
I vehicle infusion, group II r-scu-PA infusion, groups III and IV 
r-scu-PA infusion together with low and high dose taprostene in­
fusions respectively. No significant difference in these 2 
variables was found between any 2 groups at corresponding times 
(p>0.05, 2-tailed t-test, unpaired data).
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L V  PLANIM ETRY/Dog LCX Throm bosis 






















INFARCT SIZE Dog LCX Throm bolysis 
(% o f  LEFT VENTRICLE)
INFARCT (as %  o f AaR)






- 20 20 20 r-*cu -P A
- - 0.1 0215 Taproittno
iM -k j*1
» p <  0.05 * i  Control
30
- 20 20 20 scuPA (p g /kg xm in l
- - 0.1 0,215 T a p ro s te n e lfjg /k g x m in )
Diagram 28
Diagram 28: Left ventricular planimetry to measure: (top left) the
anatomic area of myocardium "at risk" expressed as % of left 
ventricle (%AaR/LV) ; (top right) the infarct size at 6 hours as %
of the area at risk (% I/AaR) and (below) - the infarct size as % 
of left ventricle (% I/LV) . Lines represent mean ± S.E.M.,
individual dogs shown as dots. * = p<0.05, ** p<0.01, 2-tailed
t-test, unpaired data versus control group which received no active 
drug.
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ARRHYTHMIAS/Oog LCX Thrombosis
O  Control (n « 41 
■  r-s c u -P A  120 JJg-kg'l •m in', . n *  9)
(3 r -s e u -P A  ♦ Taprostene 10.1 > jg-kg'1-m in'1, n * 6; 
H  r-s c u -P A  ♦ Taprostene 10.215 jig-kg^ -mm"'. n = 61
o
O. rx 






3 - 4 4 -  51 - 1 7  1 7 - 3 5 -  i0 - 1-1 - 0
TIME INTERVALS (HRS)
*  p < 0.05 vs r-s c u -P A  alone
Diagram 29
Diagram 29: Arrhythmic activity [number of ectopic beats per 20 
beat sequence] over each of the time intervals defined on the 
x-axis, (x •£ S.E.M.). Dogs underwent LCX thrombosis at t =  Oh 
followed by treatment started at t=1.5h of : group I vehicle, II: 
r-scu_PA (30 min infusion), III and IV r-scu-PA as for II with low 
(III) and high (IV) dose taprostene infusion (2 h duration) .
* =  p<0.05, 2-tailed t-test, unpaired data, versus group II
(r-scu-PA alone, blacked out columns).
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%  ANTIPLASMIN (AP) /  Dog LCX Thrombosis
110 -
oConfrol (n=4)
• r -s c u -P A  I20^g-kg*1-m in'1. n=9J
* r-scu -P A  ♦ Taprostene 
(01 >ig*kg-1 * rain"1. n=6)
■ r-scu -P A  * Taprostene
Iin.lrn-'. min-'
100 -
• / .  AP
90 -
80 -
r - scu-P A
Taprostene
3 40 2 51 6
TIME (HRS)
Diagram 30
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A r-scu-PA ♦ Taprostene 
10.1 pg kg‘ , min*1. n=61 
■ r-scu-PA ♦ Taprostene 
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TIME (HRS)
Diagram 31
Diagrams 30 and 31: Plasma a  -antiplasmin activity (AP) and
plasminogen activity (both as % or preischaemic baseline value) . 
Dogs underwent LCX thrombosis starting at t =  Oh followed by: group 
I vehicle infusion, group II r-scu-PA infusion, groups III and IV 
r-scu-PA infusion together with low and high dose taprostene in­
fusions respectively (x ^  S.E.M.).
* = p<0.05f ** ~ p<0.01, 2-tailed t-test, unpaired data, v e r s u s  
group I (vehicle controls: hollow circles) .
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FIBRINOGEN IN PLASMA (as %  of pretreatm enf value)/Dog LCX Thrombosis
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CREATINE KINASE (CK) IN PLASMA/Dog LCX Thrombosis
o  Control (n *  4 )
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1500 •




Diagrams 32 and 33: Plasma fibrinogen concentration [% of
preischaemic baseline value] and creatine kinase activity (CK) 
[U/l]/ both in plasma. Dogs underwent LCX thrombosis starting at t 
= Oh followed by: group I vehicle infusion, group II r-scu-PA
infusion, groups III and IV r-scu-PA infusion together with low and 
high dose taprostene infusions respectively (x t- S.E.M.).
* = p<0.05, ** = p < 0.01, 2-tailed t-test, unpaired data, versus
group II (r-scu-PA alone: blacked out circles).




PA TAP n PIV 0 0.25 0.5 1 1.5 2
Time [h] 
2.25 2.5 2.75 3 3.5 4 4.5 5 5.5 6
LVPP
I 0 0 4 152 122 110 110 110 106 104 102 101 105 104 97 88 89 88 93 76
(8) (8) (15) (16) (16) (13) (13) (12) (13) (14) (14) (18) (17) (18) (17) (17) (11)
II 20 0 9 148 140 133 132 129 127 122 122 118 115 116 111 108 110 108 103 100
(7) (7) (5) (6) (6) (5) (5) (5) (4) (3) (6) (6) (7) (6) (6) (6) (5)
III 20 0.1 6 139 123 125 126 125 127 122 124 120 118 116 112 107 106 101 103 105
(6) (8) (5) (6) (4) (4) (6) (6) (5) (10) (7) (8) (7) (6) (10) (9) (7)
IV 20 0.215 6 137 122 117 119 126 127 120 113 108 101 101 89 91 93 87 87 86
(10) (4) (4) (7) (5) (7) (5) (6) (6) (9) (7) (6) (7) (8) (9) (9) (8)
MABP
I 0 0 4 153 117 112 118 123 123 126 119 125 128 127 117 120 122 110 113 105
(5) (9) (4) (10) (11) (13) (10) (9) (7) (8) (7) (8) (10) (10) (11) (7) (11)
II 20 0 9 147 128 128 129 125 123 120 120 118 119 119 116 109 112 100 103 103
(7) (4) (5) (5) (5) (5) (4) (5) (4) (5) (7) (6) (6) (7) (7) (6) (6)
III 20 0.1 6 135 112 115 115 120 123 116 114 115 112 110 108 97 98 94 92 93
(11) (9) (9) (7) (7) (7) (8) (9) (10) (12) (11) (13) (11) (11) (13) (12) (12)
IV 20 0.215 6 138 118 119 114 120 124 119 114 110 105 112 104 106 100 93 98 96
(11) (6) (9) (11) (8) (9) (9) (9) (10) (13) (14) (14) (13) (13) (13) (13) (12)
table 4: HAEMODYNAMIC VARIABLES / LVPP and MABP / Dog LCX
Dogs were subjected to 6 h LCX thrombotic occlusion (group I), or infusions, starting 1.5 h after LCX thrombosis, of r-scu-PA (30 min duration:
groups II, III and IV) together with taprostene (TAP) infusion (t = 1.5 h to t = 3.5 h) at low dose (group III), high dose (group IV) or taprostene vehicle
(group II). LVPP = left ventricular peak pressure (mm Hg); MABP = mean arterial blood pressure (mm Hg); PIV = preischaemic value.
All values arithmetic mean + standard error (x ± S.E.M.). No intergroup difference (p < 0.05, Student's t-test, 2-tail) was observed in either variable.
VENTRICULAR CONTRACTILITY / Dog Infarct LCX
[pg/kg/iin] +dP/dt [mm Hg/s]
Time [h]
gp r-scu-PA taprostene n PIV 0 0.25 0.5 1 1.5 2 2.25 2.5 2.75 3 3.5 4 4.5 5 5.5 6
i 0 0 4 2050 1275 1050 1225 1250 1225 1125 1050 1075 1075 1100 1000 950 925 925 1000 775
(132) (165) (119) (165) (144) (125) (131) (126) (144) (149) (147) (163) (166) (175) (155) (147) (131)
ii 20 0 9 1567 1356 1500 1522 1400 1333 1167 1178 1089 1144 1089 1050 956 1017 1000 967 933
(121) (84) (115) (115) (96) (88) (88) (82) (65) (71) (101) (93) (77) (78) (55) (41) (29)
h i 20 0.1 6 1600 1133 1367 1342 1333 1217 1133 1108 1067 1067 1033 1017 917 883 825 825 850
(115) (102) (99) (100) (109) (95) (88) (95) (76) (131) (112) (111) (95) (79) (73) (96) (92)
IV 20 0.215 6 1400 4 1033 1100 1100 1133 1067 1017 942 967 900 917 783 4 817 783 4 70044 68344 68344
(121) (84) (86) (106) (95) (71) (91) (84) (76) (93) (114) (40) (60) (60) (97) (70) (70)
Table 5: VENTRICULAR CONTRACTILITY / Dog Infarct LCX
Kean maxioun rate of increase in ventricular pressure (+dP/dt) in dogs undergoing left circumflex coronary artery (LCX) thrombosis.
Dogs were grouped (I - IV) according to drug treatment above: taprostene was infused for 2 hours starting at t = 1.5 h at 2 dose levels (groups III and IV) 
or substituted with placebo (group II). r-scu-PA was infused in groups II, III and IV for 30 lin starting at t = 1.5 h.
PIV = preischaeiic baseline value.
x + S.E.M. ♦ = p<0.05; ♦♦ = p<0.02 vs. group I ; Student's t-test, 2-tail, unpaired data.




PA TAP n PIV 0 0.25 0.5 1 1.5 2
Time [h] 
2.25 2.5 2.75 3 3.5 4 4.5 5 5.5 6
HR I 0 0 4 195 199 184 191 188 188 180 184 184 184 188 191 195 191 188 195 191
(11) (7) (4) (4) (4) (4) (6) (4) (4) (7) (10) (9) (11) (9) (8) (6) (4)
II 20 0 9 193 188 190 192 193 185 180 185 190 188 188 190 190 203 203 208 209
(7) (7) (9) (9) (8) (9) (6) (6) (6) (5) (7) (5) (4) (8) (6) (7) (7)
III 20 0.1 6 200 193 190 193 190 183 183 188 188 185 190 195 195 195 198 198 203
(9) (8) (10) (9) (9) (8) (9) (8) (11) (11) (10) (9) (9) (9) (9) (9) (7)
IV 20 0.215 6 198 183 178 183 185 183 183 183 185 185 188 190 193 193 193 193 193
(7) (6) (7) (6) (7) (9) (9) (9) (10) (13) (13) (9) (11) (11) (11) (10) (10)
MABPxHR
I 0 0 4 30.0 23.4 20.6 22.7 23.3 23.3 22.9 22.0 23.1 23.7 24.1 22.7 23.8 23.5 20.9 22.0 19.9
(2.5) (2.5) (1.1) (1.9) (1.2) (2.9) (2.4) (2.2) (1.8) (2.1) (2.6) (2.5) (3.1) (3.0) (2.8) (1.8) (1.6)
II 20 0 9 28.1 24.3 24.3 25.0 24.4 22.9 21.6 22.3 22.4 22.4 22.6 22.0 20.8 22.9 20.4 21.3 21.5
(1.0) (1.4) (1.4) (1.8) (1.8) (1.7) (1.1) (1.3) (1.1) (1.2) (1.6) (1.4) (1.2) (1.6) (1.6) (1.3) (1.4)
III 20 0.1 6 27.2 21.8 19.9 22.4 23.1 22.7 21.4 21.7 21.9 21.5 21.0 21.1 19.0 19.2 18.5 18.1 18.8
(3.1) (2.7) (2.4) (2.0) (2.2) (2.2) (2.4) (2.5) (2.9) (3.2) (3.3) (3.0) (2.5) (2.3) (2.5) (2.4) (2.5)
IV 20 0.215 6 27.4 21.6 21.1 21.0 22.2 22.7 21.9 21.0 20.5 19.9 21.7 20.1 20.8 19.8 18.6 19.3 19.1
(2.8) (1.6) (2.0) (2.2) (2.0) (2.1) (2.1) (2.1) (2.5) (3.0) (3.6) (3.3) (3.3) (3.2) (3.1) (2.8) (2.8)
Table 6: HAEMODYNAMIC VARIABLES / HR and MABP x HR / Dog / LCX
Dogs were subjected to 6 h LCX thrombotic occlusion (group I), or thrombotic occlusion followed by infusions, starting at t = 1.5 h, of r-scu-PA (30 ain duration, 
groups II, III and IV) together with taprostene (TAP) (2 h infusion) at low dose (group III), high dose (group IV) or taprostene vehicle (group II). HR = heart rate 
(beats/min). MABP x HR = heart rate pressure product (aetres Hg/min) as an estimate of ayocardial work and hence energy demand.
All values arithmetic mean + standard error (x + S.E.M.) No statistical difference was observed between groups: Student's t-test, 2-tail, unpaired data.
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i 729 (6) 23.1 50.2 46.0 , 15.3 > 360
978 (6) 30.1 68.1 44.2 m 14.0 > 360
557 (6) 20.6 43.2 47.7 m 18.0 > 360
799 (6) 9.9 31.5 31.4 f 16.0 > 360
20.9+4.2 48.3+7.7 42.3+3.7 (75) 15.8+0.8
_ ---------  |
1j
n 2934 (6) 20.6 43.2 47.7 m 16.7 271 2903 (6) 3.4 8.4 40.5 f 16.7 20
2945 (6) 12.1 32.7 37.0 f 19.8 22
1425 (6) 6.5 17.5 37.1 i 15.5 141 1294 (6) 14.5 35.9 40.4 m 17.5 27
1862 (6) 5.8 18.0 32.2 m 17.6 251 1483 (6) 10.6 32.0 33.1 m 17.0 20
1766 (6) 7.1 17.3 40.9 f 16.0 31
| 1380 (6) 8.2 22.6 36.3 i 17.2 12
9.9+1.8 25.3+3.7 * 3 M + L 6
L
(67) 17.1+0.4 22.0+2.1
! h i 7152 (6) 20.8 44.6 46.7 f 17.7 25
i 1641 (6) 8.9 21.8 41.0 f 19.8 17
i 547 (6) 2.9 8.3 35.2 i 15.0 21
337 (6) 4.2 12.2 34.1 a 18.3 14
1485 (6) 16.5 35.7 46.1 m 13.2 17
i 337 (6) !.7 | 5.2 33.0 m 16.5 15
9.2+3.2 21.3+6.5 * 3974+275 (67) 17.6+0.7 18.2+1.7
IV 399 (6) 5.7 14.4 39.5 m 15.1
12673 (5) 5.1 19.2 26.3 m 18.0 27
1 1809 (5) 8.5 25.2 33.4 m 16.0 20
631 (6) 2.6 6.7 38.9 m 13.6 22
631 (6) 3.8 9.0 42.2 m 13.8 22
1
946 (6) 11.0 27.9 39.4 f 19.0
1
i 1
6.2+lj" 1771+375 * * 36.6+2.4 (84) 15.9+0.9 20.2+2.0 j
table 7: BASELINE CHARACTERISTICS AND INFARCT PARAMETERS / Dog Infarct LCX
Showing individual variables (weight, sex} and infarct parameters (size relative to left ventricle 
(I/LV), to risk area (I/AaR), and proportion of LV "at risk" (AaR/LV) and maximum observed plasma 
creatine kinase activity (in brackets: time of observed maximum: hours after initial occlusion) 
as well as the thrombolysis time (= time from start of infusions to first LCX reflow).
Gp I: 6 h LCX thrombotic occlusion; r-scu-PA infused 90 min after LCX thrombosis in gps II, III and
IV. Gps III and IV: low and high dose taprostene cotreatment respectively.
Mean of group values + S.E.M.
*p<0.05, ** p<0.01 versus group I, Student's t-test, 2-tail, unpaired data
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ARRHYTHMIA / Dog LCX Infarct
TIME INTERVAL [h]
gp n - PIV 0 - 1 1 - 1 . 7 1 . 7 - 3 3 - 4 4 - 5 5 - 6
i 4 X 0 0.6 1.7 0.1 0.3 1.8 3.5
S.E.M. - (0.4) (1.3) (0.1) (0.1) (0.8) (1.4)
range 0 0-5 0-20 0-1 0-2 . 0-8 0-17
median 0 0 0 0 0 0 3
n 9 X 0 1.4 1.4 8.0 7.3 7.8
1 | - |- -| T-. ■ - - - 
8.8
S.E.M. - (0.4) (0.3) (1.1) (1.0) (1.1) (1.2)
range 0 0-6 0-8 0-20 0-20 0-20 0-20
median 0 1 0 6 7 6 7
h i 6 X 0 0.8 0.9 3.9 4.7 4.8 6.6
S.E.M. - (0.3) (0.3) (1.2) (1.2) (1.3) (1.3)
1 ! 1 range 0 0-7 0-5 0-18 0-18 0-18 0-181
1
median 0 0 0 2 2 2 5
IV 6 X 0 0.5 0.5 6.3 3.4* 3.8* 4.5*





0 4 1 3 4
table 8: ARRHYTHMIA / Dog LCX Infarct
Mean (+ S.E.M), aedian and range of frequency of ventricular ectopic beats (per 20 beats, 
recorded over 4 periods/interval/dog), in dogs undergoing LCX thro»botic occlusion at t = 0, 
followed by infusions starting at t = 1.5 h of vehicle (group I), r-scu-PA (groups II, III 
and IV) and taprostene (vehicle: gp II, low dose: gp III, high dose: gp IV; 2 h duration).
* = p < 0.05 vs gp II, 2-tailed t-test
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2.5 3 4 5 6
AP
I 0 0 4 100 99 98 95 100 98 98 105 105
(1) (3) (2) (3) (3) (2) (4) (2)
II 20 0 9 100 97 102 95 93 83 87 82* 82*
(3) (5) (6) (7) (7) (8) (5) (6)
III 20 0.1 6 100 98 97 95 84** 78** 88* 81** 82**
(1) (1) (2) (2) (5) (3) (3) (4)
IV 20 0.215 6 100 100 102 99 93 89 93 94 92**
j (3) (2) (4) (3) (5) (4) (6) (3)
PLG 1
I 0 0 4 100 99 95 97 97 97 98 100 98
(1) (2) (1) (1) (1) (2) (4) (3)
II 20 0 9 100 98 105 97 92 86 97 86 82
(3) (4) (6) (8) (6) (5) (5) (6)
III 20 0.1 6 100 100 101 99 94 86** 91 84 78**
| (3) (3) (2) (4) (2) (8) (5) (4)
IV 20 0.215 6 100 97 97 99 97 89 97 94 87*
(3) (3) (6) (6) (7) (2) (3) 13,
FIB 1
I 0 0 4 120.8 120.0 110.8 110.3 124.3 115.3 117.3 114.3 116.8
(8.8) (8.3) (7.2) (8.1) (11.8) (6.1) (7.8) (8.5) (8.0)
II 20 0 9 113.9 112.6 112.6 109.9 100.9 98.0 100.8 102.2 107.0
1 (5.2) (6.2) (5.9) (6.1) (5.6) (3.3) (4.8) (4.4) (6.7)
III 20 0.1 6 165.7 159.0 161.8 162.8 154.5 144.7 139.8 150.2 153.71! (32.4) (32.9) (32.9) (40.5) (37.1) (35.1) (33.6) (34.6) (31.4)
IV 20 0.215 6 125.2 117.2 120.7 119.5 115.2 108.3 114.5 112.2 113.5
(11.5) (9.9) (9.7) (11.8) (10.5) (11.6) (9.3) (8.8) (10.1)
CK 1 iI
1i
I 0 0 4 26 37 77 112 180 237 416 617 766
1 (5) (4) (4) (15) (22) (9) (55) (24) (87)
11 20 0 9 22 30 97 176 941 1055 1364 1571 1990
(4) (5) (16) (39) (362) (221) (259) (260) (242)
III 20 0.1 6 26 29 130 184 582 754 1436 1718 1917
(5) (6) (59) (58) (192) (258) (787) (981) (1073)
IV 20 0.215 6 19 28 59 145 306 455 5654 7714 75044
(4) (4) (8) (34) (69) (144) (85) (221) (123)
table 9: PLASMA ASSAYS / Dog Infarct LCX
Dogs were subjected to 6 h stable LCX thrombosis (group I), or infusions, starting at t = 1.5 h after
thrombosis, of r-scu-PA (30 tin duration, groups II, III and IV) together with taprostene (TAP)
(2 h infusion) low dose (group III), high dose (group IV) or taprostene vehicle (group II).
A?= a-2-antiplasmin activity; PLG= plasminogen activity (both as % of preischaemic value (PIV)),
FI3= fibrinogen concentration (mg/lOOml), CX=_creatine kinase activity (0/1).
All values arithmetic mean ± standard error (x t S.E.M.)
* = p<0.05, ** = p<0.02; Student's t-test, 2-tail, unpaired data, versus group I
♦ = p<0.05, 4? = p<0.02; Student's t-test, 2-tail, unpaired data, versus group II
-  127 -
3.3 Rabbit carotid artery thrombosis experiments/Results
The experimental protocol is represented diagrammatically (diagram 
13, "Methods" section)
3.3.1 Haemodvnamic parameters/Rabbit
Mean arterial blood pressure (MABP)/Rabbit
The 4 group mean MABP values were similar prior to treatment (-20 
and -10 min) with the test compounds. During this interval the 
group mean values ranged from 68.8 dl 4.8 mm Hg (x £  S.E.M.) (-10
min, randomized group later to receive taprostene) to 79.8 dz 1.3 mm 
Hg (-20 min, later to receive r-scu-PA) . Before starting the infu­
sions, the individual MABP values ranged from 54.3 to 82.6 mm Hg. 
At t = -10 min the infusions were started. In the 10 minutes there­
after minimal change in MABP was observed. The dose of taprostene 
(0.215 fig*kg *“min *) had been chosen from preliminary experiments 
as the highest dose in a series of stepwise increments not exerting 
a significant hypotensive effect in pentobarbitone anaesthetized 
rabbits (n = 5) . The stenosis was implanted into the carotid artery 
at t - 0 min, immediately prior to this no significant difference 
between the group mean MABP values (x S.E.M.) was recorded (range 
of group means ^  S.E.M.: 69.9 df.3.8 mm Hg in the taprostene treated 
group to 80.8 i  2.6 mm Hg in the r-scu-PA treated group).
The presence of the unilateral stenosis had no major effect on the 
MABP in any of the groups, neither did the infusion of taprostene 
(0.215 pg'kg min * i.v. 100 min duration, starting 10 min before 
stenosis, grdup III, n = 5) or the combination of taprostene and
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r-scu-PA infusions (group IV, n =  5) . The marginally higher MABP 
values in the r-scu-PA group (group II) became significantly dif­
ferent to the r-scu-PA untreated group values (p < 0.02, t-test, 
2-tail vs. group I) after completing the infusion. The mean MABP 
values in the r-scu-PA group were consistently higher for the du­
ration of the experiment, including the pretreatment phase and is 
therefore not definitely attributable to an effect of this com­
pound. In summary the mean arterial blood pressure was not affected 
by the following factors: carotid artery stenosis, taprostene in­
fusion and taprostene and r-scu-PA combination treatment. r-scu-PA 
infusion may increase the blood pressure marginally in this model 
(table 10, diagram 34) .
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Carotid artery flow rate/Rabbit
The normal pretreatment carotid artery flow rates (ml*min **kg * 
bodyweight) showed moderate variation: the group means ( £. SEM)
ranged from 7.5 db. 0.8 (group III) to 10.6 iL 1.2 ml*min **kg * (group 
IV) and the range of individual values was between 4.7 and 
15.7 ml*min ^*kg ^ at this time point (-20 min). After 10 minutes 
equilibration the group flow rates showed little change and the 
infusions were started. Implantation of the stenosis (t - 0 min) 
was accompanied by a marked fall in the flow rates. Here the group 
mean values ( *  S.E.M) were 5.3 0.7 ml*min **kg 5.4 4l 0.8
ml*min **kg 5.8 ^  0.9 ml*min **kg * and 7.2 1.1 ml*min **kg ^
for the control-, taprostene-, r-scu-PA- and taprostene plus 
r-scu-PA-treated groups (I - IV) respectively (diagram 35) .
This equated in individual animals to a 30 - 50% reduction compared 
with normal non-stenotic flow. In the control rabbits the mean flow 
rate decreased dramatically; 1 of the 6 animals occluded within 5 
minutes, 4 within 10 minutes and 5 within 30 minutes. Spontaneous 
reflow and reocclusion occured in some of these animals but was 
relatively infrequent as occlusion tended to predominate (diagram 
37). One animal showed subtotal (1.1 ml/min x kg) occlusion at 15 
min followed however by a slow increase in flow rate and subsequent 
reduction.
The rabbits treated with r-scu-PA (21.5 pg*kg **min * i.v. 40 min 
duration, starting 10 min prior to stenosis, group II, n = 5) 
showed a significantly higher stenotic flow rate compared with the
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controls (p < 0.05, t - t e s t ,  2-tailed) at 10 and 15 min after
stenosis and approximately 30 min after discontinuing the r-scu-PA 
infusion (t =  60 min) the mean flow rate started to decline and 
continued to do so over the remaining 2 hour period approaching the 
control value (diagram 35, table 10). During the period of r-scu-PA 
infusion, and afterwards, total and subtotal occlusion occured. 
Spontaneous restoration or increase in the stenotic flow rate was 
observed more frequently here than in other treatment groups.
In a third group, taprostene infusion (0.215 pg*kg lmrnin * i.v., 
100 min duration, starting 10 min before stenosis, group III, n =  
5) caused the stenotic flow rate to be maintained over the 3 hour 
experimental period at approximately 50 % that of the prestenotic 
rate after an initial lower fall. However, due to much interanimal 
variation this was not statistically greater than the mean flow 
rate in the vehicle treated group until 150 and 180 min after 
introduction of stenosis. Interestingly, the taprostene infusion 
had been stopped prior to this time.
In group IV, rabbits (n - 5) were treated with both r-scu-PA and 
taprostene as in groups II and III. In these animals the fall in 
flow rate following stenosis was much attenuated compared to the 
separate treatment groups and more so compared to the vehicle- 
treated controls. The non-stenotic flow rate was maintained at 60 - 
80 % of the normal non-stenosic flow rate.
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The measurement of instantaneous flow rate as done above was accom­
panied by major drawbacks. In preliminary experiments to establish 
this model a "saw toothed" flow pattern was seen occasionally in 
some animals. This unstable cyclical flow pattern limits the value 
of flow rate data at fixed time points. For this reason a means of 
measuring the total volume of blood flow over certain intervals was 
developed; by electronically converting the flow-meter potential 
difference into counting rate, and then using a count rate/flow 
rate calibration curve, it was possible to determine the mean flow 
rate (adjusted for animal body weight) during the specified 
intervals (ml*min **kg * over the specified interval *= mean 
interval flow rate).
As only very mild fluctuations in flow were observed in all animals 
prior to stenosis implantation the interval mean flow rates were 
similar to the mean flow rates at fixed time points (-20 and -10 min) 
(compare diagrams 35 and 36) . The baseline mean carotid flow rates 
(interval -20 to -10 min) were subject to variation between animals 
(range 4.9 to 13.2 ml*kg **min *), but the group IV means were 
comparable with one another (diagram 36, table 11) . For the 
fraction of the infusion periods prior to stenosis (-10 to 0 min) 
the group means were also comparable and virtually unchanged, 
implying that the carotid flow rates were unaffected by r-scu-PA 
and taprostene alone and together, in the absence of an arterial 
stenosis.
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During the 15 minute period starting with the implantation of the 
stenosis, the interval mean flow rates were attenuated to different 
extents. Considering the group mean values, a ~ 90 % fall in the 
mean interval flow rate was seen in the vehicle treated group 
(group I) after stenosis. The mean value for this group remained at 
this level until decreasing towards the end of the 3 hour stenotic 
period (diagram 36, table 11) .
In the groups treated with either taprostene alone (group III) or 
r-scu-PA alone (group II) the mean interval flow rates did not fall 
to the same extent as in the vehicle treated group, either 
initially, or at any interval in the observation period. Stenosis 
caused an approximate 50 - 60 i attenuation of mean interval flow 
rates in both these groups during the first 15 min interval.
During the 30 min interval following c e s s a t i o n  o f  t h e  r - s c u - P A  
infusion (30 - 60 min) the flow rates were significantly increased 
above the corresponding control group mean values. After cessation 
of the r-scu-PA infusion, however, the flow rates decreased 
consistently with time.
In the taprostene-alone treated group, the flow rose slightly after 
an initial post-stenotic flow (40 % of non stenotic) to above 60 % 
of basal. In this group the flow was maintained at this level for 
the duration of the observation period, that is 90 minutes after 
stopping the taprostene infusion.
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Cyclical flow reduction (CFR)
Cyclical flow reductions are defined in the "Methods" section and 
recorded from the flow paper-trace. Prior to stenosis no cyclical 
flow reduction (CFR) was observed. The infusion of the test com­
pounds, starting 10 minutes before stenosis did not cause flow va­
riations (CFR) .
In the vehicle treated group, stenosis was accompanied by occlusion 
in most cases (see "Carotid artery flow rate"/Results) . Spontaneous 
increases in flow rate did occur but were infrequent (table 11
diagram 37) . r-scu-PA infusion (group II) led to a marked increase 
in the number of CFR events occuring. These were relatively evenly 
distributed between the members of the group and over the
experimental period of stenosis.
Infusion of taprostene together with r-scu-PA (group IV) totally 
abolished the CFR (p £  0.05, Chi squared test) seen with r-scu-PA 
alone except during the last 30 minute observation period (150 - 
180 min) when a total of 3 CFR events were seen in 2 of the 5 ani­
mals in the group. Taprostene, on its own (group III), also abo­
lished CFR (p £  0.05) compared to the r-scu-PA group except for 
during the initial 15 minute period after implantation of the ste­
nosis (diagram 36, table 11) .
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3.3.2 Haemostatic parameters/Rabbit 
Fibrinocren in plasma/Rabbit
Clottable fibrinogen was measured with an automated Clauss assay 
using human thrombin. The fibrinogen concentration in plasma imme­
diately prior to infusion of the test compounds (-10 min) showed 
extreme consistency in groups I - III (range of group means £  SEM - 
287 h  15 (gp I) to 301 ^  11 mg/dl (gp III)), whereas in the com­
bination treatment group (r-scu-PA + taprostene (gp IV)) a higher 
relative group mean fibrinogen level was observed (356 29 mg/dl)
prior to infusion. This was attributed to one rabbit in this group 
which had a consistently higher level of fibrinogen (462 mg/dl at 
-10 min and throughout the experiment) but the data was neverthe­
less included in the experimental results (diagram 38, table 12) . 
After 60, 120 and 180 minutes, the plasma fibrinogen values re­
mained virtually unchanged in all treatment groups when compared 
with the baseline values of the respective groups. Taprostene and 
r-scu-PA infusion, alone and together, therefore had no effect on 
clottable fibrinogen in plasma under these experimental conditions.
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Platelet aggregation/Rabbit
As this assay was included in the experimental protocol after the 
first few experiments had been completed, platelet assays were not 
performed for all animals.
Immediately prior to starting the infusions (t ** -10 min) of ta­
prostene and/or r-scu-PA and/or vehicle the % platelet aggregation 
after collagen stimulation in vitro was similar in all animals. End 
concentrations of 5 pg/ml collagen caused ~  7 5  % aggregation (range 
58 to 91 %; n - 1 7  animals) . Collagen at 2 pg/ml caused ~  40 % ag­
gregation (range 14 to 76%) at this time, and 1 pg/ml caused ap­
proximately 15 % aggregation (range 48 to 0%). Samples from 2 to 3 
of the 4 to 5 animals per group failed to respond to 1 pg/ml col­
lagen at t =  -10 min as it was a subthreshold concentration.
After 40 min of taprostene infusion (0.215 pg'kg min t ■* 30 
min) mean platelet aggregation was attenuated by 28 % after 5 pg/ml 
collagen stimulation compared to the vehicle group (diagram 39, 
table 12).
At this time (t — 30 min) there was seen a relative mean attenua­
tion of platelet aggregation of 50% at 2 pg/ml collagen compared to 
the vehicle group. The response to 1 pg/ml collagen was absent in 
all 4 taprostene treated animals but present in 2 of 4 vehicle 
group animals (62 and 17% aggregation respectively at the same time 
point (t =  30 min) . These inhibitory effects of taprostene failed 
to achieve statistical significance due to the small numbers of 
animals tested but the distinct trends are considered relevant 
however. Ninety minutes after termination of the taprostene
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infusion (t = 1 8 0  min) the mean % aggregation had risen again to 
that seen in the vehicle group 45%) after stimulation with 
5 pg/ml collagen (range in taprostene group: 0 to 84%, in vehicle 
group: 42 to 50%) . Thus during taprostene infusion the mean
aggregatory response was reduced compared to vehicle infusion and 
the threshold concentration of collagen required to produce 
aggregation may have been elevated. The aggregatory response 
recovered within 90 min of terminating the taprostene infusion 
(t = 180 min) (diagram 39, table 12).
Infusion of r-scu-PA alone (21.5 pg'kg **min 40 min duration) 
had no effect at all on the mean % aggregation compared to vehicle 
treated controls, after stimulation with 5 and 2 pg/ml collagen 
but the threshold concentration of collagen required to cause ag­
gregation may have been slightly raised by r-scu-PA. The mean % 
aggregation in vehicle and r-scu-PA treated animals was similar 150 
min after termination of the r-scu-PA infusion (t = 180 min). Thus 
platelets from r-scu-PA treated animals behaved similarly to those 
from vehicle treated animals apart from a possible slight increase 
in the collagen threshold concentration (diagram 39, table 12). 
Samples from 4 animals that received combined infusions of r-scu-PA 
and taprostene (composite of 2 infusion regimens) were available 
for the platelet assay. 40 minutes after starting both infusions 
together (t = 3 0  min) the effect of 5 pg/ml collagen on platelet 
aggregation was very similar to taprostene treatment alone, and the 
mean % attenuation compared to vehicle treatment is attributable 
therefore to taprostene alone.
In this combination r-scu-PA/taprostene group at t = 180 min the 
mean aggregation was 36 % lower than that seen in the taprostene
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alone group. In both groups, samples from 1 of the 4 animals did 
not respond to 5 pg/ml collagen, whereas 2 pg/ml caused aggregation 
in 1 of 4 taprostene group samples but none of 4 r-scu-PA/taprost­
ene group samples. The number of platelet rich plasma samples 
available for assay in this study was inadequate to provide 
refutable proof of a prolonged potentiating effect of r-scu-PA on 
taprostene inhibition of platelet aggregation, although there is 
limited evidence of this. Worthy of comment is the increase over 
time in the collagen concentration threshold causing aggregation 
and the decrease in maximum aggregation response in all groups 
(diagram 39) .
r-scuPA may not have a potentiating effect on the inhibition by 
taprostene of in vivo platelet aggregation after collagen 
stimulation under these conditions. Additionally, there was no evi­
dence of r-scu-PA-induced platelet hyperaggregability after 40 min 
of in vivo infusion and in vitro stimulation of platelet aggre­
gation with collagen. In contrast, a slight elevation of the colla­
gen threshold concentration required to produce platelet aggrega­
tion was observed, but this effect was common to the r-scuPA 
untreated groups as well.
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Summary of results from rabbit carotid artery stenosis experiments
To summarize the rabbit carotid artery stenosis experiments, in 
vehicle treated animals implantation of the unilateral stenosis 
caused thrombotic occlusion in the majority of animals, with very 
little spontaneous reopening. Treatment with a r-scuPA infusion 
(21.5 pg*kg \ min * for 40 min) temporarily increased the flow rate 
through the stenosis and delayed occlusion (diagram 35, 36, 37). 
Taprostene infusion at a non hypotensive dose (0.215 l±g»kg i min * 
for 100 min (diagram 34)) also increased the mean flow rate through 
the stenosis and delayed its occlusion. Combining infusions of 
taprostene and r-scu-PA caused a potentiated effect. Stenotic flow 
rate was maintained at a rate higher than in the separate treatment 
groups and no occlusions occurred over the observation period. 
Taprostene acted by attenuating the cyclical decreases in the 
carotid artery flow rate (diagram 37) reported to be caused by 
platelet aggregates, and in vitro collagen-induced platelet aggre­
gation showed a possible inhibitory effect of taprostene at this 
dose level although the number of animals studied was small 
(diagram 39) . Treatment with r-scuPA either alone or with 
taprostene did not exert an antithrombotic effect by degradation of 
circulating fibrinogen as in neither group was the concentration of 
fibrinogen (Clauss assay) changed after treatment (diagram 38). 
Cotreatment of taprostene with r-scuPA also completely abolished 
the cyclical flow variations seen in the r-scuPA alone group, an 
action attributed to inhibition of platelet aggregation by 
taprostene as seen again in the combined treatment group. Treatment 
with r-scuPA did not appear to either increase or decrease platelet
j
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aggregability as measured In vitro although a high frequency of 
cyclical flow variations through the stenosis was recorded (diagram 
37) possibly due to a continuous destabilization of the occlusive 
thrombus. There was a delayed trend to increased mean arterial 
p r e s s u r e  i n  t h i s  group (diagram 34).
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Diagrams 34 and 35: Mean arterial blood p^ressujre (MABP) [mm Hg] and 
mean carotid artery flow rate [ml. min . kg ] at specified time 
points. Rabbits with carotid artery stenoses, (onset t =  Oh) were 
treated, starting at t = -^10min,_^with: group I - vehicle (n=6) ,
II - scu-PA (21.5 pg J^g mjin , 30 min duration, n=5), III:
taprostene (0.215 pg kg min , 2h duration, n=5) or IV: combined 
infusions (taprostene and r-scu-PA each as above, n=5) (x £  
S.E.M. ).
* =  p<0.05, ** = p<0.02 vs group I, t-test, 2-tailed, unpaired data.
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Diagram 37
Diagrams 36 and 37:
TIME INTERVALS [min]
-1
kg 1]Mean interval flow rate [ml . m m  
(x -fc SEM) and frequency of cyclical flow reduction (CFR) (see 
"methods") both over the time inverals specified. Rabbits were 
treated as outlined in legend to tables 34 and 35, and methods.
* =  p<0.05, for flow rate (diagram 36): t-test, 2-tail, unpaired 
data v e r s u s  group I (controls: hollow circles); for CFR (diagram 
37): * = p<0.05, Chi squared test, versus group II (r-scu-PA alone: 
blacked out columns).
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Plasma Fibrinogen /  Rabbit Carotid A rte ry  Stenosis
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Diagram 39
Diagrams 38 and 39: Plasma fibrinogen concentrations [mg/dl] and in 
vitro collagen-induced aggregation in platelet-rich plasma [% of 
light transmission compared to platelet poor plasma, after collagen 
stimulation, Born aggregometer]. For diagram 38: x £  S.E.M.; 
diagram 39: x £  absolute range of values. Treatments are described 
in "methods". Fibrinogen levels were not altered by drug 
treatments.
HAEMODYNAMIC VARIABLES / Rabbit Carotid Artery Stenosis
gp
[pg/kg/min] 
r-scu-PA taprostene n - 20
J















MEAN ARTERIAL BLOOD PRESSURE (MABP) [mm Hg]
i 0 0 6 73.5 69.2 74.9 74.8 76.5 76.8 71.4 68.2 68.9 72.3 73.6 75.2
(6.5) (5.3) (5.5) (5.3) (3.1) (3.4) (3.3) (3.8) (2.7) (2.6) (2.7) (4.7)
ii 21.5 0 5 79.8 76.8 80.8 75.8 77.4 79.0 79.0 80.5 * 82.2** 85.4** 84.2** 85.1
(1.3) (1.1) (2.6) (2.1) (2.7) (3.0) (3.0) (3.1) (2.2) (2.6) (2.2) (2.4)
h i 0 0.215 5 70.6 68.8 69.9 65.9 65.0 65.7 67.7 63.8 66.8 67.4 68.6 67.6
(5.3) (4.8) (3.8) (5.1) (5.9) (5.4) (5.7) (5.2) (5.8) (5.5) (8.0) (6.2)
IV 21.5 0.215 5 76.1 71.3 69.5 69.3 68.7 67.3 71.3 69.0 68.5 69.1 74.1 78.0
(3.0) (3.7) (2.2) (3.6) (3.8) (4.5) (4.0) (2.2) (5.9) (2.2) (4.8) (4.7)
MEAN INSTANTANEOUS FLOW RATE [ml/min x kg]
i 0 0 6 10.6 10.22 5.3 2.0 0.3 0.2 1.0 1.0 0.9 1.2 0.4 0.2
(1.2) (1.6) (0.7) (1.0) (0.2) (0.1) (1.0) (1.0) (0.9) (0.9) (0.4) (0.2)
ii 21.5 0 5 8 J 8.5 5.8 3.7 3.7 * 3.4 * 4.1 4.2 3.3 3.4 2.6 1.7
(1.3) (1.2) (0.9) (1.1) (1.4) (1.2) (1.4) (1.1) (1.1) (1.1) (1.3) (1.3)
h i 0 0.215 5 7.5 7.4 5.4 2.8 2.1 * 2.5 3.9 4.0 4.0 3.9 4.0 * 4.0 *
(0.8) (0.7) (0.8) (0.9) (0.7) (1.3) (1.6) (1.6) (1.7) (1.6) (1.7) (1.7)
IV 21.5 0.215 5 8.4 7.8 7.2 5.5 * 5.8 * 6.4 * 6.5 * 6.3 * 5.9 * 6.7 * 6.5 * 5.1 *
(0.8) (1.0) (1.2) (0.5) (0.8) (1.3) (1.8) (1.6) (0.9) (1.6) (1.6) (1.7)
Table 10: HAEMODYNAMIC VARIABLES / Rabbit Carotid Artery Stenosis
Mean arterial blood pressure (MABP) [mm Hg] and mean instantaneous carotid artery flow rate [il/iin x kg body weight]. 
r-scu-PA was infused (gps II and IV) from -10 min to +30 min; taprostene was infused (gps III and IV) from -10 min to 
+ 90 min. The carotid artery was stenosed from t = 0 to t = 180 min.
* = p<0.05, ** = p<0.02 versus group I, Student's t-test, 2-tail, unpaired data.
HAEMODYNAMIC VARIABLES / Rabbit Carotid Artery Stenosis
[pg/kg/min] Time [»in] after start of stenosis
-20 -  -10r-scu-PA taprostene 90 - 120 120 - 150 1150 - 180
INTERVAL KEAN FLOW RATE [il/iin x kg]
(1 .1 ) (1.3) (1 .0)(1 .2 ) (0 .8) (1.2) (1 .0) (0 .6)
(1.4) (1 .0) (1 .1) (1 .2) (1.1) (1 .6) (0.9) (1.1)
.215III 2.9*
(0 .8 ) (0.9) (0.9) (1 .6) (2 .0) (1.5) (1.9) (1.9)
.215 5.5* 6.3* 6 .2* 6 .0* 6.5*
(1 .1 ) (1.3) (0.9) (1.7) (1 .8 ) (1.5) (1 .2) (1 .6 )




Table 11: HAEMODYNAMIC VARIABLES / Rabbit Carotid Artery Stenosis
Mean interval flow rate [ml/iin x kg body weight] over the intervals specified above and cyclical flow reductions 
(CFR) [total no. events/interval]. The stenosis was implanted at t = 0 for the duration of the experiment. 
r-scu-PA was infused (gps II and IV) from -10 min to +30 min; taprostene was infused (gps III and IV) from -10 min to 
+ 90 min.
jf = p(0.05 versus group II, Chi squared test 
* = p < 0.05 vs. group I, 2-tailed t-test unpaired data
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HAEMOSTATIC VARIABLES / Rabbit Carotid Artery Stenosis
gp i n f u s i o n  
( / j g * k g  • m i n - h
FIBRINOGEN [ m g / d l  p l a s m a ]
r - s c u -
PA
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( 1 3 )
2 9 5
( 1 0 )
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( 3 4 )
2 8 7  
( 1 4 )
2 8 8  
( 1 4 )
2 9 0
( 1 6 )
3 3 7
( 2 7 )
PLATELET AGGREGATION ,f%7
r - s c u ­
PA
TAP COLL
p g / m l
n
- 1 0  m i n +  3 0 m i n + 1 8 0  m i n
i 0 0 1 4 6 . 8 ( 6 . 8 ) 1 9 . 8 ( 1 4 .  7) 0
2 4 4 . 1 ( 7 . 3 ) 3 3 . 4 ( 1 7 . 2 ) 4 . 4  ( 3 . 0 )
5 7 3 . 5 ( 5 . 0 ) 6 0 . 5 ( 1 1 . 4 ) 4 7 . 0  ( 1 . 6 )
i i 2 1 . 5 0 1 5 1 6 . 1 ( 1 0 . 1 ) 6 . 9 ( 6 . 9 ) 0
2 4 2 . 2 ( 1 0 . 7 ) 3 4 . 1 ( 9 . 7 ) 2 . 5  ( 2 . 5 )
5 7 5 . 8 ( 6 . 0 ) 5 9 . 5 ( 4 . 5 . ) 4 9 . . 5  ( 1 2 . 2 )
h i 0 0 . 2 1 5 1 4 1 6 . 5 ( 1 0 . 9 ) (1 0
2 3 4 . 6 ( 8 . 4 ) 1 6 . 7 ( 1 0 . 1 ) 1.• 4  ( 1 . 4 )
5 7 1 . 3 ( 1 . 8 ) 4 3 . 4 ( 1 5 . 7 ) 4 2 . 2  ( 1 7 . 5 )
IV 2 1 . 5 0 . 2 1 5 1 4 1 9 . 8 ( 1 1 . 5 ) 6 . 0 ( 6 . 0 ) 0
2 4 5 . 6 ( 1 2 . 0 ) 1 8 . 1 ( 1 1 . 2 ) 0
5 7 3 . 9 ( 2 . 0 ) 4 6 . 1 ( 1 6 . 0 ) 2 7 . 2  ( 1 0 . 2 )
Table 12: HAEMOSTATIC VARIABLES / Rabbit Carotid Artery Stenosis
Mean plasma fibrinogen concentration [ig/100 ml] and collagen-induced platelet aggregation
in vitro {% change in light transmission) of platelet-rich plasma after addition of collagen
(COLL) (see Methods)]. r-scu-PA and taprostene were infused together (gp IV), separately
(gps II and III) or substituted with saline infusions (gp I). The carotid artery stenosis
was implanted at t = 0, for the remaining duration of the experiment.
No statistical difference between groups were observed.
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3.4 The effects of taprostene infusion on selected haemostatic vara 
meters in healthy male volunteers/Results
In this blinded, 3-way crossover, placebo-controlled study the fol­
lowing haemostatic parameters were measured:
CL^-antiplasmin (AP), fibrinogen, fast acting plasminogen activator 
inhibitor (PAI-I), platelet factor 4 (PF4) and the euglobulin clot 
lysis time (ECLT) . The methods are described in 2.2.4. The 
individual results were:
Antivlasmin/healthy volunteers
Prior to infusion of both doses of taprostene (80 and 400 pg i.v. 
over 2 hours) and of placebo, the photometrically determined plasma 
activities of AP (see 2.2.4.2) were very similar in all subjects 
(range 86 to 109.6 % of control plasma pool) prior to treatment the 
group mean antiplasmin activity was placebo: 94.6 i 2 . I  %; low dose 
taprostene: 95.1 ^  3.0 %; higher dose taprostene: 98.2 3.3 %
(mean percent activity relative to control plasma pool ^  S.E.M.) 
Plasma AP-activites remained unchanged in both taprostene-treated 
groups relative to the placebo group, in which a slight increase 
(~ 7 %) was observed at the end the 25 hour observation period. Ta­
prostene infusion therefore, under these conditions, had no effect 
on the endogenous inhibition of plasmin in plasma, (diagram 40, 
table 13) .
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Platelet Factor 4 (PF4) /healthy volunteers and Dlasminocren
activator inhibitor 1 assay (PAI)
The purpose of the PF4 assay was to detect plasma samples in which 
ex vivo platelet activation had occurred. This is necessary as 
platelet alpha granules also contain high concentrations of PAI-1, 
hence activation in vitro would lead to spurious results. PF4 
antigen level was measured (ELISA) in the same platelet free 
CTAD plasma supernatant used for the PAI-I activity assay.
Despite careful blood sample handling, 6 of the 180 plasma samples 
were rejected b e c a u s e  of elevated PF4 levels (> 50 ID/ml taken as 
arbitrary cut-off point, the 6 values were all > 125 U/ml) . All 6 
rejected samples were found, after breaking the blinding code, to 
have originated in the placebo group. These samples were assayed 
for PAI-1 and distinctly elevated activities were recorded.
These 6 PAI-1 values were not included in the analysis. PF4 antigen 
levels tended to be higher before midday regardless of treatment 
and the lowest values in all groups were between 16.00 and 20.00 
hours. This suggests a slight diurnal variation. The PF4 data were 
not further analyzed.
Fibrinogen/healthy volunteers
Baseline plasma fibrinogen concentrations ranged in total from 158 
to 242 mg/100 ml. The treatment group means at this time were very 
similar (placebo group: 197 : L  12 mg/100 ml, low dose taprostene: 
195 i -  10 mg/100 ml, higher dose taprostene: 203 i -  9 mg/100 ml (x i  
S.E.M.)). The plasma fibrinogen levels remained very constant over 
the 25 h period in all 3 groups. Taprostene infusion for 2 h at 
these 2 dose levels therefore had no effect on this parameter 
(diagram 41, table 13).
-  148 -
ECLT/healthv volunteers
The rate of autolysis of thrombin-clotted plasma euglobulin frac­
tions is the basis of a routine laboratory test (ECLT) employed 
here to quantify the relative fibrinolytic activity in vivo (see 
2.2.4.S) . The mean fibrinolytic rate (reciprocal of the lysis 
times: min *) was very similar in the 3 treatment groups at 8.00 
a.m., prior to starting the infusions (group mean values S.E.M.:
2.8 x 10 7.6 10 * min ^; 2.4 x 10 ^  i  8.1 x 10. * min * and 3.3
-3 -4 -1
x 10 3Z 1.0 x 10 min for placebo, 80 p.g/2 h and 400 pg/2 h
groups respectively. Plasma from placebo treated volunteers
exhibited a definite diurnal variation in the fibrinolytic activity
with a nadir at or prior to 8 am and a maximum rate 2.5 times
greater at 8 pm (diagram 43 table 13) . The lower dose taprostene
treatment group showed an earlier increase in fibrinolytic rate
than the placebo group over the infusion period and lysis rates may
have been marginally increased after infusion of taprostene in this
group. The lysis rates remained slightly elevated over the placebo
values for the remaining period. A more marked effect on the clot
lysis rates was seen after high dose taprostene infusion, here the
maximum mean rate was recorded at 10.30 am, 30 min after completing
the infusion and therefore occurring much earlier than in the other
2 treatment groups (at 20 h) . At this time point (t - 2 . 5  h) the
lytic rate was increased by 167 % relative to the pretreatment
value. This compared with corresponding increase of 122 % and 49 %
in the low dose taprostene and placebo grops respectively. The clot
lysis rates in the high dose taprostene group decreased slightly
after the maximum at t - 2.5 h, converging slowly over an 8 hour
period with the lysis rates in the low dose and placebo groups.
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None of these effects reached statistical significance, but a 
distinct dose-related trend of increased clot lysis rates is 
implicated after taprostene infusion.
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Summary of results from human study
To summarize the results from the taprostene infusion study in vo­
lunteers, neither of the infusion doses tested (80 pg/2h, 
400 pg/2h) affected the plasma levels of a-antiplasmin or fibri­
nogen either during or up to 23 hours after completing the 2 hour 
infusions (diagrams 40 and 41) . It may be possible that the infu­
sions of taprostene decreased the activity of PAI-I in plasma du­
ring the infusion period but due to moderate intergroup variation 
in the pretreatment values this effect cannot be confirmed by the 
present experiments (diagram 42).  The endogenous fibrinolytic rate 
as estimated by the euglobulin clot lysis assay (ECLT) demonstrated 
a distinct increase in the thrombolytic capacity of plasma during 
and up to 1 hour after the high dose taprostene infusion (diagram 
43) . The study design with small numbers did not have sufficient 
power to enable statistical significance of this effect to be at­
tained however.
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Plasma Alpha-2-Antiplasmin(AP)/Human volunteers
•  placebo (n=6) 
a 80pg/2h (n=6),TAP 
o t0 0 p g /2 h  ln=6).TAP
-I —  i.v. infusion Taprostene (TAP)
hours a fte r infusion s ta rt
Diagram 40







iv infusion Taprostene (TAP)
-15' 0 122 256
•  placebo (n=6)
*  80yg/2h |n=6).TAP
0 A00yg/2h ln=6).TAP
hours a fte r infusion s ta rt
Diagram 41
Diagrams 40 and 41: Plasma a^ antiplasmin activity (AP) [% of
plasma pool] and fibrinogen concentration [mg/dl] (x £  S.E.M.).
Healthy male colunteers received infusions of placebo, or
taprostene (80 pg/2h and 400 pg/2h) in a blind cross-over fashion. 
No significant difference was observed between any treatment at the 
same time points. O h corresponds to 8 am.
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iv. infusion Taprostene (TAP)
hours a fte r  infusion s ta rt
Diagram 43
Diagrams 42 and 43: Plasma activity of plasminogen
activator-inhibitor-1 (PAI-1) [arbitrary units of tPA inhibition at 
25 ’C (A.U.) per ml plasma] and endogenous fibrinolytic rate 
[reciprocal of euglobulin clot lysis times in min]. Healthy male 
volunteers received i.v. infusions of placebo, or taprostene 
(80 pg/2h) and 400 pg/2h) in a blind cross-over fashion (x ±  SEM) 
Time 0 =  8:00 am.
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PLASMA ASSAYS / Healthy Male V olunteers
TAP i.v. TIME [h]
infusion (pre)
(pg/2h) -0.25 0.5 1.0 1.5 1.8 2.5 4.0 8.0 12.0 25.0
oyANTIPLASMIN (1)
placebo 94.6 - - - 94.0 - - - 98.5 101.7
(2.1) (2.2) (1.5) (2.0)
80 95.1 - - - 95.2 - - - 99.7 103.5
(3.0) (3.0) (1.9) (2.4)
400 98.2 - - - 98.3 - - - - 102.6 103.0
(3.3) (3.7) (2.3) (2.1)
.. I
FIBRINOGEN (mg/100 ml)
placebo 197 ri —i - - 196 . - - - 194 203
(12) 1 (13) (12) (12)
80 195 - - - 193 - - - 192 191
(10) (12) (12) (11)
400 203 _ - 208 - - - 202 206
(9) (12) (12) (14)
PAI-1 (A.U./ml)
placebo 28.9 A 25.2 25.0 B 27.3 B 24.2 23.1 20.4 17.6 19.9 24.9 B
(2.0) (3.1) (2.0) (2.7) (2.1) (2.4) (2.7) (3.4) (3.4) (2.7)
80 26.2 25.5 24.3 23.0 21.6 20.6 18.7 15.8 18.8 24.0
(3.4) (3.2) (2.9) (3.0) (2.7) (2.6) (1.8) (1.9) (2.2) (2.5)
400 23.6 23.2 21.9 20.5 19.8 18.7 19.1 16.8 17.6 26.0
(3.0) (2.6) (2.6) (2.7) (2.3) (2.3) (1.7) (1.5) (1.5) (2.3)
EUGLOBULIN CLOT LYSIS RATE (/min x 10:7
placebo j 2.8 3.3 3.2 3.5 3.4 4.2 5.3 6.3 7.2 3.4
(0.8) (1.0) (0.8) (1.0) (0.9) (0.7) (0.8) (0.6) (1.0) (1.0)
80 2.4 2.6 3.1 3.5 3.9 5.4 6.2 7.5 7.9 4.61 (0.8) (0.8) j (1.1) (1.0) (1.0) (1.0) (0.7) (0.8) (0.8) | (1.0)
400 3.3 4.4 6.1 6.6 8.1 8.8 8.1 7.9 7.3 4.4
(1.0) (1.5) (3.0) (2.7) (2.7) (2.8) (2.3) (0.8) (1.6) (1.4)
Table 13: PLASMA ASSAYS / Healthy Male Volunteers
Taprostene (2 dose levels and placebo) was infused intravenously (t = 0 to t = 2 h) 
in 6 healthy lale volunteers using a blinded, randomised, cross-over protocol, 
a -antiplasmin activity = % of control plasma pool; fibrinogen: coagulation time assay; 
PAI-1 (plasminogen activator inhibitor-1): arbitrary units of tPA inhibition,
PAI-1 samples with PF4 > 50 I.U./ml were rejected (A: n=l, B: n=2 rejected due to ex vivo 
platelet activation); Euglobulin clot lysis rate = reciprocal of euglobulin clot lysis 
time (min). All values x + S.E.M.. No statistically significant difference between 
treatment groups; p<0.05, Student's t-test, 2-tail, paired data
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4. 0 Discussion
4.1 Doa infarct models
4.1.1 The model -  a  critique
In the initial series of experiments the LAD was chosen as the site 
of experimental thrombosis, but for the main series of infarction/ 
thrombolysis experiments the LCX artery was used. The reasons for 
the change over were numerous:
1) Anatomy: The high density of small bifurcations from the LAD, 
but not from the LCX, greatly hindered preparation and positioning 
of the flow probe.
2) Variability: The diameter of the LAD was smaller and more va­
riable between animals than was the LCX. The size of the the LAD 
perfused bed (%Aar/LV) in the dog was found here to be smaller than 
that of the LCX (LAD: 15.3 dk. 1.4% (range 7.9% to 23.8%; n=10) ver­
sus LCX: 38.8 £ •  1.1% (range 26.3 % to 47.7%; n=25)), in agreement 
with Becker et al (1983) (LAD: 22.3 £  1.5% versus LCX: 29.3 £  2.0%,
p<0.01). Gumm et al (Gumm, Cooper, Thompson et al. 1988) showed
that proximal occlusion of the LAD and LCX resulted in %Aar/LV va­
lues of 43 t 5 and 36 i-  2% respectively, whereas distal occlusion 
gave values of 13 ^  2% and 17 X  2%. Thus, frequent proximal bran­
ching of the LAD imparts a different "arterial tree" pattern com­
pared with the LCX, which causes greater variability in the former. 
Reimer, Ideker and Jennings (1981), by comparing different 
occlusion sites on the 2 arteries, had previously shown this 
difference.
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Becker et al. (1983) concluded, after comparing risk areas (AaR/LV) 
of similar size, that LAD perfused beds were more severely ischae­
mic than LCX beds due to a lesser collateral supply, and hence, 
that canine LCX models would provide a more sensitive test of a 
drug's effect on infarction. This is especially important in the 
LCX experiments where there were 2 variables, treatment (taprostene 
or vehicle) and the duration of ischaemia. The duration of ischae- 
mia was determined by the time taken to recanalize the vessel. In 
the LAD model more severe ischaemia would cause a more rapid and 
extensive evolution of necrosis. Therefore for a given variation in 
the duration of early ischaemia a greater variability in the rela­
tive infarct size of an LAD bed would result compared to an occlu­
ded LCX artery bed.
This possible effect was not confirmed retrospectively however in 
the LAD and LCX experiments. Comparing the relative infarct size 
after 2 hours ischaemia (group c (LAD) versus group II (LCX)), and 
after 6 hours ischaemia (groups a + b (LAD) versus group I (LCX)) 
showed that: (a) after 6 hours of ischaemia very similar propor­
tions (X 50 %) of both anatomic risk areas were infarcted and, (b) 
after approximately 2 hours of ischaemia before thrombolysis the 
LAD infarcts were less extensive than the LCX infarcts (diagrams 22 
and 28, table 7). This would imply that the severity of regional 
ischaemia is greater after LCX occlusion. The size of the occluded 
bed is however an important factor as the specific collateral flow 
rate (ml/min/g tissue) is inversely proportional to the size of the 
anatomic risk area (AaR) (Miura and Downey 1988; Gumm et al 1988) .
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3) Another reason for the change from LAD to LCX artery was the 
practicality /validity: A high proportion of LAD-occluded dogs
dropped out of the analysis (29%) due to ventricular fibrillation 
occurring either during ischaemia or reperfusion. In an attempt to 
avoid this in a subset of LAD experiments lignocaine was given 
prior to ischaemia and during the acute recanalization phase. 
Despite successful attenuation of ventricular fibrillation (in all 
4 dogs), this was later abandoned because lignocaine therapy has 
been shown to reduce various indices of infarction in canine models 
(Boudoulas, Karayannacos, Lewis et al. 1978; Nasser, Walls, Edwards 
et al. 1980) by 2 possible mechanisms, both common to PGI^ - t o  
stabilize myocardial membranes (Lesnefsky, van Benthuysen, McMurty 
et al. 1989) and to decrease neutrophil free-radical production 
(Peck, Johnston, Horwitz 1985) . Thus any effect of taprostene here 
may have been concealed with concurrent lignocaine therapy. Only 1 
of 30 dogs undergoing LCX occlusion (of which 21 underwent 
reperfusion) fibrillated.
A canine model of coronary thrombosis and thrombolysis was chosen 
because apart from primate models it seems to be the most 
comparable with man. Dog clots show the same order of sensitivity 
to lysis by scuPA in vitro as human clots do (Gurewich et al.
1984), and the pharmacokinetic profile of scuPA in vivo is similar 
(t2/2CL m *n b°th species (Van de Werf, Jang and Collen 1987; 
Van de Werf, Vanhaecke, De Geest et al 1986a)).
The canine haemostatic/fibrinolytic system is well characterized 
and the effect of various thrombolytic agents on coronary thrombi 
produced by differing methods has also been studied.
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Taprostene shows a similar cardiovascular and antiplatelet profile 
in man and the dog ("Investigators' brochure" on taprostene 
supplied by Griinenthal GmbH) . Although the general potency of ta­
prostene may vary slightly between the 2 species, it is more impor­
tant that the relationship antiplatelet/hypotensive potency does 
not vary greatly between the 2 species as the species difference 
can be compensated for by changing the infusion rate. It is 
probable that the difference between the dose of taprostene causing 
noticable antiplatelet action and that causing hypotension is 
narrower in anaesthetized models compared to conscious models and 
clinical situations as reflex compensation of hypotension is 
limited by anaesthesia.
Anaesthesia itself may have affected the infarct sizes. A single 
bolus of thiopental has been demonstrated to increase infarct size 
in a conscious canine model (Jugdutt, Rogers, Hutchins et al 1986). 
Deleterious effects of pentobarbitone on infarct size after 90 mi­
nutes canine coronary artery ligation and reperfusion had been des­
cribed previously and were attributed predominantly to chronotropy 
(Mergner, Gilman, Patch et al 1985) . In all experiments carried out 
in this present study the dose of anaesthetics used were relatively 
constant and would not have caused the marked differences in in­
farct sizes seen between certain treatment groups.
There are two further aspects of the model employed here that de­
serve critical consideration, the possible inter-animal variation 
in coronary collateral supply to the hypoperfused myocardium during 
artery occlusion and the staining technicjue employed to delineate
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the relative infarct size and anatomic risk area. The magnitude of 
residual collateral flow to the myocardium after occlusion of the 
normally perfusing coronary artery is notoriously variable between 
animal species and even within a given species, including the dog 
or in man. In an unconscious canine LCX model of infarction the 
variation in the anatomic risk area was shown to account for 77% of 
the variation in infarct size relative to the left ventricular myo­
cardium (I/AaR). After normalizing the infarct size to the area at 
risk, variation in collateral flow was found to account for 53% of 
the variability of the infarct size (Reimer, Jennings, Cobbs et al.
1985).
The determination of the collateral flow rate during occlusion in 
the present experiments by using radiolabelled microspheres was not 
possible due to a laboratory restriction of isotope use. As the 
only available countermeasures, ECG changes and visual-cyanosis of 
the myocardium on occlusion were used as criteria here to avoid in­
clusion of any animal with a well developed collateral system. Fur­
thermore the animals were randomized to treatment, which was blin­
ded until all data was available. The animals for this study were 
relatively inbred and homogeneous with respect to age and body 
weight in contrast to most published studies where it is evident 
that there is a high degree of heterogeneity. Therefore it is high­
ly unlikely that differences in myocardial collateral flow in the 
different animals could have biased the infarct size results in the 
present experiments.
Considering the staining techniques employed to delineate the in­
farct size and area at risk, the methods employed have been shown 
to generate artefacts under certain conditions. After 90 minutes of
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Ischaemia followed by reperfusion the TTC dye used to stain viable 
tissue becomes reliably discriminative (Schaper 1984), however with 
no reperfusion non staining of microscopically-confirmed necrotic 
tissue only becomes reliable after 6 hours of occlusion, possibly 
because the limiting factor involved in the staining reaction, NAD 
cofactor, is not totally absent from the necrotic myocardium until 
this time. Ex vivo coronary perfusion of TTC solution as done here 
may theoretically not lead to thorough permeation of the dye 
through the previously hypoperfused myocardial region due to a "no­
reflow” phenomenon. This possibility was countered by placing the 
heart slices in a TTC bath after photography and re-photographing. 
A shift of the border unstained/stained myocardium after this 
second staining step was not observed, confirming the acceptability 
of the whole heart perfusion method. Myocardial regions affected by 
the no reflow phenomenon would undoubtebly not remain viable in any 
case.
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4.1.2 Thrombolytic efficacy of r-scu-PA taprostene
It is possible to infer that the coronary thrombi formed by the 
method used are resistant to spontaneous breakdown as the clots 
remained occlusive over the experimental period in both LAD and LCX 
groups in the vehicle treated control groups.
That r-scu-PA infusion can successfully recanalise an experimental­
ly induced coronary thrombus has been shown here, and by other au­
thors. The rapidity and success rate of fibrinolytic recanalisation 
is undoubtedly dependent on various thrombus parameters including 
its composition, age, morphology, site and the haemostatic and 
haemodynamic environment. As many diverse methods of experimental 
coronary thrombogenesis have been described, the extent to which 
the resulting thrombi affect experimental thrombolytic outcome 
should be considered: After using an intraarterial copper coil to 
precipitate LAD thrombosis, Collen's group induced thrombolysis in 
all 4 dogs with a 20 ng'kg 1 °min * r-scu-PA infusion, the mean time 
required was 14 £  3 min ("ilS.D.) (Van der Werf, Jang and Collen 
1987) .
Using Lucchesi's intraarterial anode thrombogenesis model, Sohngen 
(1988) required a greater r-scu-PA total dose (250 pg9kg * bolus 
plus 25 pg*kg **min * infusion for 30 min) to produce comparably 
rapid (16 i  4 min (x i  S.E.M.)) and thorough (100 % of animals) 
recanalisation of the LCX. This apparent discrepancy might be 
explained by the proportionately greater contribution of platelets 
to arterial obstruction in the latter model (and in man) (Romson, 
Haack and Lucchesi 1980).
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The efficacy of r-scu-PA in breaking down thrombin-induced coronary 
thrombi in dogs has not been reported previously to this author's 
knowledge. Collen's group however (Flameng et al. 1986) reported a 
recanalisation time of 21 iz 4 min (x i t  S.D.) in a corresponding 
open-chest baboon model after infusing r-scu-PA at 20 (ig*kg **min *
i.v. .
Lijnen (Lijnen, De Wreede, Demarsin et al. 1984) examined the 
species variation in the susceptibility of plasma clots immersed in 
autologous plasma to lysis in vitro by E.coli-derived r-scu-PA. The 
following order of clot susceptibility to lysis was found: human > 
baboon > dog/rabbit. Extrapolating this observation to the present 
dog in vivo model a slower rate of recanalization (with the same 
thrombin thrombi and r-scu-PA dose) than in the baboon would be 
expected. The lysis rates were however similar (25 ^  5min dog LAD, 
22dz2 min dog LCX (Jc dz S.E.M.)) . A possible reason for the greater 
than expected thrombolytic rate in dog studies is that in these 
experiments heparin was given together with r-scu-PA whereas in the 
baboon model it was given after coronary reperfusion. Heparin 
potentiates the conversion of n-sc-UPA to the more active 2-chain 
form in vitro, and enhances glu-plasminogen activation by the 
latter (Radzewski, Takada and Takada 1989; Lijnen and Collen 1986 
a) . Heparin may promote n-scu-PA thrombolysis in man (Gulba, 
Fischer, Reil et al. 1988).
The susceptibility of thrombin-induced coronary thrombi to in vivo 
lysis by r-scu-PA may be greater than that of electrically induced 
thrombi, but copper coil induced thrombi seem to be most suscep­
tible to lysis. There are, however, other variables; the copper
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coil model does not require thoracotomy, in contrast to the other 
two models, and surgery is widely known to imbalance the endogenous 
coagulation/thrombolytic system in favour of the former.
The concentration of acute phase inflammatory reactants including 
PAI-1 in thoracotomized animal models might possibly be more simi­
lar to the clinical concentrations after AMI than the closed chest 
model concentrations of reactants are.
In the current experiments exogenous thrombin will have activated 
both plasmatic and cellular haemostatic mechanisms, and residual 
thrombin activity could potentially inactivate a fraction of the 
r-scu-PA locally thereby delaying the lysis (Gurewich and Pannell 
1987) .
In the coronary thrombolysis experiments reported here the mean 
times to recanalization of the LAD and LCX arteries were very si­
milar: 25 t  5 min (LAD, n=4, x i  S.E.M.) and 22 i. 2 min (LCX, 
x  £  S.E.M.) after starting the r-scu-PA infusions (infusion rate 20 
fig*kg * *min *). . Taprostene coadminstration did not significantly 
increase the rate of restoration of LCX patency at the dose levels 
tested here.
After restoration of artery flow the flow probe was removed, as in 
the initial LAD experiments the flow probe often became displaced 
from the artery. No data are therefore available from these (LCX) 
experiments on the effect of coadminstration of the prostacyclin 
analogue taprostene with r-scuPA on the mainenance of artery pa­
tency after recanalization, and of the effect of taprostene coad­
ministration on the attenuation of reflow rate after ischaemia due 
to microvascular perfusion failure.
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At an arterial level, experimental and clinical thrombolysis is 
frequently followed by reocclusion. Prostacyclin infusion, at a 
hypotensive dose (400 ng*kg^mmin *) prevented coronary artery throm­
bosis in response to electrical injury of the intima (Romson, 
Haack, Abrams et al. 1981) and to severe arterial stenosis (Aiken, 
Gorman and Shebuski 1979).
Two anecdotal clinical reports in 1983 suggested that intracoronary 
prostacyclin infusion seemed to greatly increase the rate of re­
canalization occuring with streptokinase and urokinase therapy 
(Blasko, Berentey, Harsanyi et al. 1983; Uchida, Hanoi, Hasegawa et 
al. 1983). Another group provided limited clinical evidence of in­
creased coronary recanalization by cotreatment of intracoronary 
streptokinase with PGE^, a compound with similar actions to 
(Sharma, Wyeth, Gimenez et al. 1985). These observations were made 
under uncontrolled conditions and must be weighted accordingly. 
Schumacher et al. (1985) also demonstrated that intracoronary in­
fusions of enhanced the reperfusion flow rate after strepto­
kinase lysis of electrically induced LCX thrombi in dogs, and de­
creased the remaining thrombus mass, even though MABP was lowered 
by 35 mm Hg. These effects were attributable in part to concommi- 
tant heparin therapy, however. Prostaglandin E^ (PGE^) has recently 
been shown to increase the rate and extent of tPA-induced lysis of 
fibrin-rich venous thrombi in rabbits (Vaughan, Plavin, Schafer et 
al. 1989) and to promote urokinase-induced lysis of platelet-rich, 
but not platelet-free fibrin clots in vitro (Terres, Beythien, Kup- 
per et al. 1989). Similar effects might be expected after or
taprostene cotreatment with thrombolytic agents in vitro and in 
vivo.
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Consequently great disappointment surrounded the results of a re­
cent controlled clinical trial of iloprost cotreatment with tPA in 
2 groups of 25 acute myocardial infarction patients.
Ninety minutes after starting the treatment, arteriographic patency 
was 60 % in the tPA group and 44 % in the iloprost plus tPA group 
(p = 0.26). The ventricular ejection fraction was increased at 7  
days in the tPA group and decreased in the combination group. Ilo­
prost coadministration (2 ng'kg *'min * for 48 hours) markedly at­
tenuated the fibrinolytic and fibrinogenolytic activity of tPA (To­
pol, Ellis, Califf et al. 1989). This negative effect of iloprost 
cotreatment on tPA thrombolysis was confirmed experimentally in a 
dog model of electrically induced LAD thrombosis (Nicolini, Mehta, 
Nichols et al. 1990). Here the frequency of successful reperfusion 
was similar between groups (~ 65 % of animals recanalized) but ilo­
prost coinfusion (4 fig/kg over 40 min) doubled the time to recana­
lization (p < 0.02) and dramatically reduced the duration of paten­
cy thereafter. Finally, the authors provided sound evidence that 
iloprost reduced circulating levels of tPA by 30% by enhancing he­
patic flow and hence possibly tPA degradation. Although marked pla­
telet inhibition ex vivo was found in the combination group this 
paradoxically did not prevent reocclusion. In the experiments re­
ported in this thesis there was no evidence of an effect of tapro­
stene coadministration, at the 2 sub-hypotensive doses, to either 
enhance or attenuate the thrombolytic effect (speed or success 
rate) of r-scuPA in this canine LCX model. That taprostene did not 
decrease the efficacy of r-scuPA in these experiments in a similar 
fashion to the iloprost/tPA thrombolysis experiments may be related 
to:
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1. The dose of taprostene may be too low for a marked Interaction 
to occur
2. The fact that r-scuPA, in contrast to tPA, is not eliminated
from the circulation entirely by a hepatic mechanism as shown by
the fact that functional nephrectomy prolongs the plasma half 
life of scuPA, albeit to a lesser extent than does a functional 
hepatectomy (Stump, Kieckens, De Cock et al 1987).
4.1.3 Haemodvnamic parameters 
MABP
The slow fall in mean blood pressure seen in both the LAD and LCX 
experiments over the 6 hour experimental period is probably accoun­
ted for by a combination of prolonged and repeated administration 
of pentobarbitone together with evolving AMI and by varying degrees 
of blood loss (diagram 15 and 24) . The only significant fall in 
MABP due to drug treatment was in LAD thrombosed dogs treated with 
r-scu-PA. As this did not occur after r-scu-PA thrombolysis of the 
LCX (although the final quantity of r-scu-PA infused was 50% less
in the latter) it could be concluded that this is not due to a di­
rect systemic effect of r-scu-PA. Hypotension is possibly aggrava­
ted by the greater blood loss in the LAD model. The possibility of 
reperfusion induced hypotension, caused by more severe arrhythmoge- 
nesis in the LAD model was not examined. A theoretical explanation 
for moderate hypotension seen after systemic plasmin generation 
would be plasmin's effect of liberating the hypotensive mediator 
bradykinin from high molecular weight kininogen in plasma (Ver-
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straete and Vermylen 1984) .
Although a slight tendency was apparent, at the doses used, tapro­
stene treatment did not significantly lower blood pressure (MABP) 
in r-scu-PA recanalized animals (LCX model) . This is important as 
the left ventricular subendocardium, the most susceptible region to 
myocardial ischaemia, is perfused solely during ventricular dia­
stole and the perfusion rate is dependent, apart from microvascular 
changes, on a) the pressure gradient aortic- root/left ventricle 
(during diastole) and b) the relative duration of diastole.
Thus any arterial vasodilator, given at the time of reperfusion, 
including taprostene at higher doses, might theoretically prolong 
subendocardial ischaemia by decreasing the perfusion pressure. This 
effect may be further aggravated when a remaining critical steno­
sis, a result of incomplete clot lysis, causes the maldistrubution 
of reflow blood to non-ischaemic myocardium.
Arteriodilator drugs may cause reflex tachycardia which greatly 
reduces the relative duration of diastole. Increasing heart rate 
from 65 to 200 min * decreases the absolute duration of systole and 
diastole by 47 % and 7 7  % respectively (Ganong, W.F. 1979). Increa­
sed sympathetic drive with attendant cardiac catecholamine release 
could cause further detriment by promoting myocyte necrosis, 
arrhythmogenic free fatty acid release, OFR production, platelet 
aggregability and by further imbalancing the local supply/ demand 
ratio of O^. Taprostene treatment at both dose levels in the LCX 
experiments did not affect heart rate, or rate x pressure product, 
an estimate of myocardial energy requirement, and one of the 3 
major determinants of experimental infarct size (Reimer, Jennings,
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Cobb et al. 1985).
The premise is therefore that for any beneficial effect of tapro­
stene to be seen here, it m u s t  possess a differential (lower) po­
tency in its hypotensive effect compared to the "protective" effect 
and the dose must be adjusted accordingly.
In other words a bell-shaped, and not a sigmoid curve, may charac­
terize taprostene's dose/myocardial-protection relationship. Two 
doses of taprostene were tested in this model to help in detecting 
this possible effect, and doses were employed that caused no marked 
hypotension.
L.V. veak pressure and contractility
The slow decrease in LVPP and +dP/dt over the experimental period 
was similar after both LAD and LCX continuous occlusion (diagrams 
16, 17, 23, 15), but the smaller animal numbers in the LAD
experiments resulted in greater variability. The causes of decline 
in peak pressure and contractility are no doubt the same as those 
causing the fall in MABP as LVPP and MABP are directly related. 
Considering the groups of animals that underwent acute thrombolysis 
of the LAD and LCX, there was evidence of an acute deleterious 
effect of r-scu-PA thrombolysis on contractility in LAD- but not 
LCX-animals. The selectivity of this effect precludes the 
possibility of a systemic action, or of a direct action of the 
thrombolytic agent on myocardial contractility. The acute decrease 
in contractility in the LAD recanalized animals is most probably a 
result of the far greater arrhythmic disturbances compared to the
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LCX animals. In the dog the LAD perfuses the apical and anterosep- 
tal myocardium, whereas the LCX perfuses a larger mass of lateral 
free wall and papillary muscle (Reimer and Jennings 1979), thus 
from a purely mechanical point of view a greater global function 
defect would be expected after LCX occlusion as a larger expanse of 
ischaemic free wall would undergo decreased segement shortening or 
even systolic bulging and paradoxical compliance. The LCX groups 
did not exhibit a greater contractile defect on occlusion compared 
to the LAD dogs as assessed by the two parameters, LVPP and +dP/dt. 
This might be accounted for by a compensatory increase in contracti­
lity in the respective non-ischaemic regions. For this reason the 
global pump function parameters LVPP and +dP/dt are relatively in­
sensitive to any effect, positive or otherwise, of the treatments 
on the function of the ischaemic segment itself.
The rates and extents of wall thickening and segment shortening can 
be measured without ventriculography by experimental implantation 
of piezo crystal pairs, but the apparatus was not available. Laval- 
lee et al. (1983) showed after 1 hour of LAD or LCX ligation that 3 
to 4 weeks of reperfusion are required before preischaemic segmen­
tal contractile function is fully regained. With longer periods of 
ligation, 2 to 3 hours, only partial recovery is observed after 
ecjually long reperfusion. Prolonged periods of reperfusion (> 72 h) 
are required to reverse the segmental contractile defect caused by 
even brief (15 min) periods of coronary artery ligation (Kloner, 
DeBoer, Darsee et al. 1981). Protracted biochemical and ultrastruc- 
tural changes are also observed including the depletion of high 
energy phosphate compounds and, over longer ischaemic periods, of 
their precursors. Slow de novo synthesis of these may therefore
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explain the need for a prolonged recovery period (Reimer and 
Jennings 1981; DeBoer, Ingwall, Kloner et al. 1977). Prostacyclin 
and iloprost have however been shown to decrease the depletion rate 
of high energy phosphates and precursors, even after starting the 
infusion as late as 1 hour after canine LAD ligation (Pissarek et 
al. 1987).
As myocyte necrosis does not occur after 15 min periods of 
ischaemia, the term myocardial "stunning" was coined (Braunwald and 
Kloner 1982). Beneficial effects of prostacyclin analogue treatment 
on the recovery of ventricular function have been reported. 
Iloprost infusion started moments before releasing a 15 min LAD 
ligature, in open chest barbital anaesthetized dogs, increased the 
systolic segment shortening fraction over the following 3 hours 
compared to both vehicle and an equieffective dose of vasodilator 
drug. This effect of iloprost was attributed by the authors (Farber 
et al. 1988) in part to the inhibition of superoxide production by 
PMN's.
Oxygen free radical scavengers infused just before or together with 
coronary artery reperfusion have been shown in most studies (15 of 
19 reviewed by Opie 1989) to reduce stunning. All negative results 
were found in studies with periods of preceding ischaemia longer 
than 60 min including one in which an experimental coronary artery 
thrombolysis model (with r-scuPA) was cotreated with superoxide 
dismutase (SOD) (Vanhaecke, van de Werf, Jang et al. 1988). In the 
LCX experiments reported here the lack of an beneficial effect of 
taprostene cotreatment on the postischaemic ventricular function 
recovery may be due to a combination of factors; the excessively
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long preceeding period of ischaemia and inadequate convalescence 
period allowed, as well as the poor sensitivity of global function 
measurements to detect regional segment contractile characteris­
tics. The significantly lower contractility in the high dose ta­
prostene group requires some consideration (diagram 25) as this may 
be a detrimental effect, at least in the acute reperfusion phase. 
The group mean value was lower prior to ischaemia than in the other 
3 groups, and lower contractility seen later may thus be an arte­
fact. Another possibility is that taprostene, either alone or in 
conjunction with the barbiturate anaesthetic or fibrinolysis may 
have a direct cardiodepressant effect. This is unlikely as the ef­
fect was most apparent in the post-infusion phase. Alternatively if 
taprostene shares prostacylcin's and iloprost's effect of inhibi­
ting the release of neural catecholamine release during the washout 
(reperfusion) phase as a consequence of membrane stabilization 
(Schror et al. 1981), then decreased contractility may result from 
lower sympathomimetic stimulation. This suggestion is supported 
by the lower incidence of arrhythmic activity seen in this group 
during the identical time period (t - 3 to 6 hours) to which lower 
cl^-adrenoceptor stimulation could have contributed (Benfrey, Elfel- 
lah, Olgivie et al. 1984; Culling, Penny, Cunliffe et al. 1987). 
There are however sporadic unrelated reports of a deleterious ef­
fect of prostacyclin treatment on ventricular function when institu­
ted concomitant with mechanical reperfusion. In a somewhat abstract 
ischaemia/reperfusion model, the isolated buffer perfused Langen- 
dorff rat heart, pretreatment with three drugs possessing the puta­
tive common action of cyclooxygenase inhibition caused a 35% to 70% 
recovery of contractile force on reperfusion compared to untreated
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controls (11 % recovery). Re-adding pathophysiological concentra­
tions (500 pg/ml) of PGI^ to the reperfusate caused a reversal of 
the salutatory effects of each of the 3 agents as contractile force 
recovered to only 15 to 22 % of normal (Karmazyn 1986) . A complete 
contradiction of these results was provided by Berti et al (1988) 
using a very similar rabbit heart Langendorff model: cyclooxygenase 
inhibition worsened the contractile dysfunction seen after reperfu­
sion, and pretreatment with a compound which stimulates endothelial 
prostacyclin production, defibrotide, protected against the delete­
rious effects of the cyclooxygenase inhibitors. An obvious diffe­
rence between these experiments is that in the former PGI^ wou^  
have been lower during the ischaemic phase (in the former). More 
comparable are the results obtained after cotreatment with pro­
stacyclin and mimetics during coronary thrombolysis in vivo. 
Schumacher et al (1985) found that PGI administered with strep­
tokinase (and heparin) caused the regional contractile force to 
recover transiently and acutely to ~  60% of the preischaemic value 
whereas without PGI^ treatment the value was approximately 30%. In 
a clinical study with 25 AMI patients per group Topol et al (1989) 
showed that ilopost coadministration with tPA caused a reversal in 
the partial recovery of the ventricular ejection fraction after 7 
days seen with tPA treatment alone. The improvement in regional 
wall motion after tPA thrombolysis was also significantly reduced 
by ilopost cotreatment. These effects may however have been more 
directly related to an effect of ilopost to decrease the fibrino­
lytic activity of tPA by enhancing its elimination therefore to 
shorten the time to a return of the thrombotic overbalance in blood 
than to a direct effect of ilopost on the post ischaemic myocardial 
function.
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Evidence for this lies in the reportedly diminished duration and 
extent of fibrinolytic activity and a concommittant enhanced 
coronary reocclusion rate.
Although not examined here, taprostene as a PGI2 mimetic may de­
crease oedema in the reperfusion region. Chemotactic agents LTB 
complement C ^  and C^a end others are released during infarction 
(Hartmann et al. 1977, Sasaki et al. 1988, Rossen et al. 1985) and 
can cause PMN-mediated local oedema. Prostacyclin at a subhypoten­
sive dose (50 ng/kg/min, i.v.) attenuated oedema formation (rabbit 
skin model) induced by complement fragments and LTB^ (Rampart and 
Williams 1986). Oedema-induced myocardial stiffness could, depen­
ding on the extent and spatial location of the area, either hinder 
ventricular contractile force development and hence decrease the 
+dP/dt value or decrease any paradoxical systolic bulging of the 
segment and hence increase the peak pressure and maximum rate of 
increase in ventricular pressure.
The observed inverse relationship between increasing taprostene 
doses (0 to 0.215 pg*kg ^*min *) and the degree of myocardial ne­
crosis, estimated both morphologically or enzymatically, negates 
the most obvious explanation of decreased contractility by tapros­
tene - increased infarct size.
In vivo under non-ischaemic conditions i.v. PGI^ infusion caused an 
initial increase in stroke volume, -hdP/dt value and cardiac output 
in anaesthetized dogs (Chappie, Dusting, Hughes et al. 1980; Allan, 
Follenfant, Lidbury et al. 1985) and in conscious dogs (Dinerman, 
Mehta and Nichols 1988). In coronary artery disease patients PGI^ 
infusion (5 to 10 ng*kg **min *) caused an increase in ventricular
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ejection fraction (Auinger, Virgolini, Weissel et al. 1989) and 
cardiac index (Firth, Winniford, Campbell et al. 1983). The appa­
rent inotropic effect of pGI^ in vivo, and hence possibly taprost- 
ene, is dose dependent as higher doses (1 fig'kg *min * PGI^ over 10 
min in open chest anaesthetized dog) caused a moderate rise 
followed by a marked fall in +dP/dt. Possible explanations include 
a vagal reflex resulting from the stimulation of prostaglandin 
receptors mostly in the inferoposterior myocardium (reviewed Hinze,
1987), or a decrease in +dP/dt as a result of afterload reduction. 
It is unlikely that the prolonged and delayed effect seen in the 
LCX model is related to the former because of the different 
temporal characteristics. The most plausible explanations for the 
apparent decrease in +dP/dt due to taprostene may therefore be as a 
result of afterload reduction, or of enhanced intercostal bleeding 
in the combination group due to an antiplatelet action.
HR and MABP x HR
Heart rates for LAD and LCX experiments are shown in tables 1 and 6 
respectively. The apparent decrease in HR in the LAD group treated 
with r-scu-PA is undoubtebly a false positive effect as it started 
before commencing the r-scu-PA infusion. This artefact is 
attributed to the variability of group means due to small numbers 
per group in the LAD pilot experiments. No similar effect was seen 
in the LCX group undergoing r-scu-PA treatment compared to 
untreated controls. In the LCX experiments occlusion produced a 
small (< 10 %) decrease in the unnaturally high heart rates, but 
the other treatments r-scu-PA, alone and with taprostene, exerted
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no marked effect, although in the last 2 hour period the mean value 
in the r-scu-PA alone group was marginally higher. Heart rate is an 
interesting variable insofar as both myocardial energy demand and 
supply, especially in the subendocardium, are unfavourably affected 
by tachycardia. Taprostene did not, under the conditions tested, 
affect the heart rates. The heart rate-pressure-product, an index 
of myocardial metabolic demand, was therefore directly related to 
the blood pressure (MABP), which was only very marginally decreased 
by the high dose of taprostene. In a multicentre standardized 
experiment employing an unconscious open-chest canine LCX model the 
rate-pressure-product was found not to contribute significantly to 
the size of the infarct (I/AaR) after 3 hours occlusion and 3 days 
reperfusion (correlation coefficient r ■* 0.26) (NHLBI study:
Reimer, Jennings, Cobb et al. 1985). On these grounds it may be 
assumed that taprostene's effect here on infarction was unrelated 
to the slight central haemodynamic changes induced at the 2 dose 
levels tested. The high heart rates recorded here are charac­
teristic for the open chest anaesthetized dog infarction model as 
the NHLBI comparative study further demonstrated: Mean HR: 158 ver­
sus 121 beats/min for anaesthetized and conscious dogs respec­
tively.
Effects of r-scuPA taprostene on haemostatic parameters,
plasminogen, fibrinogen and antivlasmin
Flameng et al (1986) induced thrombi with thrombin in open chested 
primates (baboons) and then showed with the same treatment regimen 
(r-scu-PA infusion-rate and source same as in the current study)
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that minimal systemic depletion of the, 3 haemostatic parameters 
fibrinogen, cl -^antiplasmin and plasminogen occurred. Few bleeding 
problems were observed and efficient thrombolysis was achieved. 
This was contrasted in the same experimental series, with the 
non-specific effects of two chain urokinase (tcu-PA) at doses 
required to produce comparable thrombolytic action because marked 
systemic depletion of the 3 haemostatic parameters occurred at 
equieffective doses. Sohngen (1988) also using r-scuPA from the 
same E. coli source found that similar infusion rates of r-scuPA, 
preceded however with a bolus, caused marked systemic degradation 
of fibrinogen and other haemostatic factors, which implied that 
systemic plasmin generation was occuring.
In the LAD series of experiments r-scuPA infusion produced 
significant decreases in fibrinogen 15% decrease), a
antiplasmin (~ 30-40% decrease) and a moderate (X 20%) decrease in 
plasminogen levels in plasma (diagrams 18, 19, 20) . The decreases 
in these plasma parameters were less in the LCX experiments after 
infusion of r-scuPA at the same rate (20 ptgkg *min *) but for a 30 
min instead of a 60 min duration (diagrams 30, 31, 32) . Fibrinogen 
levels were unaffected, plasminogen levels decreased marginally and 
antiplasmin activity was decreased by  ~  20%. One of the two obvious 
variables between the two series of experiments, the total dose of 
r-scuPA infused, might account for the greater decrease in the 
haemostatic parameter levels in the LAD experiments although it is 
difficult to imagine that a higher peak or steady state level would 
result form the different durations of infusion because of the 
short plasma half life (^2/2^ °f ? to 9 min of most forms of scuPA
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(Stump, Kieckens, De Cock et al 1987) . It may therefore be that the 
degree of systemic degradation of these parameters Is a function of 
both the peak level of scuPA and the length of the exposure period. 
This supposition cannot be confirmed with this data partly because 
the other variable, the site of the coronary thrombosis, was asso­
ciated with a marked difference in the tendency to bleed as dis­
cussed above. In LAD animals, bleeding was enhanced through fine 
artery branches after thrombolysis, and saline infusions were given 
to replace the blood. These may have caused haemodilution resulting 
in an artefactual decrease in the plasma levels of the haemostatic 
parameters in the LAD experiments.
In the PRIMI clinical trial infusion of r-scuPA (20 mg bolus, 60 mg 
infusion over 1 hour) at an average dose rate of 15 to
20 pgkg *min * (converted) caused a fall in the plasma fibrinogen
levels, as estimated by the Clauss assay, from a mean pretreatment 
value of 2.5 g/1 to 0.44 g/1 at the end of the infusion (PRIMI
Trial Study Group 1989) . These results seemed to show that the fi­
brin specificity of r-scuPA was limited and that systemic plasmin 
generation caused extensive fibrinogen degradation. A very recent 
study, comparing four different assays of fibrinogen using samples 
from the above clinical study showed that the Clauss assay under­
estimates the level of fibrinogen after thrombolysis due to nega­
tive interference of fibrinogen degradation products on the assay's 
clotting-time end point. Furthermore using a dual ELISA (enzyme
linked immuno assay) which detects only fibrinogen molecules with 
at least one intact a  chain it was shown that the levels of fi­
brinogen in the PRIMI trial were 60 % of pretreatment value 2 hours
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after thrombolysis, whereas the Clauss assay produced results sug­
gesting that the levels were 14% of pretreatment values at the same 
time (Hoffmann, Vijgen, Niewenhuizen 1990). Critical sagacity is 
hence of paramount importance in the interpretation of apparent 
changes in fibrinogen levels, as measured by the Clauss assay, due 
to fibrinolytic therapy.
The effects of r-scuPA infusion in the LAD and LCX models on the 
other two haemostatic parameters, plasminogen and AP are most like­
ly directly related to each other. As plasminogen is present in 
plasma (in man) at a concentration of 2 pM and a antiplasmin at 
1 pM (Bachmann 1987), activation by r-scuPA of 10 % of the baseline 
levels of plasminogen would cause a decrease in AP activity of 
20 %, as a result of 1:1 stoichiometric molecular complexation and 
mutual inactivation. This theory is borne out to a fair degree of 
accuracy in the results obtained here. The fact that rapid and ef­
ficient clot lysis occurs with a dose of r-scuPA that does not ex­
hibit prerequisite depletion of plasma antiplasmin activity lends 
further credence to the various hypothetical models of fibrin spe­
cific action of r-scuPA.
Considering the effect of taprostene coinfusion on r-scuPA induced 
changes in the haemostatic parameter levels it must be noted that 
for plasminogen, and to a greater degree AP, high dose taprostene 
seemed to reduce these indirect estimates of the degree of plasmin 
generation, at least in plasma.
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4.1.4 Doa infarct size/discussion
Thrombolytic recanalization of the LAD artery after a mean duration 
of occlusion of almost 2 hours resulted in a 80% reduction in the 6 
hour relative infarct size compared to continuous thrombolytic 
occlusion or ligation (Table 3, diagram 22) .  Thrombolytic 
recanalization of the LCX artery after an equally long duration of 
thrombotic occlusion and otherwise identical conditions resulted in 
a 47% reduction, compared to the 6 hour thrombotic occlusion 
controls (Diagram 28, table 7) . Hence thrombolytic reperfusion of 
the antero-apical myocardium supplied by the LAD would appear to be 
more rewarding in terms of acute myocardial salvage than 
reperfusion of the inferior myocardium and papillary muscle 
supplied by the LCX in the dog. Other anatomic variables detract 
from the cogency of this conclusion however. The size of the 
anatomic risk area (AaR/LV), although quite reproducible in the LCX 
experiments (table 7, diagram 28) was markedly smaller and more 
variable in the LAD experiments (table 3, diagram 22) and as 
discussed above smaller areas at risk have been shown to have 
higher specific myocardial perfusion rates via coronary colaterals 
(Gumm et al. 1988). Intrapolating data obtained by Reimer and 
Jennings (1979) after LCX ligation and reperfusion in dogs, 
sacrificed after 4 days, suggest a potential for 40% reduction in
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infarct size after reperfusion following 2 hours ischaemia compared 
with permanent occlusion. This value is similar to the one found in 
the present LCX study with thrombolytic recanalization.
There is some evidence that release of a coronary artery ligature 
after a given period of occlusion does not necessarily lead to the 
same degree of infarction as thrombolytic recanalization does after 
the same period of preceding ischaemia (Darius, Yanagisawa, 
Brezinski et al. 1986). These authors reported that tPA infusion 
concomitant with the release of a 2 hour LAD ligature reduced the 6 
hour relative infarct size from 47% to 30% (p < 0.02) as well as 
attenuating the release of myocardial CK activity compared to 
vehicle infused controls. Haemodynamic and vasoactive effects of 
tPA were dismissed by the authors as possible explanations and 
although the potential fibrinolytic action of tPA to dissolve 
microthrombi and enhance palliative reperfusion could not be 
excluded, the possibility of a ”cytoprotective" effect was 
speculated on by this group. Another group showed in Langendorff 
perfused rabbit hearts that crystalline perfusates containing 
streptokinase (150 U/ml) partially reversed the detrimental effects 
of an electric current on myocardial vascular and contractile 
function. This effect was attributed to oxygen free radical 
scavenging by the thrombolytic agent (Mickelson, Simpson, Jackson 
et al. 1988). The same group later showed that intracoronary 
streptokinase infusion maintained reperfusion coronary blood flow 
through a critical stenosis after 90 minutes of LCX ligation in 
vivo. Infarct size was not altered compared to vehicle controls, 
nor was in vitro platelet aggregation (Mickelson, Simpson and 
Lucchesi 1989). These results taken together suggest that at least
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certain thrombolytic agents may exert effects on the evolution of 
infarction independent from restoring artery patency. Other workers 
have been unable to repeat the result using an in vivo canine LAD 
model with tPA infusion during the reperfusion phase however 
(Kloner, Alker, Campbell et al. 1989).
Other reasons why thrombolytic recanalization cannot be directly 
compared with the release of a coronary ligature are
(a) the effect of a possible rest thrombus in the former causing 
stenotic flow conditions which have a detrimental effect on the 
terminal infarct size and ventricular function, albeit in 
animals not treated with fibrinolytic agents (Schmidt,
Varghese, Bloom et al. 1986; Lefkowitz, Pace, Gallagher et al. 
1988).
(b) the effect of fibrinogenolysis and FDP generation after 
thrombolysis on the rheological and haemostatic characteristics 
of blood, especially at a microvascular level, discussed later.
(c) the effect of plasmin generation on protease sensitive 
inflammatory mediator systems including the kinin and 
complement systems (Bennet, Yawn, Migliore et al. 1987;
Bachmann 1987)
(d) the effect of at least some plasminogen activators on platelet 
activity (reviewed Coller 1990).
The results of present LAD and LCX experiments confirm that early 
r-scuPA infusion interrupts the progression of myocardial necrosis 
after coronary artery thrombotic occlusion by restoring myocardial 
perfusion secondary to thrombolytic recanalization.
Plasma creatine kinase (CK) activity was recorded in these
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thrombolysis experiments as an index of the extent of myocardial 
necrosis. As mentioned in the "methods" section no assay is avai­
lable for the relatively myocardium specific CK-MB isoenzyme frac­
tion in dogs, but in these experiments a standardized experimental 
protocol eliminated a bias effect of other possible sources of CK 
activity, for instance after intercostal muscle incision. Further­
more in contrast with CK enzyme release by the myocardium, skeletal 
muscle incisions would tend to bleed externally, avoiding recircu­
lation of the enzyme activity.
Confirming this effect, CK plasma activity between thoracotomy and 
the onset of myocardial ischaemia was normal (X 70 U/l) in all ani­
mals.
The rapid increase in plasma CK activity in animals undergoing co­
ronary artery reperfusion, compared to animals with continuous myo­
cardial ischaemia, as observed here (diagrams 21 and 33) has been 
reported in animal models with coronary artery ligation with and 
without reperfusion (Vatner, Baig, Mander et al. 1978) and in hypo- 
perfused isolated rat hearts (Mohanlal, Moeve, Zoet et al. 1988). 
The accelerated rise in CK activity associated with myocardial re­
perfusion is speculatively attributed to "reperfusion injury" 
(Bresnahan, Roberts, Shell et al. 1974) or to the rapid "washout" 
of the enzyme from myocardial regions undergoing accelerated necro­
sis after reperfusion (Van der Laarse, van der Wall, van den Pol et 
al. 1988; De Vries, Jaffe, Geltman et al. 1989). A rapid rise in 
plasma CK activity in patients is now generally accepted as an ini- 
dicatof of successful coronary artery recanalization after thrombo­
lytic therapy (Garabedian, Gold, Yascuda et al. 1988; Lewis, Ganz, 
Laramee et al. 1988).
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De Vries et al. (1989) also demonstrated that the rate of increase 
in plasma CK activity corelated closely with the infarct size when 
CK release was measured during the first 60 minutes after reperfu­
sion (r - 0.92). This is obviously only valid after reperfusion, 
and considering the animals undergoing reperfusion in the present 
LCX study a significant reduction in the CK plasma activity was 
seen after high dose taprostene cotreatment compared to r-scuPA 
alone, implying a reduction in infarct size. Using De Vries' me­
thod, calculation of the rate of increase in CK activity between t 
=  2 and t - 3 h (t = 2 h roughly corresponds to the onset of reper­
fusion) yielded the following values - group II (r-scuPA alone): 
440 Uxh/1, group III (low dose taprostene + r-scuPA): 285 Uxh/1 
group IV (high dose taprostene + r-scuPA): 115 Uxh/1. Therefore, on 
the basis of the rate of increase of plasma CK activity over the 
first 60 min of reperfusion being directly proportional to infarct 
size, low and high dose taprostene cotreatment with r-scuPA, star­
ting late in the ischaemic phase, reduced the enzymatic estimate of 
infarct size by 35% and 65% respectively compared to r-scuPA treat­
ment above. This is only moderately comparable with the planimetric 
estimates of infarct size after TTC staining where relative reduc­
tions in infarct size of 16% and 32% were recorded in the low and 
high dose taprostene cotreatment groups compared to the group trea­
ted with r-scuPA alone. Greater absolute increases in mean plasma 
CK activity 4 hours after LAD reperfusion (group C, diagram 21) 
were recorded compared with the equivalent LCX reperfused group 
(group ' II, diagram 33) despite the smaller infarcts in the former 
group. This might be explained by the smaller anatomic risk area in 
the former (Aar/LV) which enables the CK released after infarction 
to be eluted more rapidly.
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Therefore in order to compare the enzymatic estimate of infarct 
size between 2 groups with markedly different anatomic risk areas 
(AaR/LV: LAD  ~  20%, LCX  ~  40%) the area under the plasma CK acti­
vity/time curve may be more appropriate using an extended observa­
tion period (~ 24 h) .
The mechanism by which taprostene cotreatment, started relatively 
late in the ischaemic phase, can c a u s e  a  trend to a further reduc­
tion in infarct sizes (enzymatic and planimetric estimates) com­
pared to r-scuPA alone is a point of prime interest in this thesis. 
In virutally all experiments in which it was shown that prostacy­
clin and mimetics could exert an antinecrotic effect after myocar­
dial ischaemia with and without reperfusion, first exposure of the 
myocardium to the compounds occurred early during the ischaemic 
phase or even prior to ischaemia.
Considering the mechanisms suggested from these experiments by 
which prostacyclin and mimetics have reduced terminal infarct size, 
a number of these possible mechanisms can be considered in relation 
to the current experiments.
A major contributary effect of taprostene here on the myocardial 
energy demand/supply balance during the ischaemic period can be 
excluded with a moderate degree of surety. Taprostene infusion 
started after 90 minutes of ischaemia, and approximately 25 minutes 
later thrombolytic recanalization was achieved (Table 7), therefore 
the taprostene "exposure" period was only during the last fifth of 
the ischaemic period. As no changes in any of the haemodynamic para­
meters occurred during this period it can at least be stated that 
the effect of taprostene cotreatment to reduce the infarct sizes
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was not related to a reduction in myocardial energy demand during 
the ischaemic phase. An effect of taprostene on the energy supply 
to the ischaemic region during ischaemia cannot be rejected in 
these experiments as the collateral blood flow to this region was 
not measured.
Jugdutt et al. (1981) reported in a continuous LCX occlusion model 
in conscious dogs that PGI^ r e c *u c e c * the infarct size by increasing 
collateral flow to the ischaemic region. However the dose of PGI^t 
starting 5 minutes after ischaemia, produced hypotension and rela­
tive infarct size reduction by PGI^ was also seen in dogs with low 
levels of collateral flow. Other groups have since shown a reduct­
ion in infarct size by PGI^ and iloprost in the absence of an ef­
fect on the local collateral flow rates and haemodynamic parameters 
(Melin and Becker 1983; Chiariello, Golino, Cappelli-Bigazzi et al. 
1988) . Furthermore the ischaemic myocardium becomes unresponsive to 
the effects of prostacyclin mimetics on the local distribution of 
myocardial blood flow (Smith, Gallenkamper, Beckmann et al. 1984; 
Simpson et al. 1987; Farber et al. 1988) which precludes the remote 
possibility of taprostene increasing the local blood flow during 
ischaemia.
Following the restoration of LCX artery patency however two effects 
of taprostene coadministration could potentially reduce the infarct 
size at 6 hours. By maintaining myocardial perfusion after thrombo­
lysis, at any level from preventing coronary artery reocclusion to 
decreasing the "no-reflow” effect at a capillary level or by decrea­
sing the postischaemic energy demand. The lower ventricular 
contractility associated with high dose taprostene cotreatment
<
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group (diagram 25) would not account for the reduction in infarct 
size in this group (diagram 28) as it occurred late in the 
reperfusion phase. Myocardial cells "condemned" to die during the 
ischaemia phase but still with an intact cell membrane rapidly 
become necrotic with the onset of reperfusion (Hearse and Yellon 
1984) . Maintenance of myocardial perfusion after thrombolysis 
either by preventing the formation of occlusive platelet aggregates 
or by reducing the no-reflow phenomenon could prevent extension of 
the period of ischaemia despite successful thrombolysis. As 
demonstrated here in the rabbit carotid artery stenosis experiments 
(diagrams 35, 36, 37) cotreatment of taprostene with r-scu-PA
effectively abolishes acute arterial thrombosis. In the LCX model 
coronary artery flow was not recorded after recanalization occurred 
and it cannot be excluded that reinfarction occurred in the 
untreated animals (group II) however this is unlikely as a 
continuous washout of CK from the myocardium was recorded over the 
experimental period. The ability of prostacyclin mimetics to reduce 
experimental infarction can be dissociated from the in vivo 
antiplatelet effects (Schror et al. 1982), suggesting that other 
effects are involved.
Extensive evidence exists for a major role of PMN and oxygen-free 
radicals in tissue injury after ischaemia and reperfusion (review: 
Lucchesi and Mullane 1986). The cardioprotective effects of prosta­
cyclin and mimetics have increasingly been attributed at least in 
part to an inhibition of neutrophil accumulation, activation and 
oxygen-free radical production (Farber et al. 1988; Simpson et al. 
1987; Thiemermann et al. 1984). A number of important differences 
distinguish these studies from the experiments in the present study
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however.
The first difference is that the time of initial exposure of the 
prostacyclin or mimetic was shortly after or even before the onset 
of ischaemia. As this bears little relevance to a clinical situa­
tion a protocol was employed here in which the taprostene infusions 
were started together with r-scu-PA, after 90 minutes of ischaemia. 
The second difference is that no study to date has compared experi­
mental infarct sizes after a prostacyclin mimetic was infused to­
gether with a fibrinolytic agent.
Considering the first difference, one study compared the effect on 
contractility of iloprost infusions when started at the onset of or 
end of a 15 min period of LAD ligation in open chest pentobarbitone 
anaesthetized dogs (Farber et al. 1988). In this study it was shown 
that iloprost treatment starting immediately prior to reperfusion 
exerted a beneficial effect on the recovery of contractile function 
of the ischaemic segment compared to controls, although earlier 
iloprost treatment resulted in greater recovery. The authors rejec­
ted an effect of iloprost on the xanthine oxidase-free radical ge­
nerating system and attributed its effect to a reduction in the 
superoxide radical production by iloprost in response to chemotac- 
tic stimulation. Infarction would not have resulted from such brief 
periods of ischaemia however. No studies have examined a potential 
in vivo interaction: PMN function/thrombolysis /myocardial infarc­
tion, but an effect of thrombolysis to enhance PMN mediated reperfu­
sion injury must be considered from a theoretical basis; fibrin 
degradation products (FDP), produced in high concentrations during 
thrombolysis, are chemotactic for PMN (Becker 1983) and may enhance 
their accumulation and activation in the reperfused myocardium. If
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FDP do contribute significantly to this effect then fibrin specific 
thrombolytic agents may in fact have a more detrimental effect on 
the myocardium than unspecific agents as they would produce a much 
higher chemotactic gradient between the ischaemic and normal myocar­
dium. Additionally some thrombolytic agents enhance thrombin activi­
ty (Seitz 1988) which leads to the liberation of factors in plasma 
which induce neutrophil aggregation, adherence to the endothelium 
and superoxide production (Lo, Lai, Cooper et al. 1988). Also pro­
tease activity synergistically enhances the toxicity of oxygen-free 
radicals (Varani, Ginsburg, Schuger et al. 1989). In contrast, t-PA 
and plasmin have been reported to decrease PMN activation in vitro 
(Mehta, Mehta, Lawson et al. 1989). If thrombolytic therapy with 
r-scu-PA does enhance PMN-mediated cytotoxicity then the ability of 
taprostene to potently inhibit PMN activation (Stahlberg et al.
1988) would represent a further mechanism in which taprostene co­
treatment led to smaller relative infarct sizes in the present ex­
periments.
To summarize thei effects of taprostene cotreatment with r-scu-PA on 
the infarct size in this model it has been shown in this study that 
taprostene cotherapy reduces the infarcts size compared to r-scu-PA 
alone. This was demonstrated with 2 independent indices of myocar­
dial necrosis, TTC-staining of viable tissue and by the release of 
enzyme activity into plasma after cell necrosis. The purpose of 
this study was to determine whether taprostene cotreatment with 
r-scu-PA at such a late phase in ischaemia could exert further anti- 
necrotic effects, which it did.
The study was not designed to enable the protective mechanimsms to 
be elucidated, but an effect of taprostene on the myocardial energy 
demand/supply balance can be largely discounted here.
-  188 -
4.1.5 Arrhythmias /Doer
A marked increase in arrhythmia at the infarct reperfusion is com­
monly reported in coronary artery ligation models (review Sheridan 
1987), and after restoration of coronary artery patency by clinical 
thrombolysis (Pop, Erbel, Treese et al. 1987; Goldberg, Greenspan, 
Urban et al. 1983). The intensity of reperfusion arrhythmia is re­
lated to the severity of antecedent ischaemia, including residual 
collateral flow and also to the relative mass of ischaemic myocar­
dium and the heart rate (Bolli and Patel 1988) . The mechanisms in­
volved have eluded comprehensive evaluation (Manning and Hearse 
1984) but recently the involvement of oxygen free radicals has at­
tracted much attention (Manning 1988).
Prostacyclin infusion during myocardial ischaemia decreases the 
intensity of arrhythmia at subhypotensive doses when there is no 
tachycardia (Johnston et al 1983, Starnes et al 1982) but higher 
doses are arrhythmogenic (Au et al. 1979). Treatment with prosta­
cyclin during ischaemia also reduced the intensity of reperfusion 
arrhythmias (Coker and Parratt 1983). Three possible actions of 
taprostene may account for the reduction in reperfusion arrhythmia 
seen here (diagram 29) . They are by inhibiting the accumulation of 
PMN and their release of oxygen free radicals and other noxious 
products in the reperfused myocardium (review by Lucchesi and Mul- 
lane 1986), by a membrane stabilizing action similar to propranolol 
(Hieda et al. 1988) which may decrease the breakdown of phosphati­
dyl choline and ethanolamine (Darius et al 1987) with the libera­
tion of arrhythmogenic compounds (Corr et al 1984), or by decrea­
sing 2 determinants of reperfusion arrhythmias, the severity of 
ischaemia prior to reperfusion or the infarct size itself.
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The antiarrhythmic effect of taprostene seen here was not dependent 
on treatment early during ischaemia, and is probably not dependent 
on haemodynamic effects at these doses. Diverse vasodilator drugs 
did not affect the occurence of ventricular arrhythmias and fibril­
lation after LAD occlusion and reperfusion in pentobarbitone anae­
sthetized open chest dogs (Elfellah and Ogilvie 1985), which would 
suggest that pre- and after-load reduction does not affect the occu­
rence of reperfusion arrhythmia.
The involvement of PMN in reperfusion arrhythmia can be demonstra­
ted by leucocyte depletion which reduced the occurence of reperfu­
sion ventricular fibrillation from 60% to 10% of dogs (Engler 
1987). Also using multiple linear regression analysis of baseline 
parameters from myocardial infarction patients on admission it was 
found that both the initial and peak PMN counts were the most impor­
tant predictors of acute ventricular fibrillation (Maisel, Gilpin, 
Le Winter et al. 1985). Other drugs including nafazatron and BW755C 
reduced the incidence of reperfusion arrhythmias concurrently with 
a reduction of postischaemic PMN accumulation similar to that 
caused by prostacyclin (Simpson et al 1987) . Thus assuming the ar­
rhythmic activity is related to PMN activity the antiplatelet ac­
tion of taprostene may contribute to the ant iar rhythmic activity as 
the presence of platelets increases PMN activity (Dinerman, Metha, 
Lawson et al. 1988). Furthermore some thrombolytic agents may de­
crease neutrophil function (Mehta, Mehta, Lawson et al. 1989).
Although the antiplatelet action of some prostacyclin analogues is 
not required for an antiischaemic effect to be seen (Schror et al.
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1982) and platelet depletion does not affect the infarct size after 
ischaemia (Mullane et al. 1985) platelets may contribute to 
arrhythmias via thromboxane production (Parratt and Coker 1985) . In 
myocardial infarction in man platelet activity increases greatly 
and marked resistance to exogenous prostacyclin is seen (Muller et 
al. 1985). The compensatory increase in vascular production of PGI^ 
in ischaemia is decreased after (thrombolytic) reperfusion (with 
tPA) (Kerins et al. 1989) which is indicative of reperfusion injury 
to the endothelium. Therefore this provides a further rationale for 
supportive exogenous prostacyclin treatment during thrombolysis. 
The antineutrophil effect of taprostene (Stahlberg et al. 1988) may 
have a further indirect effect on platelets as neutrophils have 
been shown to regulate the accumulation of platelets in the reper­
fusion myocardium (Mullane 1989).
The dose-dependent reduction in arrhythmic activity by taprostene 
cotreatment with r-scuPA is probably connected with the 
dose-related decrease in infarct sizes (enzymatic and morphological 
indices) either directly, or by an affect of taprostene to reduce 
(or postpone) some disruptive mechanism in the reperfused 
myocardium. Current knowledge would suggest that this mechanism is 
the deleterious effect caused by neutrophils accumulating in the 
myocardium on reperfusion. As a final comment, it was hoped that 
the accumulation of PMN could be compared between groups here. 
After establishing the myeloperoxidase (MPO) assay which has been 
employed to quantify PMN presence (Williams, Paterson, Eatkins et 
al. 1983, Bradley, Priebat, Christensen et al. 1982) it was found 
that oxidized and reduced TTC present in the samples reacted 
differently in the MPO assay and the assay could not be applied in
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these studies. Furthermore as haemoproteins also interfere with the 
MPO assay (Burkhardt and Tideman 1981) an artifact scenario is 
imaginable where reperfusion haemorrhagia is reduced by a treatment 
without an effect on PMN accumulation and MPO activity is 
paradoxically elevated.
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4.2 Rabbit experiments/discussion
Early reocclusion, that is during or shortly after the infusion of 
thrombolytic agent is one of the factors limiting the success of 
early thrombolysis: on average 5% to 20%, but even up to 45% of 
successfully treated patients reocclude at this stage (Heras, Che- 
sebro, Thompson et al 1989). The risk of reocclusion after success­
ful thrombolysis may, (Harrison, Ferguson, Collins et al 1984) or 
may not, (Ellis, Topol, George et al 1989) be directly linked to 
the degree of persisting stenosis. Furthermore, intermittent occ­
lusion and reopening of the coronary artery during fibrinolysis 
(and beforehand) has been demonstrated electrocardiographically in 
AMI-patients (Hackett, Davies, Chierchia et al 1987) suggesting the 
instability of at least some early reocclusions. The pathiophysiolo- 
gical mechanisms operating here may therefore be the same as those 
causing cyclic arterial flow variations (CFR) in animal models. The 
initial studies on CFR were done by Folts and coworkers (Folts, 
Gallagher and Rowe 1982) on externally stenosed dog LCX arteries. A 
60-80 % reduction in luminal diameter abolished the postischaemic 
hyperaemic response and* caused CFR, eventually leading to LCX occlu­
sion.
In the Folts Model, prostacyclin (Aiken, Gorman and Shebuski 1979), 
aspirin (Folts, Crowell and Rowe 1976), a ^  and/or 5HT receptor 
blockade (Bush, Campbell, Kern et al 1984), TxAsynthetase inhibi­
tion (Bush, Campbell, Buja et al 1984) and TxA^/PGH^ receptor blo­
ckade (Ashton, Schmitz, Campbell et al 1986) all inhibited the CFR. 
This, in addition to angiographic and microscopic evidence, sug­
gests an inappropriate but central role of platelets in
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obstructing the arterial flow. In addition, ancrod, an extract of 
viper venom which cleaves fibrinogen rendering it unclottable, was 
shown to reduce the frequency of CFR, albeit to a lesser degree, in 
a similar model (Apprill, Ashton, Guerrero et al 1987). This sug­
gests that fibrin (ogen) stabilizes platelet aggregates involved in 
producing CFR. It may therefore be reasonable to expect, on this 
basis alone, that any possible advantage of "fibrin-specific” throm­
bolytic agents is offset by an inherently greater tendency to reoc- 
clude and that antiplatelet drugs may make a major contribution to 
the maintenance of artery patency as a thrombolytic adjunct, espe­
cially in situations where thrombolytic therapy causes platelet 
hyperactivity.
A model was required to examine the separate and combined effects 
of taprostene and r-scu-PA on simulated arterial thrombosis and 
therefore, indirectly, the tendency to reocclude after thrombo­
lysis.
These experiments could not have been done in the preceeding dog 
study in parallel, for instance on another coronary artery, due to 
the possible effects on redistribution of coronary blood-flow, glo­
bal ventricular function and resulting extent of infarction in the 
latter.
A first series of attempts not reported in this thesis to find a 
reproducible model of arterial thrombogenesis involved Cotton 
thread, soaked in thrombin, inserted through the carotid artery 
lumen (axis) over fixed distances using a surgical needle. This 
method had three major drawbacks: occlusion was very rapid,
complete, and virtually irreversible; the arterial segment also
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underwent intense spasm possibly due to mechanical injury and/or 
the effect of thrombin on platelets and endothelium to elicit the 
release of vasoactive agents, and lastly treatment with r-scu-PA 
led to profuse (preferential) bleeding through the puncture holes. 
This model would also not allow discrimination between the 
potential antiplatelet and any antispasmic effect of taprostene. In 
conclusion this model was flawed with many unpracticalities and was 
therefore rejected.
The rationale for the final model used are as follows:
Implantation of polythene tubing of a previously established opti­
mum length and internal diameter enabled standardization of the 
stenosis and to a limited extent the shear rate. The rigidity 
eliminated local vasomotor effects.
In these experiments the test substances were infused for 10 min­
utes prior to the introduction of the stenosis. This was necessary 
because in the rabbit, as between the aortic arch and the first 
bifurcation to the facial artery the carotid artery runs for ~  5  
cm. Distal thrombosis in this column would preclude access of the 
drugs to the thrombus if given later, and any recanalisation would 
most likely have occured spontaneously, at least initially.
Very little data is available on the effect of r-scu-PA on platelet 
function in vivo or in vitro, and extrapolating data from 
Streptokinase or tPA may be inappropriate. Apparently conflicting 
observations of enhanced and decreased platelet aggregation after 
exposure to tPA and SK.
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In the present experiments r-scu-PA significantly increased the
mean interval flow rate through the stenosis at the end of the
infusion period (30 - 60 min) and later on (90 - 120 min after the
end of the infusion) . In rabbits and in primates the rate of
125
disappearance of r-scu-PA antigen, I-label and fibrinolytic 
(ECLT) activity was shown previously to be extremely rapid (^^/2a 
3 - 6  min) (Collen, De Cock and Lijnen 1984) . Although the hepatic 
clearance mode shows extreme dominance it cannot be excluded that a 
small quantity of scu-PA resists elimination for example by binding 
to endothelium or blood elements as recovery of label was not 
complete in these studies. The results of these ex vivo lysis rate 
studies showing rapid decay of lytic activity after stopping scu-PA 
infusion may be queried for two reasons: scu-PA is partially and 
variably precipitated in the ECLT fraction at pH 5.8 (Gurewich, 
Pannell, Louie et al 1984) and thrombin, added to form the ex vivo 
clots, degrades scu-PA.
These studies provide reasonable evidence that a form of functional 
cooperation exists between taprostene and r-scu-PA in preventing 
arterial thrombotic occlusion. The presumed separate effects of the 
two compounds, that is antiplatelet and fibrinolytic effects 
respectively, may play major roles in this cooperation, but there 
is also evidence in other studies of reciprocity, i.e. 
profibrinolytic action of prostacyclin (Winther, Snorrason, Knudsen 
et al 1987) and of an antiplatelet effect of fibrinolytic agents 
(review Coller 1990). In the case of fibrinolytic agents this is 
reportedly related to the formation of fibrin degradation prducts 
(FDP) (Kowalski, Kopec and Wegrzynowicz 1964) or to the proteolytic
-  196 -
degradation by plasmin of platelet aggregation cofactors (fibrino­
gen, clotting factors, platelet glycoprotein receptors. As no 
change in plasma fibrinogen levels was observed, this study dis­
sociates the ability of r-scu-PA to prevent arterial occlusion, for 
the duration of the infusion, from an effect of producing systemic 
fibrinogen degradation. Furthermore the Clauss fibrinogen assay is 
sensitive to FDP presence in the plasma samples (Garbedian, Gold, 
Leinbach et al 1988). So another conclusion arising from the experi­
ments is that the effect seen with r-scu-PA on arterial patency is 
probably not dependent on the generation of high concentrations of 
FDP and their subsequent effects on haemostasis. Probably of little 
relevance here, but an intriguing observation nevertheless, is that 
certain FDP cause endogenous prostacyclin release (Mehta, Nichols 
and Saldeen 1989).
Considering physical factors which would variably affect stenotic 
flow and thrombosis, as neither r-scu-PA nor taprostene affected 
the arterial blood pressure here, the flow rate would not have been 
directly affected. Hence, the shear rate, one determinant of the 
platelet deposition rate (Badimon, Benedict, Todd et al. 1987), 
would not be directly affected by the compounds.
The determination of plasma fibrinogen in this carotid flow study 
was necessary for another reason: for Newtonian fluids including 
plasma the flow rate is inversely proportional to viscosity. Fibri­
nogen, an elongated, large molecule is the major determinant of 
plasma ' viscosity; at 4 % w/w it accounts for the 30 % increase in 
viscosity beyond that of water alone and doubling of the plasma 
fibrinogen level increases its viscosity by 20 % (Rampling 1988) .
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Changes in plasma fibrinogen levels would therefore affect the ste­
notic flow rate. No changes in fibrinogen levels were, however, 
detected in any of the groups and therefore the possibility of this 
effect, especially after fibrinolytic treatment,may be rejected 
here. Furthermore the relatively rapid return of the tendency to 
occlude after cessation of the r-scu-PA infusion points to an on­
going effect and not to a marked depletion of the circulating pool 
of fibrinogen or clotting factors, or an effect on platelet count, 
because their low physiological replacement rates would result in a 
prolonged antiocclusive effect. This effect cannot be fully exclu­
ded here however as evidence exists of rapid repletion of fibrino­
gen after fibrinogenolysis, possibly by release of reserve pools.
The viscosity of whole blood is highly dependent on the haemato- 
crit, which was not examined in these experiments, but any changes 
caused by blood sampling and haemodilution by the infusions were 
constant between all groups. Thrombolytic agents may lower the pla­
telet count to a moderate extent starting shortly after infusion, 
and as this potential variable was not examined in these studies it 
cannot be excluded, although it is unlikely to have contributed 
much to the observed effect of r-scu-PA.
The frequency of cyclic flow variations in the r-scu-PA treated 
group was much higher than in the vehicle treated group. The ob­
vious conclusion is that in the vehicle group occlusion was less 
reversible. Conversely, the frequent spontaneous increases in ste­
notic flow rate in the r-scu-PA group may represent variable com­
bination of 3 factors:
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a) ongoing local fibrinolysis with degradation of the fibrin net 
binding the platelet aggregates together.
b) reduced tensile strength of clots formed from fibrinogen pre­
viously exposed to limited proteolysis (Hirsch, Fletcher and Sherry 
1986)
c) diminished stability of the interplatelet binding.
Of uncertain commonality is the effect of some thrombolytic agents 
to activate platelets, which might aid stenosis occlusion. (Kerins, 
Roy, Fitzgerald et al. 1989; Udvardy, Harsfalvi, Boda et al. 1990) 
This effect is yet to be examined two chain (tc) or single chain 
(sc) uPA, but a comparison with streptokinase (SK) here in this 
model would have been inappropriate as SK is a poor activator of 
lapine plasminogen (Reddy 1988).
The intentional omission of heparin in these experiments was for 2 
reasons: Heparin treatment has been reported both to prevent,
(Benedict, Todd, Sheng et al. 1988) and not to affect (Folts et al 
1982) thrombosis resulting from experimental artery stenoses, and 
probably depends on the severity of stenosis. Heparin may enhance 
platelet aggregation (Ljungberg, Bevering, Egberg et al. 1988) or 
augment experimental thrombolysis (with SK) (Schumacher, Lee and 
Lucchesi 1985) thus treatment of the rabbits with heparin would 
have inextricably complicated any interaction between r-scu-PA and 
taprostene.
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A number of important differences exist between the Folts' model 
(canine coronary artery stenosis) and this one, apart from the spe­
cies difference: The site of the stenosis is important from at
least two aspects, firstly the pressure/flow/time relationship in 
coronary arteries is different to that in peripheral arteries.
The second difference is the effect of myocardial ischaemia, re­
sulting from severe artery stenosis and occlusion, on local and 
systemic haemostasis, in particular of enhancing platelet function 
(see discussion canine thrombolysis model).
Furthermore in a more traumatic open chest model haemostatic and 
sympathetic activation may dominate, with accompanying effects on 
haemodynamic variable and platelet aggregation.
In this model the choice of anaesthetic agent, pentobarbitone was a 
compromise. Pentobarbitone (i.v.) seemed to have a narrow thera­
peutic index in the rabbit and also seemed to cause a transient 
increase in cerebral blood flow when given rapidly. For this reason 
it was diluted and given slowly as required at about 20 minute in­
tervals.
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4.3. Human experiments
Rationale
A few sparse and sometimes contradictory reports exist describing 
the effect of prostacyclin treatment to increase the endogenous 
fibrinolytic potential in vivo. Experimentally, in dogs (Utsumo- 
miya, Krausz, Valeri et al. 1989) and rats (Hussaini and Moore 
1985) prostacyclin infusion was reported to increase the plasma 
fibrinolytic activity as measured by the euglobulin clot lysis as­
say (ECLT). Similar effects have been observed with certain pro­
stacyclin analogues including iloprost in rats (Witt and Baldus 
1989) and taprostene in rats (Schneider 1987) . Positive reports of 
a profibrinolytic effect of prostacyclin infusion in patients with 
peripheral arterial disease (PAD) originated predominantly from two 
collaborating groups: repeated prostacyclin infusions decreased the 
ECLT by 50 % after 3 hours (Dembinska-Kiec, Kostka-Trabka and Gry- 
glewski 1982) . In PAD patients receiving 3 hour long infusions of 
prostacyclin a similar effect was reported, accompanied by a de­
crease in plasma plasminogen and antiplasmin levels. This served as 
evidence for enhanced thrombolytic activity although fibrinogen 
levels were unaffected (Szczeklik, Kopec, Sladek et al. 1983). In 
more recent experiments in PAD patients prostacyclin and iloprost 
infusions caused modest decreases in euglobulin clot lysis times 
(17 % and 19 % decrease respectively) compared to controls (12 % 
decrea&e) (Musial, Wilcyznska, Sladek et al. 1986). Other groups 
have been unable to show an effect of iloprost infusion on the ECLT 
in healthy volunteers (Belch, Greer, McLaren et al. 1984), and clau-
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dication patients (Hay, Waller, Carter et al. 1987). When comparing 
these reports 3 main variables might explain the different results, 
apart from the test subjects:
1)
Not all work takes into account the normal diurnal variation in 
endogenous fibrinolytic activity (60 % decrease in ECLT between 
8.00 a.m. and 8.00 p.m.) (Grimaudo, Hauert, Bachman et al. 1988), 
still a source of false positive results (Grimaudo, Omri, Kruithof 
et al. 1988)
2)
The lack of standardization of the ECLT assay (discussed later) and 
3)
The ECLT assay time point in relation to the start of the infusion.
The purpose of this series of experiments was to closely examine 
the effect of taprostene infusions, at two dose levels, on the 
endogenous fibrinolytic activity in healthy male volunteers under 
placebo controlled, blinded conditions by frequent ECLT sampling. 
Moderate stimulation of fibrinolysis might be expected to cause a 
decrease in plasma antiplasmin activity, and marked stimulation a 
decrease in fibrinogen levels. For this reason the two factors were 
assayed here. In addition the clot lysis time is, in part, depen­
dent on the density of the fibrin net and hence the concentration 
of fibrinogen in the blood samples, another justification for this 
assay to quantify a variable with potential to affect the main as­
say, the ECLT.
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Critique ECLT assay
The euglobulin clot lysis assay and the fibrin plate assay are by 
far the most ubiquitous tests of the "endogenous fibrinolytic ac­
tivity". Both assays require the removal of plasmatic inhibitors 
from plasma, by euglobulin fraction formation in order to unveil 
fibrinolytic activity. The chosen methodology of euglobulin frac­
tion precipitation differs between laboratories, e.g. pH of pre­
cipitation between 5.2 and 6.0, and not surprisingly, the compo­
sition of the euglobulin fraction, produced from a complex starting 
material like plasma, is poorly characterized with regard to the 
degree of separation of individual factors involved in fibrinoly­
tics, e.g. PAI and C^-inactivator (Kluft 1979; Kluft and Jie 1986). 
Parenthetically but interestingly although scu-PA is normally pre­
sent in human plasma, it seems to play only a minor role in the 
lysis of euglobulin clots (Grimaudo, Hauert, Bachman et al. 1988) 
although this may be underestimated however as thrombin, added PAI 
to form the starting clots, inactivates r-scu-PA (Pannell and Gure- 
wich 1986) especially under the ideal ECLT assay conditions (37'C, 
many hours incubation). However as u-PA antigen levels do not under­
go diurnal variation in contrast to t-PA and PAI-1 antigen levels, 
the observed diurnal variation in endogenous fibrinolytic rate is 
attributed primarily to the net balance of activity of the latter 
two (Andreotti, Davies, Hackett et al. 1988). Furthermore as PAI, 
which forms a 1:1 stoichiometric inhibitor complex with t-PA, is 
usually present in excess in plasma of sedentary healthy individual 
small changes in t-PA or PAI activity will go unnoticed. On 
stimulation of t-PA release, by venous occlusion or exercise a 
rapid increase in t-PA s u r m o u n t s  P A I  inhibition and minor increases
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in t-PA activity should be detected by the ECLT by the assay.
It can be stated categorically that on the basis of the results of 
the clottable fibrinogen (Clauss) assay and the AP activity assay 
that there is no evidence of extensive activation of the fibrinoly­
tic system by taprostene here, however as the physiological fibrino- 
lytisis is fibrin specific, stimulation would not c a u s e  degradation 
of clotting factors as seen after treatment with streptokinase. The 
ECLT results suggest that moderate stimulation of the endogenous 
fibrinolysis system occurred after high dose taprostene infusion. 
This may be of clinical relevance as synergism between exogenous 
fibrinolytic drugs (tPA and scuPA) has been reported (Collen 
1988 b ) .
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5 Summary and Conclusion
The results of these studies, under the limitations imposed by the 
short observation periods (hours), species difference and perfect 
health of the experimental animals used, showed that a number of 
effects are exerted by taprostene in vivo which render it a useful 
adjuvant in thrombolytic therapy with r-scuPA. Taprostene cotreat­
ment reduced infarct size and arrhythmias after r-scuPA recanali­
zation of canine coronary arteries, without markedly affecting its 
thrombolytic specificity, selectivity or intensity. Treatment with 
taprostene greatly potentiated the antiocclusive effect in a coro­
nary artery thrombosis model when given with r-scuPA, and in 
healthy volunteers taprostene infusion moderately stimulated endo­
genous fibrinolysis possibly by stimulating endogenous tPA release, 
which has been shown elsewhere to act synergistically with scuPA in 
thrombolysis, enabling the doses to be reduced. The potential dis­
advantages of cotreatment of taprostene with r-scuPA are probably 
mostly related to the dose of the former, and its hypotensive ef­
fect, especially in acute myocardial infarction where cardiogenic 
shock is not uncommon.
The relatively short chemical half lifes of the 2 compounds in plas­
ma could be used to advantage to terminate their actions when re­
quired, although an unexpected prolongation of the biological ef­
fects of combined therapy cannot be excluded on the basis of re­
sults from these experiments.
The current search for modified ("third generation") thrombolytic 
agents with enhanced fibrin binding-affinity should yield compounds 
with greater potency and thrombolytic success rates, assuming that
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thrombosis is the occlusive mechanism in greater than 90% of AMI 
patients. These agents will probably be burdened by an increased 
rate of cerebral and other spontaneous bleeding events as the 
selective effect of a "short sharp" local thrombolytic effect on 
recent thrombi is lost and old haemostatic plugs are increasingly 
affected. Exclusion criteria for therapy could be restricted to 
reduce this risk.
The ubiquity of responses, desirable and otherwise, in vivo to 
systemic prostacyclin therapy will remain a major drawback. The 
side effects must be weighed against the expected beneficial effect 
for each disease state, and the balance might be achieved in the 
dosing in AMI.
In the treatment of AMI rapid recanalization of the infarct related 
artery remains the primary acute goal and maintenance of patency 
is a long term goal. Thrombin inhibitors should prove to be 
valuable adjuvants in thrombolytic therapy due to thrombin's 
central role . in both fibrin and platelet haemostasis. 
Antineutrophil and antiinflammatory drugs may reduce the 
reperfusion injury attributed in part to PMN but the effects of 
long term treatment on infarct resolution, scar-tissue formation 
and normal immune defense remains to be elucidated. In hospital 
mortality after AMI has been reduced dramatically to approximately 
6 to 10% at present, to which thrombolytic therapy has made a major 
contribution. The potential benefit of adjuvant therapy in thrombo­
lysis is therefore relatively small as a percentage but great in 
terms of numbers of lives saved.
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